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Summary 
 
Pharmaceuticals are used worldwide at increasing consumption rates which are 
not expected to decrease on short time horizons. Large quantities of administrated 
pharmaceuticals are excreted unaltered or as metabolites via faeces or urine and end-
up via the toilet and sewer system at the wastewater treatment plant.  
Conventional wastewater treatment plants employing activated sludge 
treatment are designed to remove bulk constituents, like organic matter, nitrogen 
and phosphorous, which are present at concentrations of milligrams per litre. These 
treatment plants were not designed for removing the broad spectrum of 
pharmaceuticals comprising thousands of highly complex molecules present in 
wastewater. These compounds, found at low concentrations of nanograms to 
micrograms per litre, are therefore generally only poorly removed. The biodegradable 
pharmaceuticals that are removed are rather transformed than mineralized. As a 
matter of fact, countless pharmaceuticals or their human metabolites and 
transformation products are discharged into the environment. 
The presence of these insidious compounds in the environment are one of the 
main challenges humanity is facing as they jeopardise the aquatic environment and 
human health. Adverse effects on the aquatic ecosystem like the feminization of fish 
are well reported and threaten the entire ecosystem. Intake waters for drinking water 
production were found to contain high pharmaceutical concentrations emitted by 
wastewater effluents posing risks to the public health in case drinking water is poorly 
treated. The presence of pharmaceuticals hampers the reuse of wastewater effluents 
whereas worldwide water scarcity problems could partially be solved by effluent 
reuse. Hence, there is a strong motivation to remove pharmaceuticals before they 
enter the aquatic environment. 
Being a main hub in the water cycle, wastewater treatment plants are the most 
optimal place to raise barriers against pharmaceuticals before they are discharged. 
Various biological and chemical processes have been studied for their capacities to 
remove pharmaceuticals of which some have been locally implemented. Nevertheless, 
these processes show either insufficient pharmaceutical removal or are considered 
costly and unsustainable. Thus, there is a lack of cost-effective pharmaceutical 
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treatment processes. Therefore, this dissertation investigates different processes for 
the cost-effective removal of pharmaceuticals to be applied in wastewater treatment, 
with a focus on the synergy between biological and chemical treatment processes for 
an enhanced pharmaceutical removal (Chapter 1). 
The low costs associated to biological treatment increases its implementation 
potential and favours the research on biological processes. Among the various 
parameters affecting biological processes, redox conditions are considered one of the 
most important parameters. In batch and column experiments employing constructed 
wetland sediments aerobic, sulfate reducing and methanogenic redox conditions were 
most favourable for pharmaceutical removal (Chapter 2). In contrast, micro-
aerophilic and nitrate reducing conditions were less effective. Biodegradation and 
sorption contributed to the observed removal and both were influenced by the applied 
redox conditions. Saturation of sorption sites for propranolol, i.e. the compound with 
the highest sorption coefficient among the investigated pharmaceuticals, was found 
to occur after 300 pore volume changes under most favourable redox conditions. This 
suggests that in biological filtration applications sorption of pharmaceuticals is of 
minor importance compared to biodegradation. The persistence of biorecalcitrant 
pharmaceuticals such as carbamazepine towards biodegradation and sorption under 
all redox conditions stresses the shortcoming of biological treatment and indicates the 
need for additional treatment processes. 
Mild UV-LED TiO2 photocatalysis combined with subsequent biological 
treatment demonstrated improved pharmaceutical removal over single photocatalysis 
or biological treatment (Chapter 3). Mild photocatalytic treatment removed three out 
of the nine studied pharmaceuticals. Interestingly, the biodegradation of four 
pharmaceuticals enhanced after mild photocatalytic pre-treatment, even though only 
one of them was targeted by photocatalysis. In addition, biodegradation of diclofenac, 
which persisted during single process biological treatment, was observed after mild 
photocatalytic pre-treatment. Based on the literature it is postulated that 
intermediates formed during mild photocatalysis enhanced the biodegradation of 
pharmaceuticals by the activation of enzymatic systems responsible for initial attack 
of organic molecules. 
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The presence of ozone scavengers in wastewater effluent like organic carbon, 
reduce the effectiveness of ozonation for the oxidation of pharmaceuticals. Elevated 
total organic carbon (TOC) concentrations, such as the 17.3 mg TOC/L present in the 
investigated effluent, consequently demand high absolute ozone inputs for 
pharmaceutical removal, thus reducing the cost-effectiveness of ozonation. A three 
step bio-ozone-bio process (BO3B) consisting of two identical trickling filters utilizing 
sand as biomass carriers and an ozone reactor was therefore designed (Chapter 4). 
Various hydraulic retention times (HRTs) and ozone doses were investigated aiming 
at a cost-effective pharmaceutical removal from wastewater effluent. At an HRT of 
1.5 hours a 38% TOC removal was found over the first biological reactor, thereby 
proportionally reducing the ozone demand in the subsequent ozone reactor. Enhanced 
pharmaceutical removal was observed over the first biological reactor compared to 
conventional wastewater treatment, despite of the short HRT and low amount of 
biomass in the BO3B system. Even pharmaceuticals known to be moderately 
biodegradable such as sulfamethoxazole were effectively biodegraded. At ozone doses 
down to 0.2 g O3/g TOC an effective removal of biorecalcitrant pharmaceuticals such 
as carbamazepine was found. The 17% TOC removal over the last biological reactor 
demonstrated the removal of transformation products formed during ozonation. 
Simultaneous nutrient recovery and pharmaceutical removal was found in algal 
photobioreactors running on anaerobically treated black water or urine (Chapter 5). 
Algae, known to take up nitrogen and phosphorus from these highly concentrated 
source separated wastewater streams, demonstrated to contribute to the 
pharmaceutical removal observed in the algal photobioreactors. Control experiments 
revealed that algae, bacteria and light contributed to the pharmaceutical removal. 
Pharmaceuticals susceptible to photolysis such as diclofenac were photodegraded, 
whereas paracetamol and metoprolol were removed by a combination of 
biodegradation and photodegradation. The sorption of pharmaceuticals to algal 
biomass was limited which favours the use of harvested algal biomass as fertilizer in 
agriculture over for instance direct urine application. 
The outcomes of this dissertation provide insight into the limitations of single 
biological and chemical processes for pharmaceutical removal and illuminate the 
importance of combinations of complementary processes to overcome single process 
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disadvantages (Chapter 6). Site-specific conditions such as wastewater composition 
dictate which combination is locally most favourable as there is no universal cost-
effective combination of processes. Implementation should therefore rather focus on 
tailor-made combinations as there is a wide arsenal of biological and chemical 
treatment processes available. To further improve the cost-effectiveness of combined 
processes future research should focus on underlying removal mechanisms including 
the enzymatic pathways of pharmaceutical degradation and transformation product 
formation and removal.  
For the studied removal processes in this dissertation an outlook on further 
research and upscaling is presented. The BO3B process and the algal treatment 
system are ready to be tested on a pilot scale. Especially the upscaling potential of 
the BO3B system is high as on lab-scale it was successfully tested for almost a year 
on real wastewater. During this period high pharmaceutical removal efficiencies were 
achieved in a cost-effective manner. Upscaling should mainly focus on the operation 
of the biological reactors as they make the BO3B process cost-effective. The algal 
treatment system is currently tested on pilot scale. A focus on the removal of a broad 
suite of micropollutants is recommended for pilot scale testing. The combination of 
photocatalysis and biodegradation requires further lab-scale research as TiO2 
immobilization is needed to make the system more sustainable and the system was 
only tested on a clean matrix. 
Obtained knowledge of the past decades stresses the importance of effect 
based removal strategies as most studies, including this dissertation, primarily rely 
on chemical parameters such as individual pharmaceutical concentrations, 
overlooking the effects of pharmaceuticals on for instance the aquatic environment. 
Source separation based sanitation systems enabling cost-effective pharmaceutical 
removal and interventions at earlier stages in the chain from pharmaceutical 
manufacturing to drinking water production reducing the need for end-of-pipe 
solutions are highly recommended solutions to reduce pharmaceutical emission into 
the environment. Moreover, stricter legislation regarding the regulation of 
pharmaceutical concentrations in the effluent is recommended. 
The results of this dissertation provide further understanding of combining 
biological and chemical treatment processes for pharmaceutical removal and is 
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achieved in a cost-effective manner. Upscaling should mainly focus on the operation 
of the biological reactors as they make the BO3B process cost-effective. The algal 
treatment system is currently tested on pilot scale. A focus on the removal of a broad 
suite of micropollutants is recommended for pilot scale testing. The combination of 
photocatalysis and biodegradation requires further lab-scale research as TiO2 
immobilization is needed to make the system more sustainable and the system was 
only tested on a clean matrix. 
Obtained knowledge of the past decades stresses the importance of effect 
based removal strategies as most studies, including this dissertation, primarily rely 
on chemical parameters such as individual pharmaceutical concentrations, 
overlooking the effects of pharmaceuticals on for instance the aquatic environment. 
Source separation based sanitation systems enabling cost-effective pharmaceutical 
removal and interventions at earlier stages in the chain from pharmaceutical 
manufacturing to drinking water production reducing the need for end-of-pipe 
solutions are highly recommended solutions to reduce pharmaceutical emission into 
the environment. Moreover, stricter legislation regarding the regulation of 
pharmaceutical concentrations in the effluent is recommended. 
The results of this dissertation provide further understanding of combining 
biological and chemical treatment processes for pharmaceutical removal and is 
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1.1 Pharmaceuticals in the water cycle 
1.1.1 Occurrence  
Human pharmaceuticals comprise a wide group of various organic compounds 
intended to treat human illness and diseases. They are mostly synthetically 
manufactured and are therefore considered xenobiotic. Pharmaceuticals are being 
used worldwide, though usage of type and quantity differs per country [138]. Around 
3000 different medical substances are used in the European Union [85]. In 2007 the 
estimated human consumption of pharmaceuticals in the Netherlands totalled 1.273 
metric tonnes, which equals approximately 78 gram per capita per year. By then a 
consumption increase of 17% was expected by 2020 due to aging of the population, 
while for 2050 an increase of 37% was predicted [283]. However, more recent data 
shows an higher realised increase in Dutch pharmaceutical consumption. Expressed 
as daily standard doses the consumption of pharmaceuticals in the Netherlands grew 
per year by 2.6%, 2.9%, 2.5%, 1.1% and 6.4% in 2015, 2014, 2013, 2012 and 2011 
respectively [249, 250]. 
Consumed pharmaceuticals are mainly excreted via urine and faeces [60]. 
After excretion, human pharmaceuticals end up in wastewater and are transported to 
wastewater treatment plants (WWTPs) [85, 129, 139]. Conventional WWTPs are 
commonly designed for the removal of bulk organic matter, nitrogen and phosphorus 
but not for pharmaceutical removal. Although some pharmaceuticals are removed 
during wastewater treatment, numerous pharmaceuticals are ineffectively removed 
and are discharged with the WWTP effluent [65, 287]. Hence, wide ranges of 
numerous pharmaceuticals at ng/L up to low µg/L concentrations have been 
measured in wastewater effluents and in surface waters [196] Moreover, low 
concentrations up to 0.1 µg/L of pharmaceuticals are also detected in various drinking 
water sources [286, 288]. Pharmaceuticals were only detected in the water cycle over 
the last decades as only recently analytical techniques allowed the detection of these 
compounds in aqueous environments at low concentrations [262].  
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Figure 1.1 Pathways of pharmaceuticals and other micropollutants from production to 
drinking water (Figure from [22]). 
 
1.1.2 Fate 
Effluents of WWTPs treating merely wastewater from households are identified 
as the main source of pharmaceuticals entering the environment [128]. Besides 
administration and excretion of pharmaceuticals, unused and expired 
pharmaceuticals are also disposed down household drains. In a German survey 18% 
of the respondents said they flushed outdated pharmaceuticals down the drain [95]. 
In a U.S. study only 23% of the respondents reported to return expired 
pharmaceuticals to the pharmacy, whereas more than 50% had flushed 
pharmaceuticals through the toilet [236]. In addition to households, hospitals, 
agriculture and livestock and industries are also recognised as sources of 
pharmaceuticals entering the environment (Figure 1.1). Hospital wastewaters contain 
high concentrations of pharmaceuticals [94]. However, due to the relatively small size 
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of this stream it is typically diluted by a factor 100 in the sewer system before it 
enters the WWTPs [137]. In addition, some hospitals have their own tailor made 
wastewater treatment plant aiming at low pharmaceutical emissions to the sewer 
system [204]. Both the dilution of wastewater in the sewer system and treatment by 
some individual hospitals explains why less than 15% of the total pharmaceutical load 
fed to WWTPs is estimated to originate from hospitals [147].  
Pharmaceutical use in agriculture and livestock mainly concerns the use of 
antibiotics. Sim et al. [240] compared WWTPs treating domestic, hospital, livestock 
and industrial wastewater in Korea and found highest total pharmaceutical 
concentrations in the influents of livestock WWTPs. Although livestock WWTPs had 
the highest pharmaceutical influent concentrations, municipal WWTPs were found the 
principal source of pharmaceuticals to the aquatic environment as their disposed loads 
were highest. Nevertheless, these findings might be different for other countries. 
Pharmaceutical producing industries in Europe and North America are assumed to 
have minimal pharmaceutical emissions into the environment due to good 
manufacturing practice regulations [51, 304]. However, no data is available to verify 
this assumption [139]. In the effluent of an Indian WWTP serving pharmaceutical 
manufacturers elevated concentrations of the antibiotic ciprofloxacin up to 31 mg/L 
and high concentrations of numerous other pharmaceuticals have been detected. 
These concentrations exceed toxic levels to various organisms by multiple orders of 
magnitude [146]. Similar findings were reported for a manufacturer of the antibiotic 
oxytetracycline in China which was found in WWTP effluent at concentrations up to 
19 mg/L [153]. 
 
1.1.3 Characteristics 
Pharmaceuticals cover a broad range of compounds with chemically complex 
structures and many different chemical and physical properties (Table 1.1). 
Pharmaceuticals are typically polar or charged compounds and thereby hydrophilic 
[139, 260]. Many of them contain acidic groups which favours speciation of the 
compound [77]. Polar compounds mostly dissolve well in water and are therefore 
easily dispersed in aquatic environments. The spread of hydrophobic pharmaceuticals 
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in aquatic environments is relatively limited and much slower as they tend to 
accumulate in the fatty tissues of organisms [114].  
Metabolic processes in the human body can alter the pharmaceutical into 
metabolites before excretion (Figure 1.2). After excretion further transformation of 
the pharmaceutical or its metabolites can take place in wastewater treatment plants 
and the environment resulting in countless transformation products. Some of the 
products formed during specific treatment are known to exhibit higher toxicity levels 
compared to the original compounds [118]. 
 
 
 
Figure 1.2 Transformation pathways of pharmaceuticals (adapted from [139]). 
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1.2 Effects of pharmaceuticals in the water cycle 
1.2.1 Environmental effects 
Improved analytics of the last two decades allowed the detection of 
pharmaceuticals in various matrices and enabled investigations into the fate and 
ecological effects of these compounds [196, 262, 283]. Though the fate of 
pharmaceuticals, i.e. pathways of pharmaceuticals through the environment, is 
now relatively well known, the actual ecological effects in the environment are still 
poorly understood [85, 139, 190, 315]. Effects of numerous individual 
pharmaceuticals on specific test organisms like bacteria, algae, daphnia and other 
aquatic organisms are well studied, but limited studies report the effects of 
pharmaceutical mixtures in the environment [287]. The number of 
pharmaceuticals emitted into the environment is world-wide still increasing and 
this is not expected to change in the near future.  
Due to the enormous variety in types of pharmaceuticals used and emitted, 
exposure to organisms in the environment concerns predominantly mixtures rather 
than to individual compounds. Although concentrations of individual compounds in 
water and soils are often non-toxic, exposure to these mixtures could result in a 
synergistic toxicity, thus leading to high risks [233]. Brian et al. [34] studied the 
effects on fish of exposure to a mixture of estrogenic compounds. They found 
estrogenic compounds to act together in an additive manner imposing fish toxicity 
at concentrations of which the individual compounds did not induce a response. 
Similarly, Cleuvers [50] demonstrated elevated toxicity for a mixture of anti-
inflammatory drugs over the toxicity of the individual compounds which could be 
explained by the principle of concentration-addition.  
Also for mixtures of compounds with different modes of toxic action, additive 
toxic effects were found compared to the individual compounds [5]. Thus, the 
presence of numerous individual pharmaceuticals in wastewater could result in 
risks for the aquatic environment near the effluent discharge areas of the WWTPs 
[77, 141, 325]. The variety among the broad array of individual pharmaceuticals 
results in that different modes of toxic action and multiple toxicological end-points 
need to be accounted for to determine actual toxicities [85]. For instance, Guler 
and Ford [98] discovered behavioural changes resulting in increased predation 
risks for the marine amphipod Echinogammarus marinus when exposed to the 
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anti-depressant fluoxetine at environmentally relevant concentrations. Decreased 
activity of the benthic invertebrate Gammarus pulex was found at ibuprofen and 
fluoxetine concentrations of 10-100 ng/L [63]. Kidney, liver and gill cell alterations 
were observed in rainbow trout (Oncorhynchus mykiss) exposed to 1 µg/L 
concentrations of diclofenac [274].  
Acute toxicity tests with standard testing organisms like daphnia, algae and 
bacteria revealed that the lowest observed effect concentrations (LOEC) are about 
two orders of magnitude higher than concentrations found in WWTP effluents. 
However, for other specific organisms LOEC of individual compounds were found 
at typical WWTP effluent concentrations, e.g. diclofenac for fish, and propranolol 
and fluoxetine for zooplankton and benthic organisms [85].  
All above mentioned toxicity studies were conducted at laboratory scale. 
Translating results of laboratory toxicity tests to the real aquatic environment is 
complicated since there seems not to be a single assessment factor which can be 
applied for all aquatic species and for all pharmaceuticals. Moreover, laboratory 
tests mostly focus on acute toxic effects rather than on chronic toxicity [57]. In 
their review on ecotoxicology of pharmaceuticals Fent, et al. [85] state that only 
little is known about long term effects and chronic toxicity to aquatic organisms. 
Moreover, limited studies report the actual impact of pharmaceuticals on the 
aquatic environment as the presence of other potential ecological stress 
compounds (such as pesticides, personal care products, industrial additives, etc.) 
complicates parsing out the actual contribution of pharmaceuticals.  
Various authors therefore handle a more pragmatic approach and study the 
ecological effects of WWTP effluent discharge into the aquatic environment without 
unravelling the contributions of individual compounds. Field studies on river 
systems receiving WWTP effluents have shown endocrine-disruptive effects 
resulting in intersex rainbow darters (Etheostoma caeruleum) [259, 270]. 
Moreover, discharge of various anti-depressants by WWTPs resulted in the 
bioaccumulation of these compounds in the brain, liver, muscle and gonads of 
various fish species in the Niagara River and are hypothesized to affect the 
biological diversity [17].  
The abovementioned lab-scale and field studies demonstrate that the 
current understanding of the actual acute and chronic effects of pharmaceuticals 
mixtures on the environment is incomprehensive and inconclusive. Further 
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research is required to elucidate especially the potentially harmful long term 
ecological effects of pharmaceutical mixtures on the aquatic environment at 
environmentally relevant concentrations, i.e. to assess LOECs of pharmaceutical 
mixtures for aquatic biota networks in the environment. 
 
1.2.2 Effects on human health 
Pharmaceuticals have been detected in various sources of drinking water 
and thereby pose a potential risk to human health [32]. Touraud et al. [273] 
concluded in 2011 that there was no consensus among scientists on what risks 
pharmaceuticals actually pose to human health as their reviewed studies often 
reported uncertainties and the toxicity of mixture effects on human health is 
difficult to quantify. Even in very recent studies, utilizing an extensive 
environmental monitoring dataset with a large number of pharmaceuticals for the 
human health risk assessment of pharmaceutical mixtures in drinking water, no 
complete risk overview can be given [113]. Moreover, there are no institutionalized 
risk assessment methods for the presence of pharmaceuticals in drinking water 
[273]. Therefore methods using indirect exposure, based on predicted 
environmental concentrations, and human pharmacology and toxicology data of 
pharmaceuticals have been applied to assess the toxicological effects of drinking 
water or fish consumption on human health.  
For various individual or groups of pharmaceuticals no appreciable human 
health risks have been found [25, 58, 59, 122, 226, 252]. Thus, to date there is 
no direct science based reason for concern as there are no clear indications of 
adverse effects on human health. However, unlike ecological and aquatic organism 
studies, studies on the effects of low levels of wide ranges of chemicals on human 
health are hampered by the impossibility to do controlled exposure experiments 
with populations. Therefore, it cannot yet be excluded that adverse human health 
effects exist due to a continuous exposure to low levels of a wide range of 
chemicals. A recent meta-analysis showed that between 1973 and 2011 the sperm 
count of Western men expressed as sperm concentration and total sperm count 
reduced by 52% and 59%, respectively [152]. The authors state that these 
findings are plausibly associated to multiple environmental influences such as 
exposure to chemicals. The implications of reduced sperm count go beyond fertility 
and reproduction concerns as they also pose serious public health, societal and 
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economical related problems. For this and other reasons, drinking water 
companies often imply the precautionary principle or a so called “clean source” 
strategy and policy: they give high value to the image of their water products 
which is related to the quality of the water resources they use and the perception 
of drinking water consumers [113, 242]. Thus, drinking water companies strive for 
use of water resources that are free from unnatural organic components, such as 
pesticides, pharmaceuticals and other compounds, and this is a strong “society-
driven” motivation for considering measures to remove pharmaceuticals from 
WWTP effluents.  
The situation is different for the presence of a specific group of 
pharmaceuticals, namely antibiotics, in wastewater and in water resource systems 
used for drinking water that are affected by WWTP effluents. For these compounds 
environmental exposure raises human and animal health concerns due to the 
proven development of clinically relevant antibiotic-resistant bacteria [41, 48]. The 
extent of natural bacterial populations that have acquired resistance to these 
antibiotics (often used as life-saving medicines) is increasing [31, 168]. This may 
cause yet also unknown human health risks via exposure of humans to these 
antibiotic-resistant bacteria through the natural environment, via crops and live-
stock food products or via poorly disinfected drinking water.  
 
1.2.3 Need for measures 
The abovementioned concerns regarding widespread and continuous 
emissions of mixtures of pharmaceuticals at low concentrations through WWTP 
effluents to the aquatic environment is suspected to cause –largely unknown- 
acute and/or chronic toxicity effects in aquatic populations. As mentioned above, 
to date there are no direct science based reasons concerning acute risks to human 
health regarding pharmaceutical emissions. Nevertheless, there are multiple 
reasons as mentioned above which stress the need to remove these insidious 
compounds quickly after they enter the water cycle. Thus, from an environmental 
and human health related perspective to reduce the possible risks pharmaceuticals 
pose, there are strong motivations to conduct further research on ways to reduce 
pharmaceutical emissions, i.e. by prevention and technological removal measures 
like the further treatment of WWTP effluents. 
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1.3 Legislation 
From a legislative perspective first steps have been taken concerning the 
presence of pharmaceuticals in the water cycle. To date, the most progressive 
policies have been implemented in Switzerland. In the early 2000s the issue of 
micropollutants entered the Swiss political agenda [184]. Actions were taken from 
2009 onwards when the Swiss Federal Office for the Environment proposed 
revisions to the nationwide Swiss Waters Protection Ordinance with respect to 
micropollutants (including pharmaceuticals). In 2016 a revised Waters Protection 
Act passed both Swiss parliamentary chambers and came into force. Thereafter 
the implementation of the revised Waters Protection Ordinance was started, which 
is currently in progress. In brief, the Waters Protection Ordinance foresees the 
upgrade of large size WWTPs (>100 000 population equivalents (PE)) and 
moderate size WWTPs (10 000 - 100 000 PE) which discharge into streams with 
minute dilution or those being used for drinking water extraction. In practice this 
implies that approximately 50% of the Swiss wastewater will undergo advanced 
post-treatment as about 100 out of 800 WWTPs will be upgraded [232]. With the 
upgrade, WWTPs have to meet an 80% removal efficiency of 5 compounds from a 
list of 12 micropollutants (11 pharmaceuticals and 1 biocide). Individual Cantons 
are free in their choice for the 5 compounds they monitor and every 5 years the 
list of 12 compounds is subject to change. The upgrade concerns the investment 
costs of about 1.2 billion CHF and additional operational costs of 130 million CHF 
per year. As the polluter pays principle is practiced [184] the Swiss inhabitants are 
charged an additional 9 CHF per person per year for the next 25 years [232].  
 Although to date there are no discharge regulation for pharmaceuticals in 
the European Union, an European wide water policy started already in the year 
2000 [22]. This “Water Framework Directive” and its regulations concern the 
prioritization of potentially harmful substances (amongst other pharmaceuticals) 
and has already been extended with several directives and amendments. In the 
Directive 2013/39/EU for the first time a pharmaceutical (diclofenac) and a 
synthetic hormone (17-alpha-ethinylestradiol) were added to the so called ‘watch 
list’. This watch list comprises of potentially hazardous compounds for which it is 
recommended that monitoring and treatment solutions should receive extra 
attention with the objective to protect the aquatic environment and the human 
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health. Recently three antibiotics (azithromycin, clarithromycin and erythromycin) 
were added to the watch list via an amendment (Decision 2015/495/EU).  
To the best of my knowledge no policies and regulation have been 
implemented in other countries. Although there is a raise in scientific attention for 
micropollutants in various countries, this is commonly not reflected in implemented 
policies. For instance the current environmental quality standard for surface water 
in China do not mention pharmaceuticals [185]. Similarly Singapore, Japan New 
Zealand and Australia have no specific legislation for the discharge of 
pharmaceuticals to the environment even though their water acts aim at reducing 
risks for human health [203]. Likewise, the primary objective of the United States 
Federal Clean Water Act is “to restore and maintain the chemical, physical and 
biological integrity of U.S. waters”, but the Act doesn’t include legislation on the 
monitoring or discharge of pharmaceuticals, and the Safe Drinking Water Act does 
neither. 
 
1.4 Pharmaceutical removal 
1.4.1 Current (biological) treatment 
WWTPs have a crucial role in the emissions of pharmaceuticals to surface 
waters [14, 125]. Moreover, they are one of the few main hubs in the entire water 
cycle. Hence, WWTPs are an ideal spot to prevent pharmaceutical emissions into 
the environment. Despite pharmaceutical removal is currently not a design 
parameter for WWTPs, various researchers have reported the removal of 
pharmaceuticals in WWTPs, indicating the potential of biological treatment [124, 
190, 238]. In general, high variations in pharmaceutical elimination efficiencies 
are found among different WWTPs which are typically linked to the WWTP design 
[47]. This suggests that pharmaceutical treatment can possibly improve when 
pharmaceutical removal would be regarded as a design parameter. Various WWTP 
characteristics and design parameters have therefore been studied to gain a better 
understanding of the underlying pharmaceutical removal mechanisms. Removal 
rates seem to depend on treatment plant configurations and parameters like 
biological nitrogen removal, diversity of the microbial community, hydraulic 
retention time, sludge retention time and the use of biofilm carriers [47, 49, 81, 
82, 123, 124, 241]. Moreover, redox conditions are also found to affect the 
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pharmaceutical removal [247]. Most pharmaceuticals are best degraded under 
aerobic conditions while others might need anoxic or anaerobic redox conditions 
[36, 83, 105]. Besides the design of a WWTP the characteristics of individual 
pharmaceuticals largely influences their fate during water treatment [312]. Within 
a given WWTP some pharmaceuticals are generally marginally removed (<5%) 
while others show removal percentages of over 95% [37, 287]. For instance, 
aspirin, estradiol, ibuprofen, and paracetamol are known to be effectively 
biodegraded during wastewater treatment, while crotamiton, diazepam and 
diclofenac are typically not eliminated [125]. In general, biodegradation and 
sorption are the mechanisms controlling pharmaceutical removal during biological 
wastewater treatment [267]. The biodegradability and sorption behaviour of an 
individual pharmaceutical largely depends on its chemical structure and physico-
chemical properties. The great variety in observed removal mechanisms can 
therefore be explained by the broad array of chemical structures and physico-
chemical properties of the pharmaceuticals (Table 1.1).  
 
1.4.2 Room for improvement within biological treatment  
The influence of the compound characteristics and the effect of the type of 
treatment plant configuration suggests that a variety of treatment conditions and 
processes with different modes of action might be needed for realising effective 
pharmaceutical removal. WWTPs could be upgraded or extended with additional 
treatment steps to reduce pharmaceutical emissions. On the one hand, this may 
be achieved by improving or extending current biological process. I hypothesize 
that this can be achieved by for instance the implementation of more diverse redox 
gradients over a treatment plant, oligotrophic zones for specific pharmaceutical 
degrading biomass, retention of specific biomass, non-continuous feeding (e.g. 
feed-famine regimes), longer hydraulic retention times, use of other biomass than 
activated sludge (e.g. fungi or algae). On the other hand, non-biological treatment 
processes can be applied for a better pharmaceutical removal.  
 
1.4.3 Chemical treatment 
Chemical treatment processes like advanced oxidation processes (AOPs) 
making use of photolysis, photocatalysis, ozone, hydrogen peroxide or Fenton 
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process, or sorptive processes like activated carbon (AC) addition or filtration can 
effectively eliminate pharmaceuticals [1, 164, 262]. Most chemical treatment 
processes originate from drinking water treatment, however they have also been 
successfully applied in wastewater treatment as a post-treatment step [109, 197, 
264, 293, 303, 329]. AOPs rely on the direct or indirect oxidation of a compound 
[225]. Oxidative processes like ozonation typically break down compounds into 
smaller fragments, but do not completely mineralize compounds into CO2 and H2O 
[293]. Moreover, in a complex matrix like wastewater ozone will not only react 
with the target compounds (e.g. pharmaceuticals) but also with other matrix 
constituents. This reduces the process efficiency and results in the formation of 
countless by-products which possibly expose a higher toxicity than the 
pharmaceuticals treated [208]. Ozonation is therefore often combined with a 
subsequent AC filtration step [90, 134, 218]. Though AOPs can effectively remove 
pharmaceuticals they require high energy and/or chemical inputs. Sorptive 
processes like AC filtration rely on the interaction of a sorbate (e.g. a 
pharmaceutical) with a sorbent like AC. These systems do not transform sorbates 
but bind them onto the AC sorbent [198]. High pharmaceutical removal efficiencies 
can be obtained by AC filtration, however removal efficiencies decrease over time 
due to saturation of the AC and not all pharmaceuticals are effectively removed 
[96]. Once the sorbent is saturated it should be replaced or regenerated as non-
regularly regenerated filters demonstrate low to nil pharmaceutical removal [244]. 
Disposal of saturated sorbent only shifts the problem, e.g. to landfilling, whereas 
regeneration requires high energy inputs. In summary, a possible solution to 
prevent pharmaceuticals entering the environment could be the upgrade of WWTPs 
supplemented with chemical treatment. Until now these processes have 
demonstrated higher removal efficiencies compared to biological treatment [164, 
222, 287]. Although chemical treatment processes are promising for 
pharmaceutical removal the wide scale implementation is hampered by some 
major issues. They require high energy, chemical or material inputs which all 
translate into high operational costs and are not environmentally sustainable. 
Moreover, these processes often result in the formation numerous unknown by-
products which possibly jeopardise the receiving aquatic environment to a greater 
extent than the compounds removed. 
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1.4.4 Combined treatment 
Biological and chemical treatment processes for pharmaceutical removal 
both have their downsides and limitations, e.g. incomplete pharmaceutical 
removal, high energy and chemical inputs, high operational costs, environmental 
unsustainability. A combination of complementary treatment processes, abating 
the limitations of individual processes, could therefore be a versatile alternative. 
Scott and Ollis [235] reviewed the literature on combined biological and chemical 
treatment processes for the removal of organic contaminants from water and 
concluded that combined process can have advantages over single processes. 
When economical, physical and technological strengths and limitations of individual 
processes are recognized, the synergy of complementary processes can be used 
to design a cost-effective combination of processes.  
In theory, avoiding the limitations and using the strengths of two different 
types of processes and to create synergy could be the combination of biological 
treatment and ozonation. The first is a cheap process but incapable of effectively 
removing all individual pharmaceuticals, e.g. clofibric acid and bezafibrate are 
known to be well removed, whereas diclofenac and carbamazepine are reported to 
be very poorly removed [124]. On the contrary, ozonation has high operational 
cost and results in by-product formation, for instance it hardly removes clofibric 
acid and bezafibrate, but effectively oxidises diclofenac and carbamazepine [264]. 
In addition, biological treatment can possibly be used to remove the harmful 
ozonation by-products as they are typically biodegradable [243].  
In practice, various combinations of processes have already been studied 
and applied for the removal of organic contaminants from water. Though these 
studies often report enhanced removal efficiencies compared to single processes, 
they merely focus on a single compound often in model (simple) matrices rather 
than on a mixture of compounds in a complex matrix like wastewater [46, 80, 93, 
107, 201, 297, 313]. Concerning the removal of a broad array of pharmaceuticals 
from wastewater, Hofman-Caris, et al. [109] found that anion exchange followed 
by UV/H2O2 treatment was a versatile combination of two chemical treatment 
processes. Biological activated carbon filtration, a combination of biological 
treatment and activated carbon filtration, was proven to effectively remove 
pharmaceuticals and reduce toxicity from WWTP effluents [217]. Ozonation 
followed by biological activated carbon filtration of WWTP effluent showed even 
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higher pharmaceutical removal [218]. Sand-filtration followed by ozonation of a 
secondary clarified effluent effectively removed estrogenicity, whereas sand-
filtration only or sand-filtration followed by a moving-bed bioreactor were less 
effective [99]. Oller, et al. [198] reviewed the combination of AOPs and biological 
treatment for wastewaters containing pharmaceuticals. They concluded that 
photocatalysis, ozonation and ultrasound oxidation were well studied and typically 
result in an increased biodegradability and a decreased toxicity. Moreover, they 
concluded that the potential of combinations of AOPs and biological treatment is 
still under exploited since not many cost-effective combinations of chemical and 
biological treatment are available.  
 
1.5 Knowledge gaps and research opportunities 
The need to prevent pharmaceutical emissions into the environment for the 
abovementioned reasons related to ecological risks and human health, stresses 
the necessity for versatile treatment processes to eliminate pharmaceuticals from 
wastewater. As the research on pharmaceutical removal only started some 
decades ago [263] combined with the wide variety in possible treatment processes 
[164], there are still numerous knowledge gaps on the fundamental and practical 
aspects of pharmaceutical removal. These knowledge gaps concern pressing 
questions on single treatment processes as well as on the combination of 
treatment processes.  
Taking into consideration that current WWTPs merely use biological 
treatment processes, this suggests that if biological pharmaceutical removal can 
be improved it would potentially be the most sustainable and cost-effective 
solution. First, within biological treatment, redox conditions are regarded as one 
of the key parameters in biological conversions [306]. Though the most prevalent 
redox conditions in biological processes at WWTPs (aerobic and anaerobic) are well 
studied [36, 83, 247], there is limited information on how specific redox conditions 
influence biodegradation and sorption behaviour of pharmaceuticals, which are 
regarded as the most important removal mechanisms during biological treatment. 
Second, the type and presence of organisms utilized in biological treatment 
is of great importance. Typical biological processes at WWTPs make use of 
activated sludge, which is in essence a diverse microbial population consisting of 
mainly bacteria which are loosely bound in a settable floc. As raw wastewater 
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contains multiple orders of magnitude more easy biodegradable compounds than 
pharmaceuticals, it is likely that organisms degrading complex substrates, such as 
pharmaceuticals, are easily outcompeted. Providing oligotrophic environments 
with minimal substrate competition is therefore hypothesized to be an effective 
strategy to enrich for pharmaceutical degrading microorganisms. Moreover, 
pharmaceuticals are typically present in the ng/L to µg/L range, these low 
substrate levels only support minimal microbial growth, therefore retention of 
organisms is of great importance to successfully operate biological treatment 
processes.  
In addition to the commonly used microbial populations in wastewater 
treatment, also other organisms can be employed for the typical objectives of a 
WWTP. One of the other organisms capable of wastewater treatment are green 
microalgae. These phototropic organisms are therefore utilized in some 
wastewater treatment configurations [3, 61, 100, 110]. Algal treatment is well 
studied for the effective removal and recovery of nutrients from highly 
concentrated wastewater streams like black water or urine [276, 285]. Little is 
known however, whether algae are capable of removing the high concentrations 
of pharmaceuticals which are also present in those streams [36, 157]. Moreover, 
as the recovered nutrients present in the algal biomass are potentially used as 
fertilizer in agriculture it is of great importance to known whether pharmaceuticals 
sorb onto the algal biomass to prevent their introduction into the food chain.  
As long as biological treatment does not form an adequate barrier against 
the majority of the pharmaceuticals present in sewage, further research is also 
needed on other treatment processes or combinations of them. As described 
above, combinations of complementary processes are found to have beneficial 
effects over single processes and therefore have a great potential to reduce 
pharmaceutical loads into the environment. Nonetheless, there is still a lack of 
sustainable and cost-effective combined treatment options which motivates the 
further investigation into these treatment processes.  
The work on algal treatment processes for wastewater treatment typically 
utilize photobioreactors to cultivate the algae [276, 285]. These reactors are 
illuminated to support algae growth, however the influence of illumination in 
photobioreactors on pharmaceutical removal is not well studied whereas it is 
known that photolysis in the natural environment can degrade pharmaceuticals 
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[140, 143]. As various removal mechanisms like algal degradation, microbial 
degradation, sorption to biomass and photolysis occur concurrently in 
photobioreactors, this provides an unique opportunity to study the synergy 
between biological and chemical treatment processes. 
Photocatalysis and biodegradation are known complementary processes for 
the removal of various organic contaminants such as quinolone, pyridine and 
pesticides from water [297, 311, 322, 323]. For a limited number of individual 
pharmaceuticals this combination has been studied [93, 201, 307], but for 
pharmaceutical mixtures the effectiveness of the combined treatment remains 
unknown. Moreover, photocatalytic processes commonly require considerable 
amounts of energy inputs and are thereby not very sustainable. Hence, it is of 
great importance to improve the resource efficiency, e.g. in an energy efficient 
combination with biological treatment, before this treatment process can find its 
way to large scale application in wastewater treatment. 
Ozonation and biological treatment is a potentially versatile combination of 
treatment processes for the removal of pharmaceuticals. Ozonation followed by 
biological treatment is well established in drinking water treatment [212, 293], but 
to a lesser extend in wastewater treatment [111, 329]. On the one hand, this is 
mainly due to the current absence of pharmaceutical removal requirements during 
wastewater treatment, whereas drinking water production requirements are much 
more strict. On the other hand, the composition of wastewater is highly different 
than drinking water sources like surface- or groundwater. Compared to matrices 
of drinking water sources, wastewater matrices (influent and effluent) typically 
consist of higher concentrations of a wide array of matrix constituents like organic 
matter, nutrients, trace elements and other chemicals such as pharmaceuticals, 
personal care products and pesticides. As ozonation targets multiple matrix 
constituents others than pharmaceuticals, post-treatment by ozonation is not very 
resource-efficient for the specific removal of pharmaceuticals. Most of the studies 
that investigated ozonation as tertiary WWTP step reported relatively low amounts 
of matrix constituents [111, 117, 329]. Matrices however, are known to be 
different at each individual treatment plant (e.g. due to different ‘clients’) and can 
also vary per geographical region (e.g. due to local water hardness and 
background natural organic matter). Getting a more comprehensive and local 
(Dutch) understanding of the versatility of this treatment is therefore of scientific 
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interest and can help decision makers in implementation of treatment processes. 
A well-studied aspect of ozonation in drinking water production is the formation of 
ozonation by-products. These are of concern as they potentially increase toxicity 
[118]. For ozonation in wastewater treatment toxicity aspects are studied to a 
lesser extent. Thus, besides increasing the resource efficiency, trapping or 
transforming the possibly harmful by-products is of great importance. Both issues 
motivate further research on the combination of ozonation and biological 
treatment and challenge researchers to come up with innovative ideas how to 
overcome the issues. 
In summary, there are still many knowledge gaps on how to enhance 
pharmaceutical removal by single and/or combined treatment processes. 
Inherently, this shows the potential of research opportunities to improve single 
processes and to search for synergetic combinations of processes. 
 
1.6 Objective of this dissertation 
To prevent future pharmaceutical emissions into the environment, adequate 
measures for the removal of pharmaceuticals from WWTP effluents need to be 
developed. Development of wide scale implementation of such measures is 
hampered by the fact that known biological and chemical removal processes result 
in incomplete removal, and that insufficient insight exists in the functioning and 
effectiveness of processes used in the synergetic use of combined treatment 
processes. Therefore, the objective of this dissertation is to contribute to a better 
understanding and the further development of treatment processes for the 
removal of pharmaceuticals from wastewater. 
 
1.7 Scope and outline of this dissertation 
This dissertation focuses on the research opportunities on single and 
combined processes for pharmaceutical removal. The experimental work of this 
dissertation aims at a better understanding of specific aspects of biological 
treatment processes, like the effect of redox conditions and the type of involved 
microorganisms, and the interaction between biological and chemical removal 
processes. Moreover, combinations of treatment processes were developed for a 
better pharmaceutical removal. Among the broad spectrum of pharmaceuticals a 
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limited amount was selected for the experimental work of this dissertation. 
Selection criteria were; consumption, occurrence in wastewater, physico-chemical 
properties and removal efficiencies during biological treatment. The selected 
pharmaceuticals are among the most sold in the Netherlands [283] and commonly 
found in wastewater [287]. Furthermore, they cover a wide range of physico-
chemical properties and their reported removal efficiencies in WWTPs range from 
high to low removal [164].  
The influence of specific redox conditions on the biological removal of 
pharmaceuticals is elucidated in Chapter 2 with a focus on the influence of redox 
conditions on biodegradation and sorption behaviour.  
In Chapter 3 we describe the combination of a mild photocatalytic treatment 
process and a subsequent biological treatment process for a resource-efficient 
pharmaceutical treatment. 
In Chapter 4 we present a three-step biological-ozone-biological process 
combining the strengths of biological treatment and ozonation with the aim to 
minimize the energy input and hydraulic retention time, while effectively removing 
pharmaceuticals and their associated toxicity. 
In Chapter 5 we focus on the removal of pharmaceuticals by algae in 
alternative sanitation systems. We investigated the effectiveness of an algal 
photobioreactor for the simultaneous removal of nutrients and pharmaceuticals. 
 Finally, in Chapter 6 findings and outcomes of the presented work in this 
dissertation are synthesized and reflected. An outlook on single and combined 
treatment processes for pharmaceutical removal is given, including the 
identification of current knowledge gaps and recommendations for further research 
and the scale up of the processes studied in this dissertation. Attention is paid to 
the developments in analytical chemistry, including metabolite and transformation 
product identification, and the need for effect based removal strategies. Moreover, 
developments in other fields such as restrictive discharge legislation, the role and 
awareness of other actors in the pharmaceutical chain and the benefits of 
alternative sanitation systems are discussed as environmental problem solving 
generally requires a multidisciplinary approach. All together, the synergy between 
biological and chemical treatment processes and developments in legislation, 
awareness of other actors and benefits of alternative sanitation systems can be a 
boost towards lower pharmaceutical emissions into the environment.  
IGeneral introduction 
26 
 
interest and can help decision makers in implementation of treatment processes. 
A well-studied aspect of ozonation in drinking water production is the formation of 
ozonation by-products. These are of concern as they potentially increase toxicity 
[118]. For ozonation in wastewater treatment toxicity aspects are studied to a 
lesser extent. Thus, besides increasing the resource efficiency, trapping or 
transforming the possibly harmful by-products is of great importance. Both issues 
motivate further research on the combination of ozonation and biological 
treatment and challenge researchers to come up with innovative ideas how to 
overcome the issues. 
In summary, there are still many knowledge gaps on how to enhance 
pharmaceutical removal by single and/or combined treatment processes. 
Inherently, this shows the potential of research opportunities to improve single 
processes and to search for synergetic combinations of processes. 
 
1.6 Objective of this dissertation 
To prevent future pharmaceutical emissions into the environment, adequate 
measures for the removal of pharmaceuticals from WWTP effluents need to be 
developed. Development of wide scale implementation of such measures is 
hampered by the fact that known biological and chemical removal processes result 
in incomplete removal, and that insufficient insight exists in the functioning and 
effectiveness of processes used in the synergetic use of combined treatment 
processes. Therefore, the objective of this dissertation is to contribute to a better 
understanding and the further development of treatment processes for the 
removal of pharmaceuticals from wastewater. 
 
1.7 Scope and outline of this dissertation 
This dissertation focuses on the research opportunities on single and 
combined processes for pharmaceutical removal. The experimental work of this 
dissertation aims at a better understanding of specific aspects of biological 
treatment processes, like the effect of redox conditions and the type of involved 
microorganisms, and the interaction between biological and chemical removal 
processes. Moreover, combinations of treatment processes were developed for a 
better pharmaceutical removal. Among the broad spectrum of pharmaceuticals a 
Chapter 1 
27 
 
limited amount was selected for the experimental work of this dissertation. 
Selection criteria were; consumption, occurrence in wastewater, physico-chemical 
properties and removal efficiencies during biological treatment. The selected 
pharmaceuticals are among the most sold in the Netherlands [283] and commonly 
found in wastewater [287]. Furthermore, they cover a wide range of physico-
chemical properties and their reported removal efficiencies in WWTPs range from 
high to low removal [164].  
The influence of specific redox conditions on the biological removal of 
pharmaceuticals is elucidated in Chapter 2 with a focus on the influence of redox 
conditions on biodegradation and sorption behaviour.  
In Chapter 3 we describe the combination of a mild photocatalytic treatment 
process and a subsequent biological treatment process for a resource-efficient 
pharmaceutical treatment. 
In Chapter 4 we present a three-step biological-ozone-biological process 
combining the strengths of biological treatment and ozonation with the aim to 
minimize the energy input and hydraulic retention time, while effectively removing 
pharmaceuticals and their associated toxicity. 
In Chapter 5 we focus on the removal of pharmaceuticals by algae in 
alternative sanitation systems. We investigated the effectiveness of an algal 
photobioreactor for the simultaneous removal of nutrients and pharmaceuticals. 
 Finally, in Chapter 6 findings and outcomes of the presented work in this 
dissertation are synthesized and reflected. An outlook on single and combined 
treatment processes for pharmaceutical removal is given, including the 
identification of current knowledge gaps and recommendations for further research 
and the scale up of the processes studied in this dissertation. Attention is paid to 
the developments in analytical chemistry, including metabolite and transformation 
product identification, and the need for effect based removal strategies. Moreover, 
developments in other fields such as restrictive discharge legislation, the role and 
awareness of other actors in the pharmaceutical chain and the benefits of 
alternative sanitation systems are discussed as environmental problem solving 
generally requires a multidisciplinary approach. All together, the synergy between 
biological and chemical treatment processes and developments in legislation, 
awareness of other actors and benefits of alternative sanitation systems can be a 
boost towards lower pharmaceutical emissions into the environment.  
 29 
 
 29 
 

A modified version of this chapter has been published as
 
Arnoud de Wilt*, Yujie He*, Nora Sutton, Alette Langenhoff and Huub Rijnaarts. 
Sorption and biodegradation of six pharmaceutically active compounds under four different 
redox conditions. Chemosphere, 193 (2018) 811-819 
* Equally contributing authors
Chapter 2
Sorption and biodegradation of pharmaceuticals under 
different redox conditions 
Influence of redox conditions on biodegradation and sorption 
32 
 
Abstract 
This study explored the removal of six pharmaceuticals in lab-scale 
experiments with sediments under four redox conditions, namely aerobic, nitrate 
reducing, sulfate reducing, and methanogenic conditions using batch and column 
set-ups. Redox conditions were found to influence pharmaceutical removal by 
sorption and biodegradation. The most optimal pharmaceutical removal was 
observed at the outer ranges of the redox spectrum, i.e. either aerobic or deeply 
anaerobic (sulfate reducing and methanogenic conditions), whereas nitrate 
reducing conditions were found least effective for pharmaceuticals biodegradation 
and sorption. For instance, sorption coefficient Kd values for metoprolol in column 
experiments were 90, 65, 42 and 11 L/kg for sulfate reducing, methanogenic, 
aerobic and nitrate reducing conditions, respectively. For the same conditions Kd 
values for propranolol were 101, 94, 55 and 55 L/kg, respectively. As expected, 
biodegradation efficiencies were highest under aerobic conditions, showing >99% 
removal of caffeine and naproxen, but no removal for propranolol and 
carbamazepine. The adaptive capacity of sediment was demonstrated by pre-
exposure to pharmaceuticals leading to improved pharmaceutical biodegradation. 
The results of this study indicate the necessity to combine diverse redox 
conditions, including aerobic conditions, for maximizing pharmaceutical removal 
by sorption and biodegradation. Furthermore, our findings stress the need for 
additional treatment measures as recalcitrant pharmaceuticals are not effectively 
removed under any redox condition. 
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2.1 Introduction 
Pharmaceuticals were developed to target specific human physiological 
pathways [180]. After consumption, residual pharmaceuticals or/and their 
metabolites are excreted from human bodies into sewage systems. Conventional 
wastewater treatment plants (WWTPs) are not specifically designed for removing 
pharmaceuticals [230]. Therefore, pharmaceuticals that are not completely 
removed are discharged to the aquatic environment and may even reach drinking 
water intakes [40]. In this context, efficient post-treatment technologies for 
removing pharmaceuticals are needed and emerging. 
Biological technologies are robust and attractive as post-treatment 
processes. However, processes involved in biotechnological systems are more 
complex and require a proper understanding to come to a robust design and 
operation. In most biological technologies, both sorption and biodegradation play 
an important role in removing organic contaminants. It is well known that organic 
matter, temperature and pH affect sorption of organic contaminants [183], 
however the effect of redox conditions (electron acceptors) on sorption behaviour 
on organic contaminants is less known. On the contrary for biodegradation, specific 
electron acceptors select for specific microbial communities with different targeted 
functions, and thereby strongly influence the biological removal of organic 
contaminants [84]. For example, transformation of sulfamethoxazole was reported 
to strongly depend on the occurrence of nitrate reducing conditions and be 
sensitive to the concentration of nitrate [21].  
Although redox conditions are identified as one of the controlling factors for 
biodegrading pharmaceuticals, the reported dependencies of removal processes 
on redox conditions vary significantly for specific pharmaceuticals for various 
reasons. Firstly, most of the previous works only study the removal efficiencies of 
pharmaceuticals under oxic and anoxic conditions without identifying the dominant 
terminal electron acceptor [309, 330]. Secondly, results reported for 
pharmaceutical biodegradation in terms of redox effects are often contradictory. 
For example, sulfamethoxazole (SMX) was proven to be more rapidly eliminated 
under anoxic conditions than under aerobic conditions in bank filtration in the work 
of Heberer et al. [106], while Baumgarten et al. [24] concluded that SMX was 
more rapidly removed under aerobic conditions compared to anoxic conditions. 
Conkle et al. [53] concluded that degradation of carbamazepine (CBZ) was 
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enhanced under aerobic conditions as compared to anaerobic conditions in 
sediment collected from three types of wetlands; in contrast, Hai et al. [101] 
reported that CBZ showed degradation only in an anoxic environment instead of 
under oxic conditions in a membrane bioreactor. Furthermore, the various studies 
that report the effects of redox conditions on pharmaceutical removal are difficult 
to compare as they use different reactor setups, different concentrations and 
different compounds.  
Thus, there is a significant knowledge gap on comparative effects of redox 
conditions on removal of pharmaceuticals in biotechnological systems. To get a 
more comprehensive understanding of the influence of selected redox conditions 
on specific pharmaceutical removal via sorption and biodegradation, it is necessary 
to investigate this in defined experimental setups varying the applied redox 
conditions. Therefore, the objective of this study is to elucidate the influence of 
redox conditions on removal mechanisms of six pharmaceuticals applying four 
specific conditions of the wide redox spectrum. Batch and column systems were 
used for controlled biological tests under aerobic, nitrate reducing, sulfate 
reducing, and methanogenic conditions. The results of this study give insight into 
understanding the influence of redox conditions on pharmaceutical removal in 
biotechnological systems. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and regents  
Pharmaceuticals metoprolol (MET), caffeine (CAF), propranolol (PRO), 
carbamazepine (CBZ), naproxen (NAP), ibuprofen (IBP) were purchased from 
Sigma-Aldrich (U.S.). Details of the pharmaceutical stock solution, other chemicals 
used and physio-chemical properties of pharmaceuticals are given in Text S2.1 
and Table S2.1. 
  
2.2.2 Experimental setup 
2.2.2.1 Sediment 
Sediment of constructed wetlands (CWs) at WWTPs Hapert and Land van 
Cuijk (both in the Netherlands) was collected as a solid phase of the batch and 
column systems. In addition, the sediments contain microorganisms that serve as 
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a natural inoculant of the biologically active laboratory systems. CWs at both 
facilities have received WWTP effluent for several years. Sediment dry matter (DM) 
and organic matter (OM) content were determined gravimetrically after drying at 
105 °C following combustion at 550 °C. 
The aerobic column was inoculated with upper layer sediment (0-5 cm) with 
an OM content of 6.2 g OM/kg DM. Sediment at a depth of 10-20 cm below the 
surface level with an OM content of 16.2 g OM/kg DM was collected to inoculate 
the anaerobic columns. A mixture of upper, deeper layer, and rhizosphere 
sediment was used for batch experiments containing 19 g OM/kg DM. 
Concentrations of the six pharmaceuticals varied from 0 to 777 ng/g in CW 
sediment [104]. 
  
2.2.2.2 Batch experiments 
Four different media were used to enrich dominant bacteria in different 
redox conditions. Media were prepared according to previous works for aerobic 
(Table S2.2), nitrate reducing [79], sulfate reducing [145], and methanogenic 
conditions [112]. The ionic strength of media was calculated by OLI Studio 
Analyzer 9.2 software. In each batch bottle, 120 mL medium was mixed with 15 g 
wet sediment as inoculum. Batches were spiked with a mixture of six 
pharmaceuticals at 1 mg/L each. For analytical reasons the spiking concentration 
is far above the environmental relevant concentrations of pharmaceuticals, as also 
been applied in previous works [2, 119]. The gas phase of each bottle was filled 
with either atmospheric air for aerobic conditions or CO2/N2 (20/80, v/v) for 
anaerobic conditions. Among the four redox conditions, no extra carbon source 
was added except for the pharmaceuticals. Abiotic controls contained 1.3 g/L of 
sodium azide in aerobic batch bottles and 0.3 g/L of mercury chloride in anaerobic 
bottles to supress microbial activity.  
The aerobic batch experiment lasted for six weeks and the anaerobic batch 
lasted for three months. Samples of week 0 were collected the day after spiking 
to ensure a homogeneous distribution of pharmaceuticals. In order to determine 
the role of microbial adaptation, mixed pharmaceuticals were re-spiked three times 
in the aerobic batches (biotic and abiotic) for enrichment after week 6. Batch 
bottles were incubated on a shaker (120 rpm) at 20°C. Batch bottles were 
incubated in the dark during the experiment to prevent photolysis. Compared to 
II
Influence of redox conditions on biodegradation and sorption 
34 
 
enhanced under aerobic conditions as compared to anaerobic conditions in 
sediment collected from three types of wetlands; in contrast, Hai et al. [101] 
reported that CBZ showed degradation only in an anoxic environment instead of 
under oxic conditions in a membrane bioreactor. Furthermore, the various studies 
that report the effects of redox conditions on pharmaceutical removal are difficult 
to compare as they use different reactor setups, different concentrations and 
different compounds.  
Thus, there is a significant knowledge gap on comparative effects of redox 
conditions on removal of pharmaceuticals in biotechnological systems. To get a 
more comprehensive understanding of the influence of selected redox conditions 
on specific pharmaceutical removal via sorption and biodegradation, it is necessary 
to investigate this in defined experimental setups varying the applied redox 
conditions. Therefore, the objective of this study is to elucidate the influence of 
redox conditions on removal mechanisms of six pharmaceuticals applying four 
specific conditions of the wide redox spectrum. Batch and column systems were 
used for controlled biological tests under aerobic, nitrate reducing, sulfate 
reducing, and methanogenic conditions. The results of this study give insight into 
understanding the influence of redox conditions on pharmaceutical removal in 
biotechnological systems. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and regents  
Pharmaceuticals metoprolol (MET), caffeine (CAF), propranolol (PRO), 
carbamazepine (CBZ), naproxen (NAP), ibuprofen (IBP) were purchased from 
Sigma-Aldrich (U.S.). Details of the pharmaceutical stock solution, other chemicals 
used and physio-chemical properties of pharmaceuticals are given in Text S2.1 
and Table S2.1. 
  
2.2.2 Experimental setup 
2.2.2.1 Sediment 
Sediment of constructed wetlands (CWs) at WWTPs Hapert and Land van 
Cuijk (both in the Netherlands) was collected as a solid phase of the batch and 
column systems. In addition, the sediments contain microorganisms that serve as 
Chapter 2 
35 
 
a natural inoculant of the biologically active laboratory systems. CWs at both 
facilities have received WWTP effluent for several years. Sediment dry matter (DM) 
and organic matter (OM) content were determined gravimetrically after drying at 
105 °C following combustion at 550 °C. 
The aerobic column was inoculated with upper layer sediment (0-5 cm) with 
an OM content of 6.2 g OM/kg DM. Sediment at a depth of 10-20 cm below the 
surface level with an OM content of 16.2 g OM/kg DM was collected to inoculate 
the anaerobic columns. A mixture of upper, deeper layer, and rhizosphere 
sediment was used for batch experiments containing 19 g OM/kg DM. 
Concentrations of the six pharmaceuticals varied from 0 to 777 ng/g in CW 
sediment [104]. 
  
2.2.2.2 Batch experiments 
Four different media were used to enrich dominant bacteria in different 
redox conditions. Media were prepared according to previous works for aerobic 
(Table S2.2), nitrate reducing [79], sulfate reducing [145], and methanogenic 
conditions [112]. The ionic strength of media was calculated by OLI Studio 
Analyzer 9.2 software. In each batch bottle, 120 mL medium was mixed with 15 g 
wet sediment as inoculum. Batches were spiked with a mixture of six 
pharmaceuticals at 1 mg/L each. For analytical reasons the spiking concentration 
is far above the environmental relevant concentrations of pharmaceuticals, as also 
been applied in previous works [2, 119]. The gas phase of each bottle was filled 
with either atmospheric air for aerobic conditions or CO2/N2 (20/80, v/v) for 
anaerobic conditions. Among the four redox conditions, no extra carbon source 
was added except for the pharmaceuticals. Abiotic controls contained 1.3 g/L of 
sodium azide in aerobic batch bottles and 0.3 g/L of mercury chloride in anaerobic 
bottles to supress microbial activity.  
The aerobic batch experiment lasted for six weeks and the anaerobic batch 
lasted for three months. Samples of week 0 were collected the day after spiking 
to ensure a homogeneous distribution of pharmaceuticals. In order to determine 
the role of microbial adaptation, mixed pharmaceuticals were re-spiked three times 
in the aerobic batches (biotic and abiotic) for enrichment after week 6. Batch 
bottles were incubated on a shaker (120 rpm) at 20°C. Batch bottles were 
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the spiked pharmaceutical levels, the initial pharmaceutical concentrations in the 
sediment were minute and thus desorption of the initial pharmaceuticals to the 
liquid phase is negligible. Sorption coefficient Kd was calculated from the abiotic 
controls as the ratio of the pharmaceuticals concentration in the sediment phase 
and in the water phase at equilibrium. The concentrations of sorbed 
pharmaceuticals were calculated from the measured water phase concentrations 
based on mass balance. 
 
2.2.2.3 Column experiments 
Column experiments were conducted in four continuous-fed upflow soil 
columns (Figure 2.1). Identical to the batch experiments, aerobic, nitrate reducing, 
sulfate reducing and methanogenic conditions were tested. Cylindrical glass 
columns (0.23 L) were packed with sediment containing 292 g DM and 230 g DM 
for respectively aerobic and anaerobic experiments. Sediment was retained in the 
columns by sintered glass filters (pore size 40-100 μm). The packed sediment was 
circularly homogenised biweekly, while keeping sediment layers at their depths in 
the columns. This is needed to prevent bypass flows through the columns. Columns 
were fed with medium at a flow rate of 9.8±0.4 mL/h, resulting in a hydraulic 
retention time of 8.2±0.3 h. For each redox condition, specific media were 
prepared (Table S2.2), which contained about 100 μg/L pharmaceuticals during 
the experiment of 110 days. Prior to the experiment columns were run two weeks 
on media without pharmaceuticals to allow redox conditioning. Columns and media 
were kept in the dark during the experiment to prevent photolysis. 
Influent and effluent grab samples were collected for chemical analysis 
within 24 hours from each other per time point. Pharmaceutical removal was 
calculated based on effluent concentrations per time point over the averaged 
influent concentration of the entire experiment to deal with fluctuations in the 
influent concentration. Sorption parameter values (specific sorption coefficient Kd) 
were determined for sorptive pharmaceuticals by calculating the retardation factor 
from the time point when the effluent pharmaceutical concentration reached fifty 
percent of the influent concentration.  
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Figure 2.1 Experimental set-up of the column experiments.  
 
2.2.3 Sample collection and analysis 
Liquid samples were taken from batch media and column influents and 
effluents for pharmaceutical measurements. Samples collected from batch bottles 
were centrifuged at 10 000 rpm for 10 min and stored at -20 °C prior to analysis. 
Before analysis liquid samples of column experiments were pre-treated by solid 
phase extraction (SPE) to allow the detection of low concentrations in column 
effluents. Oasis HLB SPE cartridges (6 cc/60 mg, Waters, U.S.) were pre-
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conditioned with 5 mL methanol and equilibrated with 5 mL buffered deionized 
water (10 μL buffer/mL, pH=10, Merck, Germany). Cartridges were loaded with 3 
mL and 9 mL for influent and effluent samples, respectively. Loaded cartridges 
were washed with 5 mL buffered deionized water and eluted with 10 mL 25% 
NH4OH: methanol (8/92, v/v). Eluates were evaporated till dryness under a gentle 
nitrogen flow. Samples were reconstituted in 1 mL 3.6% methanol. Prior to SPE, 
10,11-dihydrocarbamazepine was spiked to samples as an internal standard. 
Pharmaceutical analysis was conducted on a liquid chromatograph with a 
diode array detector as described by He et al. [103]. Quantification was based on 
the internal standard and external calibration standards. SPE recoveries for all 
compounds in all samples were within 85-115% and thereby valid for 
quantification. 
Concentrations of nitrite, nitrate, and sulfate were measured by ion 
chromatography. Before measurement, samples were filtered using a 0.45 μm 
cellulose filter (VWR, U.S.) and diluted five times with MilliQ water. A Dionex ICS-
2100 IC system (Thermo, U.S.) was used for analysis. The system was equipped 
with an anion exchange column (Dionex, IonPac AS19, 4×250 mm), where the 
anions were separated using a hydroxide gradient. The eluent was made 
automatically using the eluent generator configured with a KOH cartridge (Dionex 
P/N 058900) and deionized water as the carrier. Detection was done by a DS6 
Heated conductivity cell. 
Oxygen and methane from the headspace of batches were analysed on a 
gas chromatograph. The instrument (GC-2010, Shimadzu, Japan) contained a 
parallel combination column: Porabond Q (50 m x 0.53 mm; 10 µm) and Molsieve 
5A (25 m x 0.53 mm; 50 µm). The carrier gas was helium and operated at 0.95 
bar. Column temperature was 80°C, detector temperature was 150°C, and 
injection temperature was 120°C. Pressure in the batch was measured by a digital 
pressure meter (GMH 3151, Greisinger) for calculating gas volume. In the aerobic 
column dissolved oxygen was measured by optical oxygen meter Fibox 3 trace 
(PreSens, Germany) fixed near the outlet of the column. For methanogenic column 
experiments, dissolved methane in liquid effluent samples was turned into gaseous 
methane as described by Zhang et al. [319] and analysed by GC as described 
above.  
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2.3 Results  
2.3.1 Redox conditions 
Consumption of electron acceptors and accumulation of respiration products 
were observed in all batches and columns (Figure S2.1). Under aerobic conditions, 
O2 consumption was observed. Nitrate and sulfate consumption were detected 
under nitrate and sulfate reducing conditions, respectively. Production of CH4 was 
observed under methanogenic conditions. These results indicated that the desired 
redox conditions were achieved.  
 
2.3.2 Removal of pharmaceuticals  
2.3.2.1 Batch systems 
Outcomes from abiotic controls are used to characterize the sorption 
capacity of the used sediment for targeted pharmaceuticals. In general, a high 
sorption capacity of CW sediment was found for NAP, CAF, PRO, and MET while 
CBZ and IBP were much less sorbed (Table 2.1). Sorption of pharmaceuticals 
under aerobic conditions were not used to compare with anaerobic conditions, as 
the sorption did not achieve equilibrium under aerobic conditions while it did under 
anaerobic condition due to the longer cultivation. When comparing pharmaceutical 
sorption under different anaerobic redox conditions, nitrate reducing conditions 
showed lower sorption capacity for MET, NAP, and CAF compared to sulfate 
reducing and methanogenic conditions. 
Biodegradation in batches was determined by comparing biotic and abiotic 
removal efficiencies. Under aerobic conditions, MET, CAF, NAP and IBP were almost 
completely removed within 6 weeks, which was mainly contributed to 
biodegradation as sorption only contributed to less than 30% (Table 2.1). In 
comparison, PRO and CBZ were poorly biodegraded considering their similar biotic 
and abiotic removal. Under anaerobic conditions, only CAF was readily biodegraded 
under nitrate and sulfate reducing conditions. Removal of CAF under methanogenic 
conditions was mainly caused by sorption (Table 2.1). Similarly, the observed 
removal of PRO, NAP, and MET was a result of their high sorption rather than 
biodegradation. Under all anaerobic conditions IBP and CBZ were poorly removed 
in the biotic and abiotic batches. 
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capacity of the used sediment for targeted pharmaceuticals. In general, a high 
sorption capacity of CW sediment was found for NAP, CAF, PRO, and MET while 
CBZ and IBP were much less sorbed (Table 2.1). Sorption of pharmaceuticals 
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showed lower sorption capacity for MET, NAP, and CAF compared to sulfate 
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To determine the role of microbial adaptation, the aerobic inoculum in 
batches was enriched to select for pharmaceutical removal by re-spiking 
pharmaceuticals. During the first six weeks, NAP and IBP were approximately 60-
70% removed within one week and complete removal was reached at week 3 
(Figure 2.2). After re-spiking, complete removal of NAP and IBP was reached within 
one week. This was mainly contributed to biodegradation as sorption almost 
achieved saturation after re-spiking (Figure S2.2). Therefore, microbial adaptation 
by pre-exposure did accelerate the biodegradation of NAP and IBP. Half-lives of 
NAP and IBP were 1.0 and 1.8 days, respectively; half removal of MET and CAF 
reached less than 1 day (Figure S2.3).  
 
Table 2.1 Biotic and abiotic removal (%) of pharmaceuticals in batches under different 
redox conditions: 6 weeks cultivation under aerobic conditions; 3 months cultivation under 
anaerobic redox conditions. 
Redox condition Type PRO MET CAF NAP IBP CBZ 
Aerobic 
Biotic 81 95 100 100 96 43 
Abiotic 55 29 27 15 25 22 
Nitrate reducing 
Biotic 55 -9a 94 14 -9 -14 
Abiotic 77 -32 27 26 25 28 
Sulfate reducing 
Biotic n.d.b 56 95 94 -1 -16 
Abiotic n.d. 60 48 93 -5 24 
Methanogenic 
Biotic 66 52 95 94 5 3 
Abiotic 67 32 85 87 -3 22 
a - Negative removal might be caused by analytical deviation; b - Not determined as the 
PRO concentration under sulfate reducing conditions was accidently very low (0.05 mg/L), 
which is close to the detection limit. 
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Figure 2.2 Removal of naproxen and ibuprofen under aerobic condition with re-spike of 
pharmaceuticals at day 46, 84, and 95.  
 
2.3.2.2 Column systems 
Different removal patterns were observed for individual pharmaceuticals in 
columns among the tested redox conditions (Figure 2.3). Main removal 
mechanisms were interpreted based on the observed removal patterns. Sorption 
was indicated to be a dominating removal process when initial pharmaceutical 
removal was followed by breakthrough of that compound. Biodegradation was 
identified by the presence of a lag phase, significant removal and absence of 
subsequent breakthrough behaviour. IBP and CBZ for which no significant sorption 
or biodegradation was observed in any of the columns were classified as persistent 
(Figure 2.3).  
Significant removal (>95%) of PRO and MET followed by compound 
breakthrough was apparent under all redox conditions (Figure 2.3). Therefore, 
sorption was identified to be their dominant removal mechanism. Sorption of PRO 
and MET appears to be affected by the applied redox conditions. Methanogenic and 
sulfate reducing conditions indicated better sorption compared to aerobic and 
nitrate reducing conditions for PRO and MET. Especially the removal of MET under 
nitrate reducing conditions was limited compared to the other anaerobic redox 
conditions whereas the sediment was identical.  
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CAF appeared initially to be removed by sorption in each column (65-99%) 
(Figure 2.3). However, the sorption capacity of the sediment towards CAF was low 
compared to PRO and MET as breakthrough behaviour was observed after day 4 
in all columns. Under all redox conditions, biodegradation of CAF took place after 
a lag phase: under aerobic and nitrate reducing conditions the lag phase lasted 27 
days, while only after 67 days an increase in removal was found in the sulfate 
reducing and methanogenic columns. 
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Figure 2.3 Removal of pharmaceuticals under different redox conditions in continuous 
flow-through columns: a) PRO; b) MET; c) CAF; d) NAP; e) IBP; f) CBZ. Negative removals 
are due to temporal fluctuations in influent concentrations. 
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The removal of NAP showed significant differences among the tested redox 
conditions. Complete NAP removal (>99%) was achieved in the aerobic column 
after a lag phase of 27 days. The presence of the lag phase followed by the 
continuously high removal indicates that biodegradation was the main removal 
mechanisms for NAP under aerobic conditions. Insignificant NAP removal (<25%) 
was observed under nitrate reducing conditions (Figure 2.3). In the sulfate 
reducing and methanogenic columns, a constant NAP removal throughout the 
experiment of around 80% was found. This phenomenon could not be attributed 
to sorption, as there was neither breakthrough of NAP nor a constant complete 
NAP removal. Chemical NAP removal by the reactor medium was also excluded as 
demonstrated in a separate test. Therefore most likely biodegradation is the main 
removal mechanism for NAP under sulfate reducing and methanogenic conditions. 
Why the removal did not improve over time, as would be expected due to the 
growth of more specialized NAP degrading microorganisms in a biological system, 
is not fully understood. 
 
2.4 Discussion 
2.4.1 Sorption of pharmaceuticals 
In both batches and columns, stronger sorption was indicated for PRO, MET 
and CAF while CBZ and IBP showed no significant sorption. NAP was highly sorbed 
in batches under sulfate reducing and methanogenic conditions but not in columns. 
Values of pharmaceutical sorption coefficient Kd were calculated for batch systems 
under all anaerobic conditions. In columns the breakthrough behaviour of PRO, 
MET and CAF allowed the calculation of the retardation factor and Kd. All these Kd 
values were compared to literature data on sorption behaviour of target 
pharmaceuticals in soils and sediments (Figure 2.4). Kd values found in this study 
are in accordance with reported literature values, except for MET in columns. Like 
coefficients from literature, we also demonstrate that PRO, CAF and MET sorbed 
more readily than NAP, CBZ, and IBP (median, Figure 2.4).  
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Figure 2.4 Comparison of sorption coefficients Kd between this study and literature [23, 
53, 68, 70, 159, 166, 170, 219, 231, 296, 308, 310, 320, 324]. For literature values of 
PRO, MET, CAF, NAP, IBP and CBZ, n= 12, 7, 6, 15, 19, and 8, respectively. The box plot 
shows the values found in literature in maximum, third quartile, median, first quartile, and 
minimum. The squares, triangles, crosses and circles represent the values for the different 
redox conditions in batch (no filling) and column (filled). 
 
Sorption of pharmaceuticals was reported to depend on their physico-
chemical properties, such as hydrophobicity and molecular charge [35]. In this 
study, we found that pharmaceutical sorption by the sediment is more related to 
the molecular charge of pharmaceuticals than their hydrophobicity. To characterize 
the hydrophobicity, the apparent partitioning coefficient Log Dow (Table S2.1) was 
applied to modify the octanol-water partition coefficients Log Kow with pH [149]. 
However, pharmaceutical sorption did not correlate with Log Dow (Figure S2.4). 
Based on pKa values (Table S2.1) and the pH range in our study (pH = 6.8-7.5), 
CBZ has no charge, IBP and NAP are negatively charged, while the other three 
pharmaceuticals are positively charged. Most sediment matrix components are 
negatively charged [166, 310]. This likely explains why the cationic 
pharmaceuticals (CAF, PRO, MET) showed a stronger tendency to sorb compared 
to anionic (IBP) and neutral species (CBZ). The high sorption of anionic NAP in 
batches might be caused by the OM present in the sediment. Similar results were 
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found by Martínez-Hernández, et al. [166]. These authors observed that sorption 
onto the inorganic surface of sediment was the predominant sorption mechanism 
for all positively and negatively charged pharmaceuticals examined with the 
exception of NAP, which was partitioned to OM instead. The higher OM content in 
batches in this study might explain its higher sorption compared to the columns. 
The variety among the reported Kd values per pharmaceutical in literature 
(Figure 2.4) are hypothesized to be related to the different experimental 
conditions, e.g. different soils and sediments [2]. By the unique experimental 
design of this study, we showed a strong influence of the redox conditions on the 
experimentally determined Kd values (Figure 2.4). Anaerobic column experiments 
were inoculated with the same inoculum. Similarly, all anaerobic batches were 
inoculated with the same sediment. However, different pharmaceutical sorption 
coefficients were found under different anaerobic redox conditions in both batches 
and columns (Figure 2.4). Sorption of NAP in batches was found to be lowest under 
nitrate reducing conditions and highest under sulfate reducing conditions. A similar 
phenomenon was found for PRO sorption in columns and MET sorption in both 
systems that followed the order nitrate reducing < methanogenic < sulfate 
reducing conditions. In both systems, sorption of CAF followed the order nitrate 
reducing < sulfate reducing < methanogenic conditions.  
The sorption differences under various anaerobic redox conditions could not 
be explained by the characteristics of the media we applied, such as ionic strength. 
Among all pharmaceuticals investigated in batches, only CAF sorption showed to 
be inversely correlated to ionic strength with 149.5, 108.1 and 63.8 mmol/L under 
nitrate reducing, sulfate reducing and methanogenic conditions, respectively. 
However, the correlation identified for CAF in batches was not observed in 
columns, where ionic strength are similar under three anaerobic conditions (50.4, 
69.3, and 42.6 mmol/L under nitrate reducing, sulfate reducing and methanogenic 
conditions, respectively). Overall, among all factors influencing sorption behaviour, 
redox conditions and molecular charge are found to dictate sorption behaviour in 
this study.  
Sorption coefficients Kd of MET and CAF under different redox conditions 
correlated between batches and columns (Figure 2.5), which indicates a 
consistency among the two experimental systems. However, the Kd variations 
between pharmaceuticals seem to be influenced by the experimental system, as 
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correlated between batches and columns (Figure 2.5), which indicates a 
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between pharmaceuticals seem to be influenced by the experimental system, as 
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the sorption coefficients of individual pharmaceuticals were not distributed along 
the 1:1 line (Figure 2.5). Batch experiments are commonly conducted to predict 
the sorption behaviour of target compounds in continuous systems, however our 
results demonstrate a high system dependency of the determined Kd values, which 
hampers the direct translation of Kd from batch to continuous systems. Thus, our 
data show that a variability in experimentally determined Kd values per 
pharmaceutical can be introduced by differences in redox conditions and in 
experimental system. As the effect of redox conditions and experimental system 
on sorption behaviour of pharmaceuticals is rarely described before, further studies 
need to be conducted to understand the underlying mechanisms. 
 
 
Figure 2.5 Linear relationship of sorption coefficients between batch and column 
experiments under different anaerobic redox conditions. 
 
Sorption coefficients Kd in our column study show that breakthrough is 
expected in sediment based applications. For the most sorptive pharmaceutical, 
PRO in this study, saturation of sediment sorption sites occurred after 
approximately 300 pore volumes under sulfate reducing conditions. Ramil et al. 
[213] demonstrated that sorption isotherms of PRO and MET to river and stream 
sediments are linear between 2-200 μg/L. For linear sorption behaviour retardation 
factors are independent on the pharmaceutical concentration. Thus, reflecting on 
sediment based applications treating pharmaceuticals in WWTP effluents that are 
generally in the same concentration range, the sorption capacity of sorptive 
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pharmaceuticals like PRO will reach saturation after approximately 300 pore 
volumes. 
 
2.4.2 Biodegradation of pharmaceuticals 
Aerobic batch and column experiments both demonstrated an effective CAF 
and NAP biodegradation. Their significant biodegradation is consistent with their 
biodegradation in soil columns reported by Kim et al. [130]. Additionally, in 
batches IBP and MET were biodegraded, whereas in columns no significant IBP 
removal was observed and MET was removed by sorption. The poor removal of 
IBP is contrary to what other authors reported [144], most probably due to 
insufficient oxygen throughout the entire aerobic column. The applied hydraulic 
retention time of 8 hours is in a similar range of 3-18 hours for which IBP removal 
is reported [81], and seems therefore long enough. Zwiener and Frimmel [330] 
concluded that IBP is primarily degraded under aerobic conditions and poorly in 
the absence of oxygen in biofilm reactors. Throughout our experiment, no 
dissolved oxygen (DO) was found in the aerobic column effluent as it was 
completely consumed in the column. Hence, it is assumed that competition for DO 
resulted in micro-aerophilic conditions with a too low DO concentration to support 
aerobic IBP biodegradation. MET was biodegraded and sorbed in batches whereas 
sorption was the only removal mechanisms in columns. Similar to IBP removal in 
column, a low DO concentration resulting in micro-aerophilic conditions might be 
a limiting factor in MET biodegradation in column which was also observed by 
Radke and Maier [211].  
Anaerobic batch and column experiments both demonstrated an effective 
CAF biodegradation. To our knowledge, there is a lack of studies on CAF 
biodegradation under anaerobic conditions in sediment. Among the anaerobic 
conditions, NAP biodegradation was observed in the sulfate reducing and 
methanogenic columns. In sulfate reducing and methanogenic batches NAP 
biodegradation could not be confirmed, as NAP removal was mainly ascribed to 
sorption. In accordance with the literature, PRO and CBZ were not effectively 
biodegraded under any redox condition in both batch and column experiments [83, 
207, 211].  
In our study using well-defined redox conditions, batch and column 
experiments independently showed that biodegradation of pharmaceuticals was 
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influenced by the applied redox conditions (Table 2.2). Most optimal 
pharmaceutical biodegradation was observed at the outer ranges of the redox 
spectrum, i.e. either aerobic or deeply anaerobic (sulfate reducing and 
methanogenic conditions), with fastest removal by biodegradation under aerobic 
conditions. In batch experiments, NAP, MET and IBP were readily biodegradable 
under aerobic conditions while they were recalcitrant under all anaerobic 
conditions. A similar conclusion was identified for IBP biodegradation by Conkle et 
al. [53]. Half-lives of IBP were 7-19 days or >7 months under aerobic or anaerobic 
conditions, respectively.  
Intermediate redox conditions like the micro-aerophilic and nitrate reducing 
conditions, which are often found in groundwater systems [26, 72, 169], appear 
not suitable for maximized biodegradation of a wide range of pharmaceuticals. 
According to previous research on anaerobic biodegradation of fuel hydrocarbons 
which also contain aromatic rings like pharmaceuticals, nitrate and sulfate 
appeared to be the most preferred electron acceptors for degrading toluene, 
ethylbenzene and xylenes [254]. Nevertheless, in our study NAP was poorly 
biodegraded under nitrate reducing conditions in the column, while it was 
effectively biodegraded under the other two anaerobic redox conditions.  
 
Table 2.2 Biodegradation of pharmaceuticals under the tested redox conditions in batch 
and column. Biodegradation observed (+), no biodegradation observed (-). 
Pharmaceutical 
Aerobic Nitrate reducing Sulfate reducing Methanogenic 
Batch Column Batch Column Batch Column Batch Column 
PRO - - - - - - - - 
MET + - - - - - - - 
CAF + + + + + + - + 
NAP + + - - - + - + 
IBP + - - - - - - - 
CBZ - - - - - - - - 
 
Biodegradation of pharmaceuticals is hypothesized to be limited in the 
natural environment as oxygen is typically absent in soils and sediments [195]. 
Thus, maximizing biodegradation of the complete suite of pharmaceuticals present 
in surface and wastewater should include aerobic conditions possibly combined 
with deeply anaerobic redox conditions (i.e. to save WWTP aeration costs), and is 
inadequate under micro-aerophilic and nitrate reducing conditions. In engineered 
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sediment based systems such as CWs, we therefore recommend to include aerobic 
conditions and deeply anaerobic conditions.  
Pre-exposure to pharmaceuticals can improve the biodegradation capacity 
of sediments towards pharmaceuticals. Batch experiments in this work showed a 
better removal for IBP, NAP, CAF and MET, compared to half-life times reported in 
literature [53, 161, 320]. The improved removal can be explained by the exposure 
of the sediments to pharmaceuticals prior to the laboratory scale experiments. 
Sediments used in this study were collected from CWs receiving secondary 
effluents of WWTPs and were in operation for more than 15 years. We detected 
the target pharmaceuticals in the CW influents in the range of 59-6492 ng/L (Table 
S2.3) demonstrating that the sediments have been exposed to pharmaceuticals. 
Adaptation of microorganisms to compounds can significantly improve 
biodegradation rates [245]. Especially for microbes capable of degrading 
micropollutants, pre-exposure to the compounds can enhance their biodegradation 
ability [42, 172]. Enrichment experiments by re-spiking pharmaceuticals in batch 
further improved the biodegradation rates of IBP and NAP. Thus, the significance 
of microbial growth by pre-exposure to pharmaceutical resulting in enhanced 
biodegradation was further confirmed.  
Pharmaceuticals demonstrating low to no removal by sorption and 
biodegradation under all redox conditions even after re-exposure, like CBZ, require 
additional treatment. In natural environments photo-oxidation has been reported 
to target pharmaceuticals in surface waters [140]. However, this is restricted to a 
limited number of pharmaceuticals [143] and photo-oxidation is typically not 
relevant in soil-sediment systems. Hence, in addition to sorption and 
biodegradation, other technologies such as advanced oxidation processes are 
needed in WWTPs to remove recalcitrant pharmaceuticals from treated effluents 
before they enter the natural environment.  
 
Conclusions 
In conclusion, our results show that pharmaceutical removal is influenced 
by the applied redox conditions via both sorption and biodegradation. Therefore 
this study provides insights into the importance of redox conditions in developing 
and designing biological techniques for pharmaceutical treatment. Sorption 
behaviour among different pharmaceuticals is influenced by the applied redox 
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conditions and the molecular charge of pharmaceuticals. Hydrophobicity of 
pharmaceuticals and ionic strength did not have an effect on pharmaceutical 
sorption in this study. Highest sorption coefficient Kd values are found under 
sulfate reducing and methanogenic conditions. Additionally, our study indicate a 
high variability in experimentally determined Kd values per pharmaceutical in 
different experimental system, i.e. batch and column systems. Most optimal 
pharmaceutical biodegradation is observed at the outer ranges of the redox 
spectrum, i.e. either aerobic or deeply anaerobic (sulfate reducing and 
methanogenic conditions), instead of the intermediate redox conditions like micro-
aerophilic and nitrate reducing conditions. Fastest pharmaceutical biodegradation 
is observed under aerobic conditions. From practical perspective, saturation of the 
sediment sorption capacity in sediment based applications treating 
pharmaceuticals is expected within approximately 300 pore volumes for the most 
sorptive compounds in this study.  
To increase removal efficiencies for a number pharmaceuticals, several strategies 
are recommended: adapt and enrich biomass by pre-exposure to pharmaceuticals 
in bioactive soil, sediment or other porous media filters; combine aerobic 
conditions with deeply anaerobic redox conditions in biotechnological systems; add 
advanced oxidation processes in WWTPs for removal of recalcitrant 
pharmaceuticals. 
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Table S2.1 Physico-chemical properties of target pharmaceutically active compounds 
Pharmaceutical Chemical structure pKaa Log Kowb Log Kocc Log Dowd 
Propranolol 
 
9.42 3.48 3.45 1.06 
Metoprolol 
 
9.67 1.88 2.10 -0.79 
Caffeine 
 
10.4 -0.07 1 -3.47 
Naproxen 
 
4.15 3.18 2.54 0.33 
Ibuprofen 
 
4.91 3.97 2.60 1.88 
Carbamazepine 
 
13.9 2.45 3.588 -4.45 
a - pKa: dissociation constant; b - Log Kow: octanol-water partition coefficient; c - Log Doc: 
soil organic carbon-water partitioning coefficient; d - Log Dow is the pH dependent Log Kow, 
calculated at pH=7. Data from [71, 278]. 
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Table S2.2 Medium composition for all columns and aerobic batches, adjusted from [162]. 
 
 
Reactor Compounds 
Concentration in 
medium (mg/L) 
Macro nutrients 
 
Aerobic batches and 
all columns 
NH4Cl 1020 
CaCl2.2H2O 48 
MgSO4.7H2O 54 
pH buffer 
Aerobic batches and 
all columns 
Na2HPO4 433 
NaH2PO4 234 
Trace elements 
Aerobic batches and 
all columns 
FeCl2.4H2O 1.2 
CoCl2.6H2O 1.2 
MnCl2.4H2O 0.3 
CuCl2.2H2O 0.018 
ZnCl2 0.03 
HBO3 0.03 
(NH4)6Mo7O24.4H2O 0.05 
Na2SeO3.5H2O 0.06 
NiCl2.6H2O 0.03 
EDTA (tripex 2) 0.6 
HCl 36% 0.0006 
Resazurin 0.3 
Redox specific 
compounds  
Nitrate reducing 
columns 
NaNO3 850 
Sulfate reducing 
columns 
NaSO4 1190 
Na2S.9H2O 120 
Methanogenic columns Na2S.9H2O 120 
Note: aerobic column medium was 60-80% oxygen saturated, other column media were 
flushed with N2 and did not contain oxygen. 
 
Table S2.3 Concentration of pharmaceuticals (ng/L) in the influent of the constructed 
wetland where the sediment inoculum was collected (average ± deviation, n=2). 
Pharmaceutical PRO MET CAF NAP IBP CBZ 
Concentration 58±10 1426±35 118±22 180±17 6492±261 204±7 
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Figure S2.1 Concentrations of electron acceptors and reaction products. A) O2 
concentration in aerobic batch experiment; B) CH4, NO3-, and SO42- concentrations in 
anaerobic batch experiment; C) influent and effluent NO3- and SO42- concentrations in 
nitrate and sulfate columns; D) effluent CH4 concentration in the methanogenic column. 
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Figure S2.2 Abiotic removal of pharmaceuticals after re-spiking under aerobic conditions.  
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Figure S2.3 Removal of pharmaceuticals under aerobic conditions. Pharmaceuticals were 
re-spiked three times at day 46, 84, and 95. 
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Figure S2.4 Principle component analysis of the relationship between Log Dow of 
pharmaceuticals and their Kd under the applied redox conditions. B-N, B-S, and B-M 
represent nitrate reducing, sulfate reducing, and methanogenic conditions in batches; C-
A, C-N, C-S, and C-M represent aerobic, nitrate reducing, sulfate reducing, and 
methanogenic conditions in columns. The eigenvalues of the first and second canonical axis 
are 0.56 and 0.39. The intersection angles between arrows represent their correlations, in 
which a more acute intersection angle means stronger correlations. The results show that 
Lod Dow of pharmaceuticals is not correlated with the Kd value under any applied redox 
conditions.  
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Figure S2.3 Removal of pharmaceuticals under aerobic conditions. Pharmaceuticals were 
re-spiked three times at day 46, 84, and 95. 
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Abstract 
Pharmaceuticals in the environment are of great concern as they jeopardise 
the aquatic environment and pose potential risks to human health. This stresses 
the need for technologies to remove pharmaceuticals before they enter the 
environment. Single processes for pharmaceutical removal are often found 
ineffective and resource intensive. In this study the combination of photocatalysis 
and biodegradation was investigated for the removal of nine selected 
pharmaceuticals. We designed a combined process consisting of a resource 
efficient mild photocatalysis and a subsequent biological treatment which was 
compared to the single processes of intensive photocatalysis and biological 
treatment. During the UV-TiO2 based mild and intensive photocatalysis 
atorvastatin, atenolol and fluoxetine were effectively removed. The biological 
treatment after mild photocatalytic pre-treatment removed diclofenac effectively 
while it persisted during the single biological treatment. Moreover, the 
biodegradation of atorvastatin, caffeine, gemfibrozil and ibuprofen was enhanced 
after mild photocatalytic pre-treatment compared to single biological treatment. 
The enhanced biodegradation of those pharmaceuticals was most probably 
triggered by the biodegradation of photocatalytic products. Biodegradation was the 
predominant removal mechanism and sorption was of minor importance during 
biological treatment as shown by abiotic controls. These findings show that mild 
photocatalysis followed by biological treatment is an effective and resource 
efficient combination for pharmaceutical removal. 
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treatment 
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3.1 Introduction 
The occurrence of pharmaceuticals in the aquatic environment has become 
a worldwide environmental concern [233]. After administration, pharmaceuticals 
largely end up in excreta and are transported via sewage to municipal wastewater 
treatment plants (WWTPs). WWTPs are commonly designed for cost-effective 
removal of bulk organic matter, nitrogen and phosphorus and typically make use 
of biological treatment processes. There are limitations regarding the removal of 
pharmaceuticals in biological treatment processes currently employed at WWTPs 
as pharmaceuticals are often incompletely removed [124, 287]. Advanced 
oxidation processes (AOPs) making use of photocatalysis, ozone, or hydrogen 
peroxide (the latter often in combination with Fenton’s Reagent), can effectively 
eliminate pharmaceuticals [164]. The main advantage of AOPs is the complete 
oxidation of organic contaminants in a wide variety of applications [132]. However, 
AOPs have disadvantages over biological processes. AOPs require either 
continuous energy and/or chemical inputs that are significantly higher than those 
required for biological processes. Toxic by-products can be formed during AOP 
treatment which can be more toxic than the parent compounds [118]. 
Furthermore, the various AOP reaction mechanisms are mostly non-specific, 
targeting not only the compounds of concern but also other compounds present in 
the matrix thereby reducing the elimination efficiency of AOPs for target 
compounds such as pharmaceuticals [187].  
Using the strengths of AOP and biodegradation in a combined technology 
could possibly result in better overall pharmaceutical removal. Scott and Ollis 
[235] concluded in their review of technologies for the removal of organic 
contaminants in water that two-step treatment technologies combining chemical 
and biological processes can have advantages over single processes. The benefits 
of employing a combination of processes can be obtained for wastewaters 
containing: 1) recalcitrant compounds; 2) biodegradable wastes with small 
amounts of recalcitrant compounds; 3) inhibitory compounds; and 4) intermediate 
dead-end products [235].  
In the field of water and soil contamination, this principle has been studied 
and applied to demonstrate the advantages of combined processes for the removal 
of various contaminants [80, 115, 313, 314]. A sequential combination of 
photocatalytic and biological treatment processes doubled 2,4,6-trinitrotoluene 
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(TNT) mineralisation as compared to biological treatment alone, whereas no TNT 
mineralisation was observed for the single photocatalytic process [107]. 
Furthermore, the combined treatment resulted in more soluble and polar 
transformation products when compared to the single processes. For quinoline 
removal, the maximum specific growth rate increased by 15% and the inhibition 
constant doubled when changing from biodegradation only to sequential coupled 
photocatalysis and biodegradation [311]. Photocatalytic pre-treatment that 
reduced COD by 8-10%, enhanced the subsequent biodegradation of the dye 
intermediate H-acid [186]. Chun and Yizhong [46] demonstrated the advantage of 
combining photocatalysis with biodegradation for wastewater containing non-
biodegradable azo dyes. The biodegradability of the wastewater indicated by the 
BOD5/COD ratio was enhanced from nil to 0.75, after a 20- to 30-minute 
photocatalytic oxidation. In soil remediation, combining chemical oxidation using 
Fenton’s reagent with biodegradation, removed diesel more effectively than 
applying single processes [258]. 
Specifically for micropollutant removal the combination of chemical and 
biological removal has received less attention. Positive effects on the 
biodegradation of the widely applied antibiotic tetracycline were found after pre-
treatment by ozonation [93] and photocatalysis [307]. In the study of Gómez-
Pacheco, et al. [93] tetracycline in the influent inactivated the microbial population 
of biological waste water treatment, whereas AOP pre-oxidation resulted in 100% 
mineralisable TOC and stable biological treatment. Biodegradation and 
mineralization of the broad-spectrum antibiotic sulfadiazine could be accelerated 
by 35 and 71%, respectively, when intimately coupled to photocatalysis [201]. 
Also for the pesticide 2,4,6-trichlorophenol a faster removal was found for 
sequentially and intimately coupled photocatalysis and biodegradation compared 
to the single processes [297]. Complete degradation and detoxification of the 
herbicide atrazine was obtained by photocatalytic pre-treatment followed by 
biodegradation. The single photocatalytic treatment resulted in complete atrazine 
removal but inefficiently mineralized and detoxified the transformation products 
[44]. 
The main aim of the current study was to gain insight into the influence of 
AOP pre-treatment on the subsequent biodegradation of pharmaceutical 
compounds, as there are only few reports describing this in literature. Since AOP 
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processes are generally energy and/or chemically intensive, we developed a mild 
photocatalysis method requiring low energy input. The removal of nine commonly 
detected pharmaceuticals in wastewater was studied by combining this mild 
photocatalysis method and biodegradation in batch experiments. The 
pharmaceuticals were selected as representative compounds for various classes of 
pharmaceuticals and were applied in a mixture in the treated water. The 
combination of mild photocatalysis followed by biodegradation was tested and the 
pharmaceutical removal was compared to removal in the single processes of 
intensive photocatalysis and biodegradation. 
 
3.2 Materials and Methods 
3.2.1 Chemicals 
A pharmaceutical stock solution that contained 9 compounds (Table 3.1): 
atenolol, atorvastatin, caffeine, carbamazepine, diclofenac, fluoxetine, gemfibrozil, 
ibuprofen and naproxen was employed. The stock solution (2 g/L) was prepared 
in HPLC grade methanol and stored at -20°C. Powdered TiO2, commercially 
available as P25 (99.7% purity, Sigma-Aldrich, Canada) was used for the 
photocatalytic experiments. Suppliers for all other reagents and chemicals used in 
this study are described in detail elsewhere [14]. 
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Table 3.1 Chemical structure and therapeutic function of the studied pharmaceuticals 
Atenolol Atorvastatin Caffeine 
Beta-blocker Lipid regulator Stimulant 
 
  
Carbamazepine Diclofenac Fluoxetine 
Anti-epileptic Anti-inflammatory Anti-depressant 
 
 
 
Gemfibrozil Ibuprofen Naproxen 
Lipid Regulator Anti-inflammatory Anti-inflammatory 
   
 
3.2.2 Experimental set-up 
Figure 3.1 displays the three experimental protocols that were studied: 1) 
intensive photocatalytic treatment (IP); 2) single process biological treatment (B); 
and 3) mild photocatalytic pre-treatment followed by biological treatment (MP+B). 
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Figure 3.1 Experimental protocols, 1) intensive photocatalytic treatment (IP), 2) single 
process biological treatment (B) and 3) mild photocatalytic pre-treatment followed by 
biological treatment (MP+B). 
 
3.2.2.1 Photocatalytic experiments 
Batch photocatalytic experiments were performed with the set-up described 
by Arlos, et al. [15]. Beakers (650 mL) wrapped in aluminium foil containing 600 
mL of ultrapure water were amended with TiO2 suspension to a final concentration 
of 0.5 g/L. The batches were spiked with 150 µL of the pharmaceutical stock 
solution to obtain concentrations of 500 µg/L (6 mM methanol). Prior to light 
exposure the batches were equilibrated for 30 minutes in the dark. For intensive 
photocatalytic experiments 2 mL samples were taken directly before the lamps 
were activated and after 15, 30, 45, 60 and 120 minutes of illumination. In the 
separately performed mild photocatalytic experiments, samples were taken 
directly before illumination and after 15 and 30 minutes of illumination. The 
contents of the beakers after 30 minutes of light exposure in the mild 
photocatalytic experiments were centrifuged (3500 rpm, 30 minutes) and filtered 
(0.45 µm, Supor-450 membrane filter, Pall Life Sciences, Canada). Thereafter, 
samples for pharmaceutical analysis were taken and this solution was further used 
in biological experiments. Dark control experiments without illumination were 
performed for 120 minutes to assess non-photocatalytic pharmaceutical removal. 
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3.2.2.2 Biological experiments 
Aerobic batch experiments were performed in 200 mL amber flasks, closed 
with cotton-wool stoppers. Three types of batches were prepared: 1) B protocol; 
2) MP+B protocol; and 3) abiotic controls. The MP+B batches were filled with the 
solution obtained after the mild photocatalytic experiments. The B and abiotic 
control batches were filled with demineralised water and spiked with 50 µL of 
pharmaceutical stock solution to obtain initial concentrations of 500 µg/L. All 
batches were amended with macro-nutrients, trace elements and pH buffer as 
described in Chapter 2. Biomass obtained from four locations around Waterloo, 
Canada (secondary sludge of Elmira WWTP, river sediment of Heidelberg creek, 
sand of polishing filter of Galt WWTP and Rotating Biological Contactor sludge of 
WWTP Foxboro) was used to inoculate batches until final concentrations of 49.4 g 
TSS/L and 5.5 g VSS/L. TSS and VSS were determined according to standard 
methods [8]. Batch experiments were performed in triplicate and incubated at 
room temperature on a shaker plate. Abiotic controls were initially amended with 
0.5 mM NaN3 to supress biological activity and closed with a rubber stopper. 
However, oxygen consumption in the abiotic batches could not be fully suppressed, 
showing that biologic activity was insufficiently inhibited. Additional NaN3 spikes of 
0.5 mM on days 8, 12 and 13, 0.75 mM on day 14 and 1 mM on days 15 and 17 
were added and did not completely supress oxygen consumption. Ternes et al. 
[266] reported that 30 minutes after spiking the sorption equilibrium for 
pharmaceuticals was reached in batch experiments with 2.4 g VSS/L of secondary 
sludge. Similarly, Martínez-Hernández et al. [167] achieved sorption equilibrium 
of pharmaceuticals after 12 hours in batch experiments containing 250 g soil/L. 
Hence, due to this fast sorption equilibrium only the abiotic results of day 1 were 
used to assess sorption behaviour in this study. Samples (5 mL) of the biotic 
batches were taken on day 0,1,3,7,14 and 21, directly frozen and stored at -10°C 
prior to pharmaceutical analysis. Replicate batches were tested for outliers 
according to ANCOVA statistical model (significance <0.05) in which we considered 
time as a covariate. The testing criterion was the difference in pharmaceutical 
removal (C/C0) between replicates. The same ANCOVA model was used to test for 
differences in removal (C/C0) over time in the biological experiments of the B and 
MP+B protocols.  
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3.2.3 Pharmaceutical analysis 
Samples from the AOP experiments were directly centrifuged for 45 minutes 
at 3500 rpm to separate the liquid phase and TiO2. After thawing the samples from 
the biological experiments were centrifuged for 10 minutes at 3500 rpm. 
Thereafter, the supernatants were extracted by solid phase extraction (SPE) and 
analysed by LC-MS/MS according to the procedure described by Arlos, et al. [15] 
but only using 2 mL sample instead of 4 mL was used for SPE in this study. 
 
3.3 Results and Discussion 
3.3.1 Photocatalysis 
3.3.1.1 Intensive photocatalysis (IP protocol) 
Experimental results of the illuminated batches and controls were compared 
to assess the contribution of photocatalysis to pharmaceutical removal. The results 
of the control experiments revealed that non-photocatalytic removal processes 
contributed little (<25%) to the pharmaceutical removal in our AOP experiments, 
as has been reported in the literature [15]. By contrast significant removals 
(>80%) of atorvastatin, atenolol and fluoxetine were observed in intensive 
photocatalytic (IP) experiments after 2 hours (Figure 3.2a). The other tested 
compounds were less susceptible to photocatalysis and were removed by less than 
40%. Photocatalytic degradation of organic compounds has been described by 
Langmuir-Hinshelwood kinetics [229]. A simplified model can be used for low 
compound concentrations (<mg/L) and denoted as ln( �
�0
) =  −�� in which C/C0 (µg/L 
/ µg/L) is the actual pharmaceutical concentration divided by the initial 
pharmaceutical concentration, k (min-1) is the apparent first-order reaction rate 
constant, and t (min) is time. The pharmaceutical concentrations in this study were 
in the µg/L range, therefore the dilute system condition was believed to apply and 
reaction rate constants were calculated according to the abovementioned 
equation. For atorvastatin, atenolol and fluoxetine the calculated rate constants 
(R2 >0.99%) were 41.5, 29.0 and 15.4 x 10-3 min-1, respectively. These results 
agreed with the findings of the experimental work and the literature reviewed by 
Arlos, et al. [15] on photocatalytic degradation of pharmaceuticals. Their reported 
rate constants for atorvastatin, atenolol and fluoxetine ranged between 13.4-68.8, 
7.4-14.5 and 8.4-40.8 x 10-3 min-1, respectively. Thus, atenolol was removed at a 
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higher rate in our study. The rate constants of the other pharmaceuticals did not 
exceed 4.8 x 10-3 min-1 (R2 <0.88). Similarly, Arlos, et al. [15] found low rate 
constants (<8.7 x 10-3 min-1) to no degradation for naproxen, ibuprofen and 
carbamazepine. 
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Figure 3.2 Pharmaceutical removal (C/C0) during photocatalysis of a) IP protocol and b) 
MP+B protocol. Error bars represent standard deviations between triplicates. 
 
3.3.1.2 Mild photocatalysis (MP+B protocol) 
For the MP+B photocatalytic experiments the illumination time was chosen 
based on the outcomes of the IP experiments. The illumination time was selected 
to provide (1) substantial removal of photocatalytic degradable compounds and 
(2) sufficient remaining compound concentrations to study biodegradation. 
Therefore 30 minutes illumination was selected for the resource-efficient mild 
photocatalytic experiments as substantial removal (>50%) was achieved at 75% 
less energy input than the IP tests. Further, the remaining pharmaceutical 
concentrations were sufficiently high after 30 minutes of illumination to allow for 
assessment of pharmaceutical removal in the subsequent biological experiments. 
During the mild photocatalysis substantial removals of atorvastatin (75%), 
atenolol (50%) and fluoxetine (35%) were observed, while the other 
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pharmaceuticals showed low removal (<5%) (Figure 3.2b). The photocatalysis 
results in the MP+B test were in good accordance with the findings of the IP 
protocol, as the same compounds were removed (atorvastatin, atenolol and 
fluoxetine) at similar removal rates (<20% difference between the two tests). This 
indicates the robustness of the photocatalysis process for pharmaceutical removal. 
 
3.3.2 Biological treatment 
3.3.2.1 Single process biological treatment (B protocol) 
The B protocol was employed to assess the biodegradability of the target 
pharmaceuticals (Figure 3.3). The ANCOVA testing revealed a significant outlier in 
the B protocol results when the pharmaceutical removals (C/C0) in the individual 
replicates were compared and therefore the outlier bottle results were not included 
in the trend analysis. From Figure 3.3, it can be seen that significant removal 
(>80%) of seven pharmaceuticals was observed in the first 21 days of the B 
protocol testing. Diclofenac and carbamazepine were recalcitrant towards 
biodegradation as after 21 days they were reduced by less than 50% and 40%, 
respectively. These results were in agreement with previous reports of their fate 
during biological treatment [7, 287]. In addition, to parse out the removal 
mechanisms of individual pharmaceuticals abiotic (Table 3.2) and biotic (Figure 
3.3) batches were compared in more detail.  
The concentrations of caffeine, ibuprofen, naproxen and atorvastatin were 
reduced significantly (>99%) within 7, 7, 14 and 21 days, respectively. Partial 
gemfibrozil removal (80%) was found after 21 days. These findings agree with 
those of Luo, et al. [164] who reviewed the fate of pharmaceuticals in wastewater 
treatment and classified caffeine, ibuprofen, gemfibrozil and naproxen as “highly 
removed (>70%)”. The findings for atorvastatin correspond well with those of 
Golovko et al. [92] where an average of 93% atorvastatin removal was observed 
on a yearly basis in a Czech WWTP. It was concluded that biodegradation was the 
prevalent removal mechanism for caffeine, ibuprofen, gemfibrozil, atorvastatin 
and naproxen in our experiments as during the first day their concentrations in the 
abiotic batches decreased by only 18-34% (Table 3.2). 
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Fluoxetine concentrations decreased rapidly in both the biotic and abiotic 
batches (Table 3.2, Figure 3.3) indicating that sorption was the main removal 
process. In samples taken on day 0, the fluoxetine concentrations were found to 
be less than the spiking concentrations (>25%) in both the biotic and abiotic 
batches. After 1 day, fluoxetine removal in the biotic and abiotic batches was 75% 
and 84%, respectively and by day 3 over 99% removal was observed in both 
batches. These findings correspond well with lab-scale experiments of Pomiès et 
al. [206] who concluded that sorption was the only removal mechanism for 
fluoxetine. 
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Table 3.2 Pharmaceutical removal (C/C0) after 1 day in the abiotic experiments.  
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The atenolol concentrations at day 1 were reduced by 53% in the abiotic 
batches as compared to 44% in the biotic batches (Table 3.2, Figure 3.3), 
suggesting sorption was initially the major removal mechanism. Thereafter 
biodegradation became the predominant removal mechanism as higher removals 
were observed in the biotic batches. In the literature, biodegradation has been 
reported to be the predominant removal mechanism of atenolol in wastewater 
treatment, whereas sorption to activated sludge has been found to be low [176, 
206]. The low sorption coefficients reported in the literature were contrary to the 
initial atenolol removal observed in the abiotic batches of this study. The differing 
sorption behaviour might be explained by the inoculum mixture used in this study 
as the creek sediment likely contained a significant clay fraction (not measured). 
Kodešová et al. [135] found a positive correlation between clay content and 
atenolol sorption which was driven by cationic exchange between negatively 
charged clay particles and positively charged atenolol at neutral pH. 
  
3.3.2.2 Biological treatment after mild photocatalysis 
   (MP+B protocol) 
High pharmaceutical removals (>99%) were observed after 21 days in the 
biological experiments of the MP+B protocol (Figure 3.3). Only carbamazepine was 
incompletely removed (65%) by the end of the experiments. The initial 
concentrations of atorvastatin, and atenolol were lower compared to the B protocol 
due to their photocatalytic degradation during pre-treatment. The low initial 
fluoxetine concentration was attributed to removal during photocatalysis and rapid 
sorption to the inoculum as observed in the B protocol. Moreover, approximately 
50% of the fluoxetine was lost during the centrifugation and filtration steps that 
were carried out between the photocatalytic and biodegradation experiments. The 
predominant removal mechanisms were considered to be similar in these tests as 
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Figure 3.3 Pharmaceutical concentrations in biological treatment experiments, B protocol 
(red spheres) and MP+B protocol (blue triangles). 
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concentrations of atorvastatin, and atenolol were lower compared to the B protocol 
due to their photocatalytic degradation during pre-treatment. The low initial 
fluoxetine concentration was attributed to removal during photocatalysis and rapid 
sorption to the inoculum as observed in the B protocol. Moreover, approximately 
50% of the fluoxetine was lost during the centrifugation and filtration steps that 
were carried out between the photocatalytic and biodegradation experiments. The 
predominant removal mechanisms were considered to be similar in these tests as 
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in the B protocol; sorption for fluoxetine, sorption and biodegradation for atenolol 
and biodegradation for the other pharmaceuticals.  
Significantly faster removal was found for atorvastatin, caffeine, diclofenac, 
gemfibrozil and ibuprofen in the biological experiments of the MP+B protocol as 
compared to the B protocol. Results of the ANCOVA are provided in Table S3.1. 
Out of these pharmaceuticals, only atorvastatin was partially eliminated (75%) 
during mild photocatalytic pre-treatment. The enhanced atorvastatin removal may 
have been due to a co-substrate effect as reported by other authors. Yan, et al. 
[311] found faster quinoline removal during biological treatment after photolytic 
pre-treatment. They suggested this could result from quinoline and its photolysis 
products being simultaneously biodegraded and thereby both contributing to 
biomass growth. Further, enhanced biodegradation induced by photolysis products 
was demonstrated for sulfadiazine by Pan, et al. [201], 2,4,6-trichlorophenol by 
Wang, et al. [297] and for pyridine by Zhang, et al. [323]. These authors reported 
that biodegradation of the main photolysis product generated intracellular electron 
carriers that initiated the initial mono-oxygenation reaction for biodegradation of 
target compounds. In sunlit surface water two photolysis products of atorvastatin 
were found, one as a result of N-dealkylation, the other formed by 
photonucleophilic aromatic substitution of the F atom by OH [143]. Similar to the 
2,4,6-trichlorophenol photolysis the dehalogenation of atorvastatin could indicate 
the formation of a more readily biodegradable product.  
Enhanced biological removal of caffeine, diclofenac, gemfibrozil and 
ibuprofen was observed after pre-treatment, even though they were not 
significantly removed during mild photocatalysis. Contrary to the B protocol results 
in which diclofenac was classified as recalcitrant, biological removal of diclofenac 
was found in the MP+B protocol. At day 21 more than 99% removal of diclofenac 
was observed, whereas only 50% was removed in the B protocol. In addition, 
caffeine and ibuprofen were removed within 3 days as compared to 7 days in the 
B protocol while gemfibrozil removal at day 7 was 95% compared to 50% in the B 
protocol. Like atorvastatin, it is hypothesized that the enhanced biodegradation of 
caffeine, diclofenac, gemfibrozil and ibuprofen was triggered by the presence of 
photocatalytic products. Although none of these pharmaceuticals was effectively 
removed during mild photocatalysis, the products formed during photocatalytic 
removal of atenolol, atorvastatin and fluoxetine may have enhanced their 
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biodegradation. By contrast, pre-treatment did not improve the removal of 
naproxen in subsequent biodegradation testing while naproxen was effectively 
biodegraded in the B protocol.  
The molecular structures of the pharmaceuticals (Table 3.1) were compared 
to assess whether there was a relationship between structure and the biological 
removal responses observed after pre-treatment. A carboxyl group is present in 
atorvastatin, diclofenac, gemfibrozil and ibuprofen but also in naproxen. Caffeine 
is the only pharmaceutical without a phenyl ring, yet not the only one exhibiting 
enhanced biodegradation. Atorvastatin, caffeine, gemfibrozil and ibuprofen have 
methyl groups, as does naproxen, whereas diclofenac does not have it. In 
particular, the response of naproxen after pre-treatment was elucidated as it 
behaved differently than the other pharmaceuticals that displayed enhanced 
removal. As ibuprofen removal is well described in the literature and its structure 
has many commonalities with naproxen, their reported degradation pathways were 
compared. Naproxen was the only pharmaceutical in this study that contained an 
ether group. Ether cleavage, hydroxylation and aromatic ring cleavage are known 
naproxen degradation pathways [209, 239, 302, 326], and occur mostly co-
metabolically [209, 302]. The reported ibuprofen degradation pathways are 
hydroxylation, dealkylation followed by hydroxylation, demethylation followed by 
O-hydroxylation and demethylation followed by dehydrogenation [30]. Hence, the 
literature reveals a limited overlap in the broad and complex array of 
transformation pathways for naproxen and ibuprofen. Moreover, co-metabolic 
processes appear to be important for naproxen removal. These factors could 
possibly explain why naproxen removal was not enhanced after the mild 
photocatalytic pre-treatment. Overall, no clear relation was found between the 
chemical structure and biodegradation responses of the pharmaceuticals after pre-
treatment. 
Atenolol and carbamazepine removal efficiencies were similar in the 
biological experiments conducted for the B and MP+B protocols. Atenolol sorption 
to clay particles was hypothesized to explain the lack of difference observed in 
removal efficiency between the two protocols, indicating that photocatalytic pre-
treatment did not affect atenolol sorption. The similar removal of carbamazepine 
with or without photocatalytic pre-treatment was attributed to the general 
persistence of carbamazepine towards biodegradation, as observed in many 
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previous studies [164, 287]. We could not test the differences in fluoxetine 
removal efficiencies as it was substantially removed during filtration prior to the 
biological experiments of the MP+B protocol. 
In summary, mild photocatalytic pre-treatment with a subsequent biological 
treatment was found to be an effective combination of processes to improve the 
removal of pharmaceuticals. Scott and Ollis [235] indicated that choosing 
complementary processes is a key design priority in order to benefit from 
synergistic effects. In this study, the recalcitrance of diclofenac towards 
biodegradation was overcome by pre-treatment. Furthermore, biodegradable 
pharmaceuticals like atorvastatin, caffeine, gemfibrozil and ibuprofen were 
biodegraded at a higher rate compared to biological treatment without pre-
treatment. Hence, our study demonstrates that mild photocatalytic pre-treatment 
and biodegradation are complementary processes and their synergy can result in 
a better pharmaceutical removal compared to the single processes. 
 
3.4 Conclusions 
Sequentially combined mild photocatalysis and biological treatment 
effectively removed 8 out of 9 studied pharmaceuticals. The biological degradation 
of 5 pharmaceuticals improved after mild photocatalytic pre-treatment in a 
subsequent biological treatment of which only atorvastatin was removed during 
mild photocatalysis. Biodegradation of the atorvastatin photocatalytic degradation 
products most probably triggered the enhanced atorvastatin biodegradation by 
initiation of mono-oxygenation reactions. Caffeine, diclofenac, gemfibrozil and 
ibuprofen were not susceptible to photocatalysis, however their biodegradation 
efficiency enhanced after mild photocatalytic pre-treatment. During intensive and 
mild photocatalysis 3 out of 9 pharmaceuticals were removed, atenolol, 
atorvastatin and fluoxetine. We hypothesize that their photocatalytic products 
resulted in the enhanced biodegradation of caffeine, diclofenac, gemfibrozil and 
ibuprofen. Similar observed photocatalytic rate constants of the separately 
performed intensive and mild photocatalytic experiments indicate the process 
robustness of photocatalysis for pharmaceuticals removal. Biodegradation was the 
predominant removal mechanism in biological experiments for most 
pharmaceuticals, whereas fluoxetine was removed by sorption to the inoculum and 
atenolol by both sorption and biodegradation. Carbamazepine was recalcitrant 
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towards photocatalysis and biodegradation. Overall, mild photocatalysis followed 
by biological treatment is an effective and resource efficient combination, 
achieving a substantial reduction of energy input for the photocatalysis and an 
enhanced biodegradation of biodegradable and recalcitrant pharmaceuticals 
susceptible and non-susceptible to photocatalysis. 
 
Acknowledgement 
We would like to thank Leslie Bragg for her support on the analytical work 
and Robert Liang for providing the experimental setup and the P25 powder. We 
kindly acknowledge financial support from the Association Canada Studies the 
Netherlands and the Knowledge-to-Knowledge project within the Partners in 
Business Water and Soil Canada cluster. 
 
Supplementary Information 
 
Table S3.1 Significance output of the ANCOVA statistical model in which we considered 
time as a covariate. Results are the significances of the difference in pharmaceutical 
removal (C/C0) per compound between the single process biological experiments (B 
protocol) and the mild photocatalytic pre-treated biological experiments (MP+B protocol). 
A significance of <0.05 was considered significant (highlighted in green). 
Pharmaceutical 
A
te
no
lo
l 
A
to
rv
as
ta
tin
 
C
af
fe
in
e 
C
ar
ba
m
az
ep
in
e 
D
ic
lo
fe
na
c 
Fl
uo
xe
tin
e 
G
em
fib
ro
zi
l 
Ib
up
ro
fe
n 
N
ap
ro
xe
n 
Significance 0.219 0.011 0.044 0.250 0.002 n.d. 0.008 0.024 0.184 
n.d. – not determined because too few data points available due to rapid sorption 
 
III
Combined mild photocatalysis and biodegradation 
72 
 
previous studies [164, 287]. We could not test the differences in fluoxetine 
removal efficiencies as it was substantially removed during filtration prior to the 
biological experiments of the MP+B protocol. 
In summary, mild photocatalytic pre-treatment with a subsequent biological 
treatment was found to be an effective combination of processes to improve the 
removal of pharmaceuticals. Scott and Ollis [235] indicated that choosing 
complementary processes is a key design priority in order to benefit from 
synergistic effects. In this study, the recalcitrance of diclofenac towards 
biodegradation was overcome by pre-treatment. Furthermore, biodegradable 
pharmaceuticals like atorvastatin, caffeine, gemfibrozil and ibuprofen were 
biodegraded at a higher rate compared to biological treatment without pre-
treatment. Hence, our study demonstrates that mild photocatalytic pre-treatment 
and biodegradation are complementary processes and their synergy can result in 
a better pharmaceutical removal compared to the single processes. 
 
3.4 Conclusions 
Sequentially combined mild photocatalysis and biological treatment 
effectively removed 8 out of 9 studied pharmaceuticals. The biological degradation 
of 5 pharmaceuticals improved after mild photocatalytic pre-treatment in a 
subsequent biological treatment of which only atorvastatin was removed during 
mild photocatalysis. Biodegradation of the atorvastatin photocatalytic degradation 
products most probably triggered the enhanced atorvastatin biodegradation by 
initiation of mono-oxygenation reactions. Caffeine, diclofenac, gemfibrozil and 
ibuprofen were not susceptible to photocatalysis, however their biodegradation 
efficiency enhanced after mild photocatalytic pre-treatment. During intensive and 
mild photocatalysis 3 out of 9 pharmaceuticals were removed, atenolol, 
atorvastatin and fluoxetine. We hypothesize that their photocatalytic products 
resulted in the enhanced biodegradation of caffeine, diclofenac, gemfibrozil and 
ibuprofen. Similar observed photocatalytic rate constants of the separately 
performed intensive and mild photocatalytic experiments indicate the process 
robustness of photocatalysis for pharmaceuticals removal. Biodegradation was the 
predominant removal mechanism in biological experiments for most 
pharmaceuticals, whereas fluoxetine was removed by sorption to the inoculum and 
atenolol by both sorption and biodegradation. Carbamazepine was recalcitrant 
Chapter 3 
73 
 
towards photocatalysis and biodegradation. Overall, mild photocatalysis followed 
by biological treatment is an effective and resource efficient combination, 
achieving a substantial reduction of energy input for the photocatalysis and an 
enhanced biodegradation of biodegradable and recalcitrant pharmaceuticals 
susceptible and non-susceptible to photocatalysis. 
 
Acknowledgement 
We would like to thank Leslie Bragg for her support on the analytical work 
and Robert Liang for providing the experimental setup and the P25 powder. We 
kindly acknowledge financial support from the Association Canada Studies the 
Netherlands and the Knowledge-to-Knowledge project within the Partners in 
Business Water and Soil Canada cluster. 
 
Supplementary Information 
 
Table S3.1 Significance output of the ANCOVA statistical model in which we considered 
time as a covariate. Results are the significances of the difference in pharmaceutical 
removal (C/C0) per compound between the single process biological experiments (B 
protocol) and the mild photocatalytic pre-treated biological experiments (MP+B protocol). 
A significance of <0.05 was considered significant (highlighted in green). 
Pharmaceutical 
A
te
no
lo
l 
A
to
rv
as
ta
tin
 
C
af
fe
in
e 
C
ar
ba
m
az
ep
in
e 
D
ic
lo
fe
na
c 
Fl
uo
xe
tin
e 
G
em
fib
ro
zi
l 
Ib
up
ro
fe
n 
N
ap
ro
xe
n 
Significance 0.219 0.011 0.044 0.250 0.002 n.d. 0.008 0.024 0.184 
n.d. – not determined because too few data points available due to rapid sorption 
 

A modified version of this chapter has been submitted as
Arnoud de Wilt, Koen van Gijn, Tom Verhoek, Amber Vergnes, Mirit Hoek,
Huub Rijnaarts and Alette Langenhoff. Enhanced pharmaceutical removal
from water in a three step bio-ozone-bio process
Chapter 4
Enhanced pharmaceutical removal from water
in a three step bio-ozone-bio process
A three-step Bio-Ozone-Bio process 
76 
 
Abstract 
Individual treatment processes like biological treatment or ozonation have 
their limitations for the removal of pharmaceuticals from secondary clarified 
effluents with high total organic carbon (TOC) concentrations (i.e. 17 mg/L). These 
limitations can be overcome by combining these two processes for a cost-effective 
pharmaceutical removal. A three-step biological-ozone-biological (BO3B) 
treatment process was therefore designed for the enhanced pharmaceutical 
removal from wastewater effluent. The first biological step removed 38% of ozone 
scavenging TOC, thus proportionally reducing the absolute ozone input for the 
subsequent ozonation. Complementariness between biological and ozone 
treatment, i.e. targeting different pharmaceuticals, resulted in cost-effective 
pharmaceutical removal by the overall BO3B process. At a low ozone dose of 0.2 g 
O3/g TOC and an HRT of 1.46 hours in the biological reactors, the removal of 8 out 
of 9 pharmaceuticals exceeded 85%, except for metoprolol (60%). Testing various 
ozone doses and HRTs revealed that pharmaceuticals were ineffectively removed 
at 0.1 g O3/g TOC and an HRT of 0.3 hours. At HRTs of 0.47 and 1.46 hours easily 
and moderately biodegradable pharmaceuticals such as caffeine, gemfibrozil, 
ibuprofen, naproxen and sulfamethoxazole were over 95% removed by biological 
treatment. The biorecalcitrant carbamazepine was completely ozonated at a dose 
of 0.4 g O3/g TOC. Ozonation products are likely biodegraded in the last biological 
reactor as a 17% TOC removal was found. No appreciable acute toxicity towards 
D. magna, P. subcapitata and V. fischeri was found after exposure to the influents 
and effluents of the individual BO3B reactors. The BO3B process is estimated to 
increase wastewater treatment costs by 15%, whereas the yearly tariff per 
population equivalent in the Netherlands is estimated to increase by less than 
10%. Overall, the BO3B process is a cost-effective treatment process for the 
removal of pharmaceuticals from secondary clarified effluents. 
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4.1 Introduction 
Human consumption of pharmaceuticals has increased in the past years and 
is expected to rise even more due to the growing world population and increased 
average age [283]. After administration pharmaceuticals are excreted and 
disposed into the sewer [85]. This results in elevated pharmaceutical 
concentrations in wastewater, as is illustrated by measurements of numerous 
studies over the past decades [188, 228]. Many pharmaceuticals are persistent in 
conventional wastewater treatment plants (WWTPs) [222, 287]. Pharmaceutical 
levels in WWTP effluents jeopardize the aquatic environment [77, 85, 141, 325] 
and reach drinking water resources [188]. As a result, they end up in the water 
cycle, and this stresses the need for their removal from WWTP effluents.  
Ozone treatment has been studied for pharmaceutical removal [164]. 
Ozonation is an effective technique to oxidize pharmaceuticals [116]. Ozone 
targets electrophilic compounds that contain double bonds, aromatic structures or 
amine groups which are often found in the chemical structure of pharmaceuticals 
[193]. Ozonation leads to shorter and more oxidized products which are not further 
broken down by ozone, but are more susceptible to biodegradation [243]. High 
removal rates can be obtained by ozonation, but process efficiency reduces when 
other compounds than the pollutants of interest are present [187]. WWTP effluents 
contain orders of magnitudes more harmless organic matter than residual 
pharmaceutical concentrations, both being oxidized by ozone, resulting in 
degradation processes competition for ozone. The biodegradability of recalcitrant 
compounds typically increases after ozonation [6]. However, toxic by-products can 
be formed during ozonation [118], resulting in the need of a subsequent treatment 
step after ozonation [222]. Activated carbon (AC) is a commonly proposed post-
ozone treatment step as it effectively removes organic compounds from water 
through adsorption and does not generate toxic by-products [134]. A costly 
downside of AC is the regeneration or replacement of AC when saturated. 
An alternative or addition to physical-chemical techniques is biological 
treatment, i.e. employing microorganisms to degrade pharmaceuticals. In general, 
biological treatment requires low energy and chemical inputs. However, complex 
molecules like pharmaceuticals present at low concentrations are challenging to 
biodegrade [164]. For many pharmaceuticals insufficient degradation rates result 
in incomplete removal in biological processes applied at WWTPs [124]. Moreover, 
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4.1 Introduction 
Human consumption of pharmaceuticals has increased in the past years and 
is expected to rise even more due to the growing world population and increased 
average age [283]. After administration pharmaceuticals are excreted and 
disposed into the sewer [85]. This results in elevated pharmaceutical 
concentrations in wastewater, as is illustrated by measurements of numerous 
studies over the past decades [188, 228]. Many pharmaceuticals are persistent in 
conventional wastewater treatment plants (WWTPs) [222, 287]. Pharmaceutical 
levels in WWTP effluents jeopardize the aquatic environment [77, 85, 141, 325] 
and reach drinking water resources [188]. As a result, they end up in the water 
cycle, and this stresses the need for their removal from WWTP effluents.  
Ozone treatment has been studied for pharmaceutical removal [164]. 
Ozonation is an effective technique to oxidize pharmaceuticals [116]. Ozone 
targets electrophilic compounds that contain double bonds, aromatic structures or 
amine groups which are often found in the chemical structure of pharmaceuticals 
[193]. Ozonation leads to shorter and more oxidized products which are not further 
broken down by ozone, but are more susceptible to biodegradation [243]. High 
removal rates can be obtained by ozonation, but process efficiency reduces when 
other compounds than the pollutants of interest are present [187]. WWTP effluents 
contain orders of magnitudes more harmless organic matter than residual 
pharmaceutical concentrations, both being oxidized by ozone, resulting in 
degradation processes competition for ozone. The biodegradability of recalcitrant 
compounds typically increases after ozonation [6]. However, toxic by-products can 
be formed during ozonation [118], resulting in the need of a subsequent treatment 
step after ozonation [222]. Activated carbon (AC) is a commonly proposed post-
ozone treatment step as it effectively removes organic compounds from water 
through adsorption and does not generate toxic by-products [134]. A costly 
downside of AC is the regeneration or replacement of AC when saturated. 
An alternative or addition to physical-chemical techniques is biological 
treatment, i.e. employing microorganisms to degrade pharmaceuticals. In general, 
biological treatment requires low energy and chemical inputs. However, complex 
molecules like pharmaceuticals present at low concentrations are challenging to 
biodegrade [164]. For many pharmaceuticals insufficient degradation rates result 
in incomplete removal in biological processes applied at WWTPs [124]. Moreover, 
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specific micropollutant degrading microorganisms are easily outcompeted by other 
microorganisms that depend on easily degradable substrates present at higher 
concentrations [155]. 
Combining biological and ozone treatment can be an alternative set of 
processes for enhanced pharmaceutical removal. Combinations of biological 
processes with advanced oxidation processes, including ozonation, are known to 
have beneficial effects over single process technologies [235]. Effective 
degradation and mineralisation of the degradation products was achieved in a 
combined ozone-biological process for the widely prescribed antibiotic tetracycline 
[93]. Biodegradation and mineralisation of the antibiotic sulfadiazine were 
accelerated by UV-photolysis pre-treatment by 35 and 71%, respectively, [201].  
In the study presented here, the capacities of biological and ozone 
treatment processes are combined for pharmaceutical removal in a post-treatment 
process at the WWTP. A three-step biological-ozone-biological (BO3B) treatment 
process is designed to investigate the process removal efficiency. Applied ozone 
dose and the hydraulic retention time (HRT) of the bioreactors are the studied key-
parameters to adjust the process performance. The aim of this study is therefore 
to test the influence of the applied ozone dose and HRT on the BO3B process 
performance. Both chemical and toxicological parameters are used to assess the 
BO3B process efficiency. An optimal combination of biological and ozone treatment 
is hypothesized to result in a cost-effective BO3B process to remove 
pharmaceuticals and the toxicity they impose at minimal energy input. 
 
4.2 Materials and Methods 
4.2.1 Feed solution and inoculum 
Secondary clarified effluent was obtained from WWTP Bennekom 
(Bennekom, the Netherlands) as feed solution for the experimental work. WWTP 
Bennekom has a carrousel configuration, is operated with biological nitrogen and 
phosphate removal and has a capacity to treat 20 000 population equivalents. Two 
batches of effluent were taken during the experiment. The effluent had an average 
total organic carbon (TOC) concentration of 17.3±3.3 mg/L and a pH of 7.6±0.2, 
other effluent characteristics are given in Tables S4.1 and S4.2. Inocula from three 
locations were taken and mixed. The inoculum mixture consisted of MBR sludge 
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from a hospital wastewater treatment facility (Pharmafilter, Reinier de 
Graafziekenhuis, Delft, the Netherlands), primary and secondary sludge of WWTP 
Bath (Bath, the Netherlands) treating a mixture of industrial and domestic 
wastewater, and biomass from the BioGAC polishing step of WWTP Horstermeer 
(One-Step filter, Nederhorst den Berg, the Netherlands). 
 
4.2.2 Chemicals 
The pharmaceutical stock solution was prepared in HPLC grade methanol 
and consisted of caffeine, carbamazepine, diclofenac, gemfibrozil, ibuprofen, 
metoprolol, naproxen, sulfamethoxazole and trimethoprim. To avoid the influence 
of methanol on the experiments, spikes of the stock solution were evaporated till 
dryness under a gentle nitrogen stream whereafter secondary clarified effluent was 
added to obtain the feed solution with a pharmaceutical concentration of 
approximately 200 µg/L. 
 
4.2.3 Experimental setup BO3B process  
The experimental setup, consisting of a biological reactor (BR1), an ozone 
reactor (O3R) and a second biological reactor (BR2), were operated in series 
(Figure 4.1). An adaptation period of 5 months was applied for the physical and 
biological stabilization of the BO3B process before various process parameters were 
tested. Thereafter different ozone doses in O3R and HRTs of the bioreactors were 
studied during a 5-month experimental period. HRTs of respectively 1.46, 0.47 
and 0.3 hours were tested by changing the flow rate. Four ozone doses were tested 
by varying the ozone concentration in the injected gas mixture, 0.1, 0.2, 0.4 and 
0.5 g O3/g TOC. Each time a parameter was changed the BO3B process was 
operated for 4-7 days before samples were taken and new settings were applied. 
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Figure 4.1 Schematic of the experimental set-up. BR1 represents the first biological 
reactor, O3R the ozone reactor and BR2 the second biological reactor. 
 
4.2.3.1 Biological reactors BR1 and BR2 
Two identical lab-scale reactors (BR1 and BR2) were operated in continuous 
mode. Sand with a diameter of 1.2-1.6 mm was obtained from a drinking water 
treatment plant sandfilter (Vitens, de Meern, the Netherlands) and functioned as 
the carrier material in the reactors. Sand and the inoculum mixture were mixed 
and formed the filter bed of the reactors. BR1 and BR2 were inoculated with 2.8 
and 3.3 kg of filter bed material, respectively, the effective reactor volume was 
approximately 1,4 L. The initial dry matter (DM) and organic matter (OM) content 
of the filter bed was 749.5 g DM/kg and 38.0 g OM/kg, respectively. After wash-
out of surplus filter bed material during the adaptation period these contents 
decreased to 734.9 g DM/kg and 30.8 g OM/kg at 23 weeks of operation. Reactors 
were fed from the top by continuous dripping. 
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The influent was dispersed evenly over the filter bed surface by a fine porous 
plate placed on top of the filter bed. Effluent was discharged at the bottom of the 
reactors. A net with marbles on the bottom retained the filter bed. BR1 was 
operated with a subsequent 1.5 L settler, preventing washed-out biomass to enter 
the O3R. BR1 was fed with the feed solution as described in section 4.2.1, BR2 with 
the effluent of the O3R. In both reactors aerobic conditions were obtained by a 
counter-current air flow. Fluorescein was used in a conservative tracer pulse test 
to determine the HRT. Fluorescein concentrations in the effluent were analysed at 
a frequency of 10 seconds. 
 
4.2.3.2 Ozone reactor O3R 
A glass-column ozone reactor (inner Ø 3.6 cm, height 216 cm) with an 
effective liquid volume of 1.6 L operated in a counter-current mode was 
continuously fed with effluent of BR1. A gaseous ozone/air mixture was injected 
at the bottom of the column though a diffuser to create fine bubbles. An air flow 
of 1 L/h was used to generate ozone (Ozon Netech NT-BT 2G) and continuously 
analysed (Ozone analyser BMT 964) before injection into the reactor. Ozone in the 
reactor off-gas was measured by a spectrophotometer (KRATOS Spectroflow 783 
UV/Vis Absorbance Detector model 9000-7831, path length=6 mm, λ=254) and 
residual ozone in the liquid effluent by the indigo method [18]. In both streams 
ozone was not detected during the experiment. The applied ozone dose was 
expressed as g O3/g TOC.  
 
4.2.4 Nutrient limitation experiments 
Batch experiments were performed to investigate whether the BO3B process 
was nutrient limited. Two series of duplicate serum bottles (250 mL) were fed with 
150 mL feed solution and inoculated with 3.7 g of BR1 filter bed material. The filter 
bed material was taken after 25 weeks of reactor operation. One series of batches 
was amended with a mixture of macro nutrients and trace elements (Chapter 2). 
The aerobic batches were closed with cotton-wool stoppers, incubated at 20°C on 
a shaker plate and sampled at 0, 46, 53, 69, 77 and 94 hours. 
 
IV
A three-step Bio-Ozone-Bio process 
80 
 
BR1
Effluent
Ozone
Feed
O3R
Off-gas
Settler
Wash-out
TOC
Air
Air
BR2
TOC
O3 products
 
Figure 4.1 Schematic of the experimental set-up. BR1 represents the first biological 
reactor, O3R the ozone reactor and BR2 the second biological reactor. 
 
4.2.3.1 Biological reactors BR1 and BR2 
Two identical lab-scale reactors (BR1 and BR2) were operated in continuous 
mode. Sand with a diameter of 1.2-1.6 mm was obtained from a drinking water 
treatment plant sandfilter (Vitens, de Meern, the Netherlands) and functioned as 
the carrier material in the reactors. Sand and the inoculum mixture were mixed 
and formed the filter bed of the reactors. BR1 and BR2 were inoculated with 2.8 
and 3.3 kg of filter bed material, respectively, the effective reactor volume was 
approximately 1,4 L. The initial dry matter (DM) and organic matter (OM) content 
of the filter bed was 749.5 g DM/kg and 38.0 g OM/kg, respectively. After wash-
out of surplus filter bed material during the adaptation period these contents 
decreased to 734.9 g DM/kg and 30.8 g OM/kg at 23 weeks of operation. Reactors 
were fed from the top by continuous dripping. 
Chapter 4 
81 
 
The influent was dispersed evenly over the filter bed surface by a fine porous 
plate placed on top of the filter bed. Effluent was discharged at the bottom of the 
reactors. A net with marbles on the bottom retained the filter bed. BR1 was 
operated with a subsequent 1.5 L settler, preventing washed-out biomass to enter 
the O3R. BR1 was fed with the feed solution as described in section 4.2.1, BR2 with 
the effluent of the O3R. In both reactors aerobic conditions were obtained by a 
counter-current air flow. Fluorescein was used in a conservative tracer pulse test 
to determine the HRT. Fluorescein concentrations in the effluent were analysed at 
a frequency of 10 seconds. 
 
4.2.3.2 Ozone reactor O3R 
A glass-column ozone reactor (inner Ø 3.6 cm, height 216 cm) with an 
effective liquid volume of 1.6 L operated in a counter-current mode was 
continuously fed with effluent of BR1. A gaseous ozone/air mixture was injected 
at the bottom of the column though a diffuser to create fine bubbles. An air flow 
of 1 L/h was used to generate ozone (Ozon Netech NT-BT 2G) and continuously 
analysed (Ozone analyser BMT 964) before injection into the reactor. Ozone in the 
reactor off-gas was measured by a spectrophotometer (KRATOS Spectroflow 783 
UV/Vis Absorbance Detector model 9000-7831, path length=6 mm, λ=254) and 
residual ozone in the liquid effluent by the indigo method [18]. In both streams 
ozone was not detected during the experiment. The applied ozone dose was 
expressed as g O3/g TOC.  
 
4.2.4 Nutrient limitation experiments 
Batch experiments were performed to investigate whether the BO3B process 
was nutrient limited. Two series of duplicate serum bottles (250 mL) were fed with 
150 mL feed solution and inoculated with 3.7 g of BR1 filter bed material. The filter 
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4.2.5 Analytical methods  
4.2.5.1 Pharmaceuticals 
Liquid samples for pharmaceutical analysis were taken from the influents 
and effluents of the reactors and batch experiments. Samples were directly 
centrifuged at 3620 g, after which the supernatant was frozen and stored at -10°C 
prior to extraction. Pharmaceuticals were extracted by SPE and analysed by LC-
DAD according to the procedure described in Chapter 2.  
 
4.2.5.2 TOC  
Liquid samples for TOC determination were taken from the influents and 
effluents of the reactors and batch experiments and analysed on a Shimadzu TNM-
L ROHS TOC-L. TOC was calculated as the difference between Total Carbon (TC) 
and Inorganic Carbon (IC). IC samples were acidified to pH 2 to convert inorganic 
carbonates into CO2. CO2 was converted from the liquid phase to the gas phase by 
sparging synthetic air (80% N2, 20% O2, 0% CO2) and analysed by a non-
dispersive infra-red (NDIR) detector. The carbon in the TC samples was burned at 
720°C and converted into gaseous CO2 where after it was analysed on the NDIR 
detector.  
 
4.2.5.3 Toxicity assays 
Standardized bioassays on three trophic levels involving Daphnia magna, 
Pseudokirchneriella subcapitata and Vibrio fischeri were conducted as they have 
been widely used for determining toxic effects of pharmaceuticals in wastewater 
[75, 76, 88]. The aquatic bioassays to test for acute toxicity were conducted on 
the feed solution and effluents of each BO3B treatment step operated at an ozone 
dose of 0.2 g O3/g TOC and an HRT of 1.46 hours. D. magna immobilization was 
determined with the Daphtoxkit F™ magna tests (MicroBioTests Inc.) according to 
the ISO Standard 6341. D. magna immobilization was studied after 48 hour 
exposure. P. subcapitata growth inhibition and toxicity towards V. fischeri were 
tested according to the methods described by He, et al. [103] but using K2Cr2O7 
as positive control to validate the protocol for the P. subcapitata assay. 
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4.3 Results and Discussion 
4.3.1 General performance 
Nutrient removal, pH changes and wash-out of the filter bed were 
investigated to assess the general performance of the biological reactors. 
Consistent with the prevailing aerobic conditions in BR1, ammonium and nitrite 
were completely nitrified to nitrate. No further conversion of nitrate was found 
over O3R and BR2. Phosphate concentrations were halved over the BO3B process, 
which mainly occurred in BR1. No remarkable changes in pH were found as the pH 
in the effluents of BR1, O3R and BR2 was 7.7, 8.1 and 7.7, respectively. Because 
of nutrient and trace element limitation concerns in the feed solution, the effect of 
nutrient and trace element addition was studied in batch experiments. Results of 
the batches amended with a nutrient and trace element solution did not 
demonstrate a higher TOC or pharmaceutical removal efficiency (data not shown). 
Pharmaceutical removal patterns and rates were identical between batches with 
or without the additional nutrients and trace elements. This showed that the feed 
solution (i.e. the secondary clarified effluent) contained sufficient nutrients and 
trace elements to support biological TOC and pharmaceutical removal. During the 
adaptation period of 5 months inclination of the filter bed by several centimetres 
and wash-out of surplus particulate OM was observed. Initially the OM content of 
BR1 was 50.7 g OM/kg DM, whereas this was reduced to 41.8 g OM/kg DM after 
the adaptation period. Thereafter, no appreciable wash-out was observed during 
the 5 month experimental period. No major changes in the TOC and 
pharmaceutical removal efficiency of BR1 were observed during the adaptation 
period. This implies that the biomass was well adapted to pharmaceuticals and no 
noticeable further adaptation occurred. Incidental clogging of major flow paths 
affecting the reactor hydraulics was observed throughout the entire 10 months of 
operation. In most cases the clogging was overcome by the reactor itself by water 
build-up after which new flow paths were formed.  
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4.3.2 The BO3B process 
We designed the BO3B process as a cost-effective alternative to direct 
ozonation for the removal of pharmaceuticals from WWTP effluents. As 
implementation of ozone treatment is often associated with high operational costs, 
the BO3B process aims at reducing ozone inputs. A key parameter determining the 
cost-effectiveness of ozonation is the OM concentration, i.e. TOC or dissolved 
organic carbon (DOC), as it reacts with ozone and OH radicals and thereby 
decreases the removal efficiency of target compounds [295]. Hence, Lee et al. 
[150] found that the removal of pharmaceuticals by ozonation was consistent 
when the ozone dose was normalized to the OM concentration in the liquid (i.e., g 
O3/g DOC) for various WWTP effluents with different origins. Direct ozonation of 
the feed solution used in this study, containing a moderately high OM 
concentration of 17.3±3.3 mg TOC/L, would require relatively high absolute ozone 
doses. Therefore we aimed at TOC removal in the first biological treatment step 
(BR1). At the most intensively studied HRT of 1.46 hours a TOC elimination of 
38±4% was observed over BR1. Thus, by applying a TOC normalized ozone dose, 
the absolute ozone dose in the subsequent O3R could be proportionally reduced, 
thereby increasing the cost-effectiveness of O3R to remove the present 
pharmaceuticals. In comparison, studies on post-treatment by ozonation of Swiss, 
Japanese and U.S. wastewaters used feed solutions with lower OM concentrations; 
7.0-7.7 [117], 2.9-4.2 [193], 4.2-6.0 [111], 2.4-4.8 [329] and 4.7-7.1 mg DOC/L 
[150]. However, for other wastewaters originating from the U.S., Australia and 
Germany, moderate to high OM concentrations are found, 6.6-10.3 mg TOC/L 
[298] and 15-26.4 [150] and 23.0 mg DOC/L [265]. This demonstrates the high 
variety in wastewater matrices and indicates that the benefit of biological OM 
removal prior to ozonation is not limited to this study only. The TOC removal over 
O3R was 6%. However, the average TOC removal at ozone doses ranging from 
0.1-0.5 g O3/g TOC was 13±6% and did not correlated with the ozone dose. This 
low and unsteady TOC removal during ozonation is also found by others [20]. The 
average TOC removal over BR2 was 17±3%, which is a result of the increased 
biodegradability after ozonation [243]. 
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4.3.3 Pharmaceutical removal in the BO3B process 
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Figure 4.2 Pharmaceutical removal over the BO3B process at an ozone dose of 0.2 g O3/g 
TOC and an HRT of 1.46 hours. 
 
Pharmaceutical removal over the BO3B process operated at an ozone dose 
and HRT of respectively 0.2 g O3/g TOC and 1.46 hours is depicted in Figure 4.2. 
In general, pharmaceuticals were effectively removed over the three step process 
displaying removal efficiencies of >60% to complete removal. Compounds known 
to be susceptible towards biodegradation such as caffeine, gemfibrozil, ibuprofen 
and naproxen were well removed (>95%) in the first bioreactor (BR1). Of the 
moderately biodegradable compounds sulfamethoxazole was efficiently removed 
(>99%), whereas metoprolol and trimethoprim were only partially removed during 
biological treatment, respectively 32% and 42%. Unsurprisingly, the recalcitrant 
compounds carbamazepine and diclofenac showed limited removal in BR1 (<14%). 
Carbamazepine, diclofenac and trimethoprim were targeted by ozonation in the 
subsequent O3R, demonstrating removal efficiencies of 77%, 80% and 49%, 
respectively. The other compounds were removed by <10%. The small remaining 
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(BR1). At the most intensively studied HRT of 1.46 hours a TOC elimination of 
38±4% was observed over BR1. Thus, by applying a TOC normalized ozone dose, 
the absolute ozone dose in the subsequent O3R could be proportionally reduced, 
thereby increasing the cost-effectiveness of O3R to remove the present 
pharmaceuticals. In comparison, studies on post-treatment by ozonation of Swiss, 
Japanese and U.S. wastewaters used feed solutions with lower OM concentrations; 
7.0-7.7 [117], 2.9-4.2 [193], 4.2-6.0 [111], 2.4-4.8 [329] and 4.7-7.1 mg DOC/L 
[150]. However, for other wastewaters originating from the U.S., Australia and 
Germany, moderate to high OM concentrations are found, 6.6-10.3 mg TOC/L 
[298] and 15-26.4 [150] and 23.0 mg DOC/L [265]. This demonstrates the high 
variety in wastewater matrices and indicates that the benefit of biological OM 
removal prior to ozonation is not limited to this study only. The TOC removal over 
O3R was 6%. However, the average TOC removal at ozone doses ranging from 
0.1-0.5 g O3/g TOC was 13±6% and did not correlated with the ozone dose. This 
low and unsteady TOC removal during ozonation is also found by others [20]. The 
average TOC removal over BR2 was 17±3%, which is a result of the increased 
biodegradability after ozonation [243]. 
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Figure 4.2 Pharmaceutical removal over the BO3B process at an ozone dose of 0.2 g O3/g 
TOC and an HRT of 1.46 hours. 
 
Pharmaceutical removal over the BO3B process operated at an ozone dose 
and HRT of respectively 0.2 g O3/g TOC and 1.46 hours is depicted in Figure 4.2. 
In general, pharmaceuticals were effectively removed over the three step process 
displaying removal efficiencies of >60% to complete removal. Compounds known 
to be susceptible towards biodegradation such as caffeine, gemfibrozil, ibuprofen 
and naproxen were well removed (>95%) in the first bioreactor (BR1). Of the 
moderately biodegradable compounds sulfamethoxazole was efficiently removed 
(>99%), whereas metoprolol and trimethoprim were only partially removed during 
biological treatment, respectively 32% and 42%. Unsurprisingly, the recalcitrant 
compounds carbamazepine and diclofenac showed limited removal in BR1 (<14%). 
Carbamazepine, diclofenac and trimethoprim were targeted by ozonation in the 
subsequent O3R, demonstrating removal efficiencies of 77%, 80% and 49%, 
respectively. The other compounds were removed by <10%. The small remaining 
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fractions of diclofenac and trimethoprim after ozonation were completely removed 
during the second biological treatment step (BR2), whereas metoprolol was poorly 
removed (21%). In addition, a slight increase (4%) in the carbamazepine 
concentration was found after BR2 which could indicate carbamazepine production. 
Back-transformation of conjugated metabolites to the parent compound is found 
for carbamazepine during biological treatment [210, 291]. Back-transformation of 
ozonation products is to our knowledge not described in the literature, thus no firm 
explanation could be found for this slightly increased carbamazepine 
concentration.  
The pharmaceutical removal patterns of this study were compared to the 
literature on biological treatment and ozonation. BR1 and BR2 were qualitatively 
compared to conventional activated sludge (CAS) systems, as they were inoculated 
with biomass derived from CAS systems. Taking into account that there is a high 
variance in reported removal efficiencies of individual compounds among various 
studies, removal efficiencies of caffeine, ibuprofen and naproxen in CAS processes 
are generally above 75% [65, 164, 241, 287]. This corresponds well with the fate 
of these pharmaceuticals in BR1 of this work. Similar to the moderate removal of 
metoprolol and the low removal of carbamazepine and diclofenac in BR1, reported 
removal efficiencies are typically around 40% and below 35%, respectively. In 
contrast, gemfibrozil, sulfamethoxazole and trimethoprim are relatively well 
removed in this work compared to their reported removal efficiencies in the 
literature of approximately 60%, 50% and 30%, respectively [65, 164, 241, 287]. 
Especially the removal of gemfibrozil and sulfamethoxazole in BR1 was high 
(>99%). Biodegradation is the predominant removal mechanisms in biological 
treatment [7]. Therefore, the biodegradation rates in our study were higher 
compared to CAS systems, since we employed a lower HRT, a lower amount of 
biomass and higher pharmaceutical concentrations. For other biological treatment 
systems, e.g. sand-filters, elevated removal efficiencies for individual 
pharmaceuticals have been observed compared to CAS systems [91, 217]. A better 
removal in a sand-filter than in CAS systems was found by Reungoat, et al. [217] 
for i.a. trimethoprim. Nevertheless, in that sand-filter the removal efficiencies of 
caffeine, gemfibrozil, metoprolol and sulfamethoxazole were low, ~30%, ~50%, 
<10%, no removal, respectively, compared to CAS systems and BR1 of this work. 
Correspondingly, Göbel, et al. [91] found a high (74%) trimethoprim removal 
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during sand filtration, however no effective elimination was found for 
sulfamethoxazole and other antibiotics. In sand filtration and activated sludge 
treatment aerobic conditions were found to correlate positively to pharmaceutical 
removal [7, 91, 171]. Surprisingly, the compounds for which better anaerobic 
removal is reported such as trimethoprim and sulfamethoxazole were well 
removed in BR1. Hence, the observed pharmaceutical removal suggested that BR1 
was an effective barrier to biodegradable compounds. 
The effective oxidation of diclofenac, carbamazepine and trimethoprim 
during ozone treatment at 0.2 g O3/g TOC and an HRT of 1.46 hours is in good 
agreement with their high reported ozonation rate constants (kO3) of 6.8, 3 and 
2.7 x 105 M-1 s-1, respectively [329]. The limited metoprolol removal during 
ozonation corresponds well with its moderate kO3 of 2 x 103 M-1 s-1. The results of 
this work are in accordance with the work on ozonation of secondary clarified 
effluent by Hollender, et al. [111]. Similarly, this can be attributed to the high 
ozonation rate constants, the neutral pH and the absence of ozone scavengers like 
nitrite (<0.05 mg/L). Although the removal efficiency decreased at lower ozone 
doses for most of their tested compounds, diclofenac, carbamazepine and 
trimethoprim were well removed (>95%) at 0.40 g O3/g DOC. At this dose 
metoprolol removal was approximately 60%, whereas it was effectively removed 
(>95%) at 1.16 g O3/g DOC. The observed removal by ozonation is typically a 
result of the breakdown of pharmaceuticals into smaller oxidized products rather 
than mineralisation [243]. For example, the formation of different quinazoline-
containing products during carbamazepine ozonation [178]. Therefore 
considerable amounts of ozonation products will enter BR2. 
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Figure 4.3 Pharmaceutical removal over the BO3B process at an HRT of 1.46 hours and 
ozone doses of (A) 0.1, (B) 0.2, (C) 0.4 and (D) 0.5 g O3/g TOC. 
 
Pharmaceutical removal over the BO3B process at ozone doses varying from 
0.1-0.5 g O3/g TOC at an HRT of 1.46 hours is depicted in Figure 4.3. The 
recalcitrance of carbamazepine towards biodegradation and its high ozonation rate 
constant (>105 M-1 s-1) allows this compound to be used as indicator for the O3R 
performance at different ozone doses. At ozone doses of 0.4 and 0.5 g O3/g TOC 
carbamazepine was completely removed over the BOB process, which was mainly 
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contributed to ozonation. Incomplete removal of ~90% and ~75% was found for 
ozone doses of 0.2 and 0.1 g O3/g TOC, respectively. These results are in good 
accordance with Lee, et al. [150], who reported a carbamazepine removal by 
ozonation of ~55%, 55-90% and >99% at ozone doses of 0.1, 0.25 and 0.5 g 
O3/g DOC, respectively. For the other pharmaceuticals a complete removal was 
obtained even at the lowest ozone doses, except for trimethoprim, even though 
BR1 performed poorly in that testing campaign. Thus, ozonation effectively 
contributed to the pharmaceutical removal in the BO3B process at an ozone dose 
of 0.1 g O3/g TOC (e.g. >99% diclofenac and >40% carbamazepine removal). This 
is better than the <30% pharmaceutical removal at an ozone dose of 0.1 g O3/g 
DOC reported by Reungoat et al. [216] which can possibly be explained by the 
difference in using DOC or TOC to normalize the ozone dose as the amount of DOC 
is smaller than the amount of TOC. In general, the removal of diclofenac, 
metoprolol and trimethoprim was unsteady over BR1 and O3R in the different test 
campaigns. Although their biodegradability is typically reported as moderate or 
low [65, 164, 241, 287], these compounds were effectively biodegraded during 
some of our test campaigns. In all cases, the combination of BR1 and O3R 
effectively removed diclofenac, independently of the applied ozone dose. 
Metoprolol is less susceptible to ozonation and unsteadily removed in O3R when 
BR1 showed low removal (i.e. at 0.1 and 0.2 g O3/g TOC). The low metoprolol 
removal by ozonation is similar to the findings of Hollender, Zimmermann et al. 
(2009) who found ~90% and ~60% metoprolol removal at 0.62 and 0.40 g O3/g 
DOC, respectively. Trimethoprim removal did not correlate well with the applied 
ozone dose. At the intermediate ozone doses it was removed by ozonation, 
whereas it was not removed at highest and lowest ozone doses. Regarding the 
reported high trimethoprim ozonation rate constant (>105 M-1 s-1) removal at 0.5 
g O3/g TOC was expected. No other explanation than a possible analytical error at 
the highest ozone dose could be found to explain this finding. Ozonation of 
bromide-containing water can lead to the formation of bromate, which is suspected 
to be carcinogenic to humans [292]. In our study bromide was not found above 
the detection limit (5 µg/L) in any of the samples. Hence, no toxic effects of 
bromate is expected as drinking water standards are 10 µg/L. These findings are 
in good accordance with the low bromide concentrations detected in drinking water 
intake of typically <25 μg/L [294].  
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Figure 4.3 Pharmaceutical removal over the BO3B process at an HRT of 1.46 hours and 
ozone doses of (A) 0.1, (B) 0.2, (C) 0.4 and (D) 0.5 g O3/g TOC. 
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constant (>105 M-1 s-1) allows this compound to be used as indicator for the O3R 
performance at different ozone doses. At ozone doses of 0.4 and 0.5 g O3/g TOC 
carbamazepine was completely removed over the BOB process, which was mainly 
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contributed to ozonation. Incomplete removal of ~90% and ~75% was found for 
ozone doses of 0.2 and 0.1 g O3/g TOC, respectively. These results are in good 
accordance with Lee, et al. [150], who reported a carbamazepine removal by 
ozonation of ~55%, 55-90% and >99% at ozone doses of 0.1, 0.25 and 0.5 g 
O3/g DOC, respectively. For the other pharmaceuticals a complete removal was 
obtained even at the lowest ozone doses, except for trimethoprim, even though 
BR1 performed poorly in that testing campaign. Thus, ozonation effectively 
contributed to the pharmaceutical removal in the BO3B process at an ozone dose 
of 0.1 g O3/g TOC (e.g. >99% diclofenac and >40% carbamazepine removal). This 
is better than the <30% pharmaceutical removal at an ozone dose of 0.1 g O3/g 
DOC reported by Reungoat et al. [216] which can possibly be explained by the 
difference in using DOC or TOC to normalize the ozone dose as the amount of DOC 
is smaller than the amount of TOC. In general, the removal of diclofenac, 
metoprolol and trimethoprim was unsteady over BR1 and O3R in the different test 
campaigns. Although their biodegradability is typically reported as moderate or 
low [65, 164, 241, 287], these compounds were effectively biodegraded during 
some of our test campaigns. In all cases, the combination of BR1 and O3R 
effectively removed diclofenac, independently of the applied ozone dose. 
Metoprolol is less susceptible to ozonation and unsteadily removed in O3R when 
BR1 showed low removal (i.e. at 0.1 and 0.2 g O3/g TOC). The low metoprolol 
removal by ozonation is similar to the findings of Hollender, Zimmermann et al. 
(2009) who found ~90% and ~60% metoprolol removal at 0.62 and 0.40 g O3/g 
DOC, respectively. Trimethoprim removal did not correlate well with the applied 
ozone dose. At the intermediate ozone doses it was removed by ozonation, 
whereas it was not removed at highest and lowest ozone doses. Regarding the 
reported high trimethoprim ozonation rate constant (>105 M-1 s-1) removal at 0.5 
g O3/g TOC was expected. No other explanation than a possible analytical error at 
the highest ozone dose could be found to explain this finding. Ozonation of 
bromide-containing water can lead to the formation of bromate, which is suspected 
to be carcinogenic to humans [292]. In our study bromide was not found above 
the detection limit (5 µg/L) in any of the samples. Hence, no toxic effects of 
bromate is expected as drinking water standards are 10 µg/L. These findings are 
in good accordance with the low bromide concentrations detected in drinking water 
intake of typically <25 μg/L [294].  
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Figure 4.4 Pharmaceutical removal over the BO3B process at an ozone dose of 0.2 g O3/g 
TOC and HRTs of 0.3 (A), 0.47 (B) and 1.46 (C) hours. 
 
Pharmaceutical removal over the BO3B process at varying HRTs from 0.3-
1.46 hours at an ozone dose of 0.2 g O3/g TOC is depicted in Figure 4.4. The easily 
biodegradable pharmaceuticals caffeine, ibuprofen and naproxen were used to 
assess the influence of HRT on the BO3B process pharmaceutical removal. At HRTs 
of 0.47 and 1.46 hours the removal of these and most other compounds is highly 
similar, resulting in an efficient removal. Only metoprolol behaved different as it 
was better removed at an HRT of 0.47 hours. This agrees well with the results of 
the ozone dose tests (Figure 4.3) in which the biological removal of metoprolol 
was unsteady over the different test campaigns. Similarly, trimethoprim removal 
over BR1 also fluctuated. In contrast to metoprolol, trimethoprim was effectively 
removed in O3R and BR2. The limited biological removal of caffeine, ibuprofen and 
naproxen at an HRT of 0.3 hours compared to the longer HRTs suggests that 0.3 
hours is too short for an effective biological treatment. Matamoros, et al. [171] 
reported a similar trend of decreasing pharmaceutical removal efficiencies at 
increasing hydraulic loading rates for a sand-filter. At a loading rate of 70 mm day-
1, corresponding to an HRT of 4-6 hours, caffeine, diclofenac, ibuprofen and 
naproxen were removed at 98, 76, 90 and 80%, respectively. However, at a 
loading rate of 160 mm day-1 the removal efficiencies decreased to approximately 
66, 58, 50 and 54%, respectively. Assuming a linear relation for the sand-filter 
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between hydraulic loading rate and HRT, whereby these results can be 
quantitatively compared to those at the HRT of 1.46 hours of this study, this 
suggest that the pharmaceutical removal of BR1 was relatively high. Escolà Casas 
and Bester [78] studied and reviewed diclofenac removal in various sand-filters 
(i.e. slow and fast filtration) and found HRT related reaction rate constants k 
(ln ����
���
= � × ���) of 0.004, 0.04, 0.37 and 1.92 hours-1 at HRTs of 5.7, 9.01, 0.108 
and 0.13 hours, respectively. The HRT related reaction rate constants of diclofenac 
in this study are 0.10, 0.96 and 0.59 hours-1 at HRTs of 1.46, 0.47 and 0.3 hours, 
respectively, and thereby at the higher end compared to the reported rate 
constants by Escolà Casas and Bester [78]. An HRT based rate constant calculation 
is a simplification of reality, neglecting heterogeneity aspects of filter beds such as 
redox, substrate and biomass gradients. However, the high variety among 
reported rates suggests that the difference between studies (e.g. inoculation of 
the sand-filter, type of wastewater and operational conditions) justifies the 
comparison of HRT based rate constants. In the literature oxygen or biomass levels 
are reported to be rate limiting in sand-filters [78, 171]. In this study an overdose 
of oxygen was supplied and a surplus of well-adapted biomass was present at 
inoculation resulting in the wash out of biomass. Therefore, it is hypothesized that 
the contact time between biomass and pharmaceuticals is the rate limiting factor. 
Even though the pharmaceutical removal over BR1 was limited at an HRT of 0.3 
hours, the removal over the entire BO3B process was similar at the three HRTs. 
Remaining fractions of pharmaceuticals were effectively ozonated in O3R resulting 
in a complete removal of most pharmaceuticals except for carbamazepine (~80%) 
and trimethoprim (~50%). TOC removal over BR1 reduced from 38%, to 31% to 
19% at HRTs of 1.46, 0.47 and 0.3 hours, respectively. Similarly, Matamoros, et 
al. [171] found a decrease in TSS and BOD5 at decreasing HRTs. 
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Figure 4.4 Pharmaceutical removal over the BO3B process at an ozone dose of 0.2 g O3/g 
TOC and HRTs of 0.3 (A), 0.47 (B) and 1.46 (C) hours. 
 
Pharmaceutical removal over the BO3B process at varying HRTs from 0.3-
1.46 hours at an ozone dose of 0.2 g O3/g TOC is depicted in Figure 4.4. The easily 
biodegradable pharmaceuticals caffeine, ibuprofen and naproxen were used to 
assess the influence of HRT on the BO3B process pharmaceutical removal. At HRTs 
of 0.47 and 1.46 hours the removal of these and most other compounds is highly 
similar, resulting in an efficient removal. Only metoprolol behaved different as it 
was better removed at an HRT of 0.47 hours. This agrees well with the results of 
the ozone dose tests (Figure 4.3) in which the biological removal of metoprolol 
was unsteady over the different test campaigns. Similarly, trimethoprim removal 
over BR1 also fluctuated. In contrast to metoprolol, trimethoprim was effectively 
removed in O3R and BR2. The limited biological removal of caffeine, ibuprofen and 
naproxen at an HRT of 0.3 hours compared to the longer HRTs suggests that 0.3 
hours is too short for an effective biological treatment. Matamoros, et al. [171] 
reported a similar trend of decreasing pharmaceutical removal efficiencies at 
increasing hydraulic loading rates for a sand-filter. At a loading rate of 70 mm day-
1, corresponding to an HRT of 4-6 hours, caffeine, diclofenac, ibuprofen and 
naproxen were removed at 98, 76, 90 and 80%, respectively. However, at a 
loading rate of 160 mm day-1 the removal efficiencies decreased to approximately 
66, 58, 50 and 54%, respectively. Assuming a linear relation for the sand-filter 
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between hydraulic loading rate and HRT, whereby these results can be 
quantitatively compared to those at the HRT of 1.46 hours of this study, this 
suggest that the pharmaceutical removal of BR1 was relatively high. Escolà Casas 
and Bester [78] studied and reviewed diclofenac removal in various sand-filters 
(i.e. slow and fast filtration) and found HRT related reaction rate constants k 
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and 0.13 hours, respectively. The HRT related reaction rate constants of diclofenac 
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hours, the removal over the entire BO3B process was similar at the three HRTs. 
Remaining fractions of pharmaceuticals were effectively ozonated in O3R resulting 
in a complete removal of most pharmaceuticals except for carbamazepine (~80%) 
and trimethoprim (~50%). TOC removal over BR1 reduced from 38%, to 31% to 
19% at HRTs of 1.46, 0.47 and 0.3 hours, respectively. Similarly, Matamoros, et 
al. [171] found a decrease in TSS and BOD5 at decreasing HRTs. 
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Figure 4.5 Pharmaceutical removal over the BO3B process at an ozone dose of 0.1 g O3/g 
TOC and an HRT of 0.3 hours. 
 
The pharmaceutical removal at an ozone dose of 0.1 g O3/g TOC and an HRT 
of 0.3 hours is depicted in Figure 4.5. A complete pharmaceutical removal is 
achieved, except for carbamazepine and trimethoprim. The pharmaceutical 
removal over BR1 in this campaign is higher compared to the HRT of 0.3 hours at 
an ozone dose of 0.2 g O3/g TOC (Figure 4.4). This can be explained by the 
incidental changes in the outflow regime due to clogging of the BR1 filter bed. 
Especially at short HRTs this hydraulic behaviour can locally strongly influence the 
pharmaceutical removal in the reactor. Therefore an HRT longer than 0.3 hours is 
recommended to achieve a continuous and high pharmaceutical removal. At an 
HRT of 0.3 hours the pharmaceutical removal over O3R was low. The low removal 
of carbamazepine is in the same range as its low removal over O3R at an ozone 
dose of 0.1 g O3/g TOC at an HRT of 1.46 hours (Figure 4.3). The ineffective 
ozonation of pharmaceuticals that are recalcitrant towards biological treatment, 
such as carbamazepine, indicates that an ozone dose of 0.1 g O3/g TOC is too low 
for the effective removal of a broad pallet of pharmaceuticals and therefore higher 
doses are recommended for full scale implementation. 
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4.3.7 Toxicity 
The pharmaceutical removal during the campaign in which toxicity was 
tested is depicted in Figure S4.1. Although the pharmaceutical concentrations in 
the BO3B influent in this study were above environmental relevant concentrations, 
no significant inhibition was found for D. magna, P. subcapitata and V. fischeri in 
the toxicity bioassays (Figure S4.2-S4.4). The bioassays with P. subcapitata and 
V. fischeri demonstrated the highest toxicity, however inhibition did not exceed 
25% and showed no significant difference between effluent samples of the 
individual steps of the BO3B process. This is contrary to the increased toxicity 
towards D. magna, P. subcapitata and V. fischeri found after ozonation of other 
pharmaceuticals such as ketoprofen [118]. However, this can be explained by the 
high concentrations (>mg/L) applied in that study compared to this study. Kaiser 
et al. [127] found that transformation products after biological treatment of 
carbamazepine can be more toxic for V. fischeri than carbamazepine. As 
carbamazepine persisted in BR1 it is unlikely that many transformation products 
were formed resulting in low observed toxicities in this study. The three applied 
bioassays test for acute toxicity towards the test organisms. This limits an in-depth 
toxicological evaluation as chronic toxicity such as genotoxic effects are not studied 
in these bioassays. For instance, bio-transformation products of carbamazepine 
were found to have a higher genotoxicity potential than carbamazepine, however 
these products were effectively removed during ozonation [33]. Although the low 
observed acute toxic effects hampered the evaluation of individual BO3B process 
steps in toxicity reduction, the combination of ozonation with a subsequent 
biological treatment (i.e. sand filtration) was found to effectively reduce toxicity 
[248]. Nevertheless, further ecotoxicological investigations are recommended as 
pharmaceuticals and their transformation products formed during biological and 
ozone treatment can pose diverse ecotoxicological risks [164]. 
 
4.3.8 Costs and energy demand 
Depending on the energy price and the system requirements, production 
costs of ozone are reported to be 0.8 - 1.6 €/kg O3, which represents 20-40% of 
the total costs for large scale ozonation installations [265]. The BO3B process 
operated at an ozone dose of 0.2 g O3/g TOC and HRT of 1.46 hours effectively 
removed pharmaceuticals in this study. Moreover, 38% TOC removal was achieved 
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during biological treatment prior to ozonation (i.e. BR1). Therefore the costs for 
ozone production in the BO3B process are <0.004 €/m3 considering a secondary 
clarified effluent with an average TOC concentration of 17.3 mg/L. Thereby the 
total costs for ozonation (investment and operational costs) are estimated to be 
<0.03 €/m3. The investment and operational costs for biological pre- and post-
treatment (i.e. BR1 and BR2, respectively) are hypothesized to be smaller or equal 
to the costs for ozonation as the operational costs of sand-filters is known to be 
low. The total costs for additional treatment by the BO3B process are therefore 
estimated to be <0.06 €/m3. These costs are on the lower end of the costs 
estimated by Joss, et al. [125], who reported the additional investment and 
operational costs for ozonation and post-filtration to be 0.05 – 0.15 €/m3 
depending on the WWTP size and DOC concentration. According to the Dutch Water 
Authorities, the investment and operational costs for conventional wastewater 
treatment (excluding sewer transport costs) in the Netherlands are 0.45 €/m3 
[280]. Thus, the additional costs for BO3B treatment are less than 15% of the total 
treatment costs. In addition, the yearly average wastewater treatment tariff is 
€55.69 per population equivalent [280]. Based on the <0.06 €/m3 for BO3B 
treatment the yearly additional costs are estimated to be <5 € per population 
equivalent, which corresponds to a less than 10% tariff increase. The energy 
requirements for ozone production are approximately 15 and 35 kWh/kg O3 when 
manufactured from oxygen and air, respectively [89]. Hence, the energy demand 
is about 0.03 - 0.07 kWh/m3. Together with the energy demand of pumps and 
other equipment the total demand is estimated to be 0.1 – 0.15 kWh/m3, which 
corresponds well with literature estimations of 0.1 – 0.3 kWh/m3 [125]. The energy 
demand for conventional wastewater treatment in the Netherlands is about 0.39 
kWh/m3 of which 0.17 kWh/m3 is needed for aeration [280]. Post-treatment by a 
BO3B process would therefore increase the energy consumption by approximately 
25-38%. Overall, this study demonstrates that even for secondary clarified 
effluents with high TOC levels ozonation can be a cost-effective treatment process 
when combined with biological pre- and post- treatment steps, i.e. the BO3B 
process. Therefore, BO3B treatment is found an effective process for the reduction 
of emission of potentially harmful compounds into the aquatic environment. 
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4.4 Conclusions 
The combination of biological treatment and ozonation in the designed 
three-step BO3B process is found an effective treatment process for the removal 
of pharmaceuticals from secondary clarified effluent with high TOC concentrations. 
Ozonation and biological treatment are complementary processes targeting 
different pharmaceuticals. Pharmaceutical removal over the BO3B process 
exceeded 85%, except for metoprolol (60%), at a low ozone dose of 0.2 g O3/g 
TOC and an HRT of 1.46 hours in the biological reactors. Carbamazepine that 
persisted during biological treatment was completely ozonated at increased ozone 
doses of 0.4 g O3/g TOC, whereas at a dose of 0.1 g O3/g TOC it showed low 
removal (<40%). Easily and moderately biodegradable pharmaceuticals such as 
caffeine, gemfibrozil, ibuprofen, naproxen and sulfamethoxazole were >95% 
removed by biological treatment at HRTs of 0.47 and 1.46 hours. At the lowest 
tested HRT of 0.3 hours these pharmaceuticals were incompletely removed (35%-
95%). The input of absolute amounts of ozone was effectively reduced by the 
elimination of TOC over the first biological step, i.e. BR1. At HRTs of 1.46, 0.47 
and 0.3 hours a decrease in TOC concentration was found over BR1of respectively 
38%, 31% and 19%, resulting in a proportional reduction of ozone in the 
subsequent ozone reactor, i.e. O3R. No appreciable acute toxicity towards D. 
magna, P. subcapitata and V. fischeri was found after exposure to the influents 
and effluents of the individual BO3B reactors. However, further ecotoxicological 
investigations are suggested. The secondary clarified effluent contains sufficient 
nutrients and trace elements to support biological pharmaceutical removal. Costs 
associated to BO3B treatment are estimated to increase the current treatment 
costs for conventional wastewater treatment by 15%, whereas the yearly tariff per 
population equivalent in a country like the Netherlands is estimated to increase by 
less than 10%. The energy demand for wastewater treatment is expected to 
increase by 25-38%. Overall, the BO3B process is a cost-effective treatment 
process for the removal of pharmaceuticals from secondary clarified effluents. 
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Supplementary Information 
 
Table S4.1 Concentrations (mg/L) of the ionic constituents from the WWTP Bennekom 
secondary clarified effluent. 
 F- Cl- NO2- NO3- NH4+ SO24- PO43- Br- 
Batch 1 0.14 260.4 n.d. 5.98 0.08 6.65 1.62 n.d. 
Batch 2 0.08 60.2 0.53 4.50 4.70 3.32 1.01 n.d. 
n.d. – not detected, NO2- detection limit is <50 µg/L, Br- detection limit is 5 µg/L. Anions 
were analysed on an Ion Chromatograph (Dionex ICS 2100, Dionex IonPac AS17, 4 x 2505 
mm). An injection volume of 10 μL was used with a constant flow of 1 mL / minute and 
the following flow program: 10 minutes at 5 mM KOH, in 15 minutes a linear increase to 
30 mM KOH, 3 minutes on 30 mM KOH and back to 5 mM KOH in 2 minutes. Samples were 
diluted 10 times. Measurements were performed in triplicate, stated values are the 
average. Ammonium was analysed by Hach Lange kits LCK 303 and 304. 
 
Table S4.2 Average concentrations (mg/L) and standard deviations of the carbon fractions 
in the feed solution of the BO3B process over the 5-month experimental period. 
Total carbon Total inorganic carbon Total organic carbon 
48.5±9.1 31.2±6.3 17.3±3.3 
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Figure S4.1 Pharmaceutical removal over the BO3B process during the toxicity tests at an 
ozone dose of 0.2 g O3/g TOC and an HRT of 1.46 hours. 
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Figure S4.2 Toxicity towards V. fischeri of the feed water (Infl.), first biological reactor 
(BR1), ozone reactor (O3R) and second biological reactor (BR2). Columns represent the 
average toxicity (n=6), error bars represent standard deviations. 
 
 
Figure S4.3 Toxicity towards P. subcapitata of the feed water (Infl.), first biological reactor 
(BR1), ozone reactor (O3R) and second biological reactor (BR2). Columns represent the 
average toxicity (n=6), error bars represent standard deviations. 
 
 
Figure S4.4 Toxicity towards D. magna of the feed water (Infl.), first biological reactor 
(BR1), ozone reactor (O3R) and second biological reactor (BR2). Columns represent the 
average toxicity (n=4), error bars represent standard deviations. 
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Chapter 5
Micropollutant removal in an algal treatment system 
fed with source separated wastewater streams
Treatment in an algal photobioreactor 
100 
Abstract 
Micropollutant removal in an algal treatment system fed with source 
separated wastewater streams was studied. Batch experiments with the 
microalgae Chlorella sorokiniana grown on urine, anaerobically treated black water 
and synthetic urine were performed to assess the removal of six spiked 
pharmaceuticals (diclofenac, ibuprofen, paracetamol, metoprolol, carbamazepine 
and trimethoprim). Additionally, incorporation of these pharmaceuticals and three 
estrogens (estrone, 17β-estradiol and ethinylestradiol) into algal biomass was 
studied. Biodegradation and photolysis led to 60 – 100% removal of diclofenac, 
ibuprofen, paracetamol and metoprolol. Removal of carbamazepine and 
trimethoprim was incomplete and did not exceed 30% and 60%, respectively. 
Sorption to algal biomass accounted for less than 20% of the micropollutant 
removal. Furthermore, the presence of micropollutants did not inhibit C. 
sorokiniana growth at applied concentrations. Algal treatment systems allow 
simultaneous removal of micropollutants and recovery of nutrients from source 
separated wastewater. Nutrient rich algal biomass can be harvested and applied 
as fertilizer in agriculture, as lower input of micropollutants to soil is achieved when 
algal biomass is applied as fertilizer instead of urine. 
Keywords 
Micropollutants; Wastewater; Algae; Source separation; Pharmaceuticals 
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5.1 Introduction
The global increase of population and consequent shortage of natural
resources causes increasing interest in mining of commodities present in waste
streams, such as the domestic wastewater, which is a potential source of energy,
organic matter and nutrients [199, 289]. 
The use of algae in wastewater treatment is promising for their high nutrient
recovery capacity. Algae have demonstrated simultaneous removal of nitrogen and
phosphorus from domestic wastewater down to very low concentrations of 2.2
mg/L and 0.15 mg/L, respectively, by uptake of the nutrients into their cells [28]. 
High biomass yields can be achieved when growing algae heterotrophically in the
presence of ammonia and nitrate [131]. Harvested algal biomass is a potential
source for production of fertilizer and bioenergy [38, 179, 205, 224].
Source separated collection of toilet wastewater makes recovery of organic
matter and nutrients economically feasible because of their high concentration in 
a relatively small volume [316]. This volume is less than 30% of the total volume 
of domestic wastewater when conventional toilets are used, and even less than 
5% when vacuum toilets are used due to the reduced volume of flush water [268]. 
It contains 38% of organic matter, 88% of nitrogen and 68% of phosphorus of the
domestic wastewater [136]. Toilet wastewater, comprising of urine, faeces, toilet
paper and flush water, can be collected either as a single stream, called black
water, or as two separate streams, urine (yellow water) and faeces (brown water)
[200]. Most of the organic matter comes from faeces, while nutrients are mainly
present in urine [136]. Treatment of black water in an up-flow anaerobic sludge
blanket (UASB) reactor allows conversion of organic matter into biogas [317]. 
Numerous techniques are available to remove nitrogen and phosphorus from the
nutrient rich anaerobically treated black water (AnBW) or urine. However, most of 
these techniques are characterized by nutrient removal rather than by nutrient
recovery [261, 284]. Techniques that allow nutrient recovery like struvite or
calcium phosphate precipitation often have the drawback that they cannot 
adequately recover nitrogen and phosphorus simultaneously [179, 269, 317]. 
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Abstract 
Micropollutant removal in an algal treatment system fed with source
separated wastewater streams was studied. Batch experiments with the
microalgae Chlorella sorokiniana grown on urine, anaerobically treated black water
and synthetic urine were performed to assess the removal of six spiked
pharmaceuticals (diclofenac, ibuprofen, paracetamol, metoprolol, carbamazepine
and trimethoprim). Additionally, incorporation of these pharmaceuticals and three
estrogens (estrone, 17β-estradiol and ethinylestradiol) into algal biomass was
studied. Biodegradation and photolysis led to 60 – 100% removal of diclofenac,
ibuprofen, paracetamol and metoprolol. Removal of carbamazepine and
trimethoprim was incomplete and did not exceed 30% and 60%, respectively.
Sorption to algal biomass accounted for less than 20% of the micropollutant
removal. Furthermore, the presence of micropollutants did not inhibit C. 
sorokiniana growth at applied concentrations. Algal treatment systems allow 
simultaneous removal of micropollutants and recovery of nutrients from source
separated wastewater. Nutrient rich algal biomass can be harvested and applied
as fertilizer in agriculture, as lower input of micropollutants to soil is achieved when 
algal biomass is applied as fertilizer instead of urine.
Keywords
Micropollutants; Wastewater; Algae; Source separation; Pharmaceuticals
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5.1 Introduction 
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(Figure 5.1) as it is one of the few techniques demonstrating simultaneous nitrogen 
and phosphorus recovery. 
Tuantet, et al. [276] showed that 85% of phosphorus and 90% of nitrogen 
are recovered from urine by incorporation into algal biomass. Vasconcelos 
Fernandes, et al. [285] also showed high recovery of nitrogen (74%) and 
phosphorus (98%) from AnBW, when growing Chlorella sorokiniana in batch [86]. 
The algal biomass, enriched with nutrients, can be used as fertilizer [277]. 
 
 
 
 
Figure 5.1 Two options of algal treatment system utilization for treatment of source 
separated wastewater streams. 
 
In addition to carbon and nutrients, black water contains pathogens and 
organic micropollutants. Lienert, et al. [157] investigated excretory routes of 212 
pharmaceuticals, and showed that nearly two thirds of them are excreted with 
urine, while the rest are excreted with faeces.  
Micropollutants are insufficiently removed during anaerobic treatment of 
black water and end up in the AnBW [62]. Thus, successful treatment of AnBW or 
urine should provide adequate removal of micropollutants before the treated 
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effluent is discharged or reused. Shi et al. [237] showed that natural and synthetic 
estrogens can be effectively removed in algae-based wastewater treatment 
systems. However, little is known about the removal of pharmaceuticals by algae. 
The quality of the algal biomass, grown on AnBW or urine, is also a focus for 
research, because algae can potentially accumulate persistent organic 
micropollutants [54]. The presence of micropollutants in algal biomass grown on 
AnBW or urine can hinder the possibilities for biomass utilization as fertilizer and 
needs to be addressed [158, 301].  
The aim of this study is to assess micropollutant removal and sorption to 
biomass in an algal treatment system with AnBW and urine used as growth media. 
Six pharmaceuticals (ibuprofen, diclofenac, paracetamol, trimethoprim, metoprolol 
and carbamazepine) and three estrogens (estrone (E1), estradiol (E2), and 
ethinylestradiol (EE2)) were studied, with the estrogens determined in algal 
biomass only. The possibilities for reuse of algal biomass in agriculture are further 
discussed. Additionally, the inhibiting effect of elevated concentrations of 
micropollutants on algae growth is presented. 
  
5.2 Materials and Methods 
5.2.1 Micropollutants 
Ibuprofen, diclofenac, metoprolol, trimethoprim, paracetamol, fenoprofen, 
diaveridine, dihydrocarbamazepine, trimethoprim-d9, estrone, 17β-estradiol, 
ethinylestradiol and 17β-estradiol-d3 were purchased from Sigma-Aldrich 
(Germany). Carbamazepine was purchased from Fagron (the Netherlands). The 
standard and spiking solutions of the compounds were prepared in methanol. The 
chosen pharmaceuticals represent different therapeutic groups and are widely 
used in large quantities in Europe and North America. Most of them are persistent, 
as they are not readily degradable in municipal wastewater treatment plants, 
except for paracetamol [124]. The studied compounds also cover a wide range of 
physical-chemical properties and biodegradability. 
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5.2.2 Inoculum and media 
C. sorokiniana CCAP211/8K was obtained from the Culture Collection of 
Algae and Protozoa (Oban, UK). Algae were pre-cultivated in an incubator at 35°C 
in 250 mL shake flasks containing 100 mL M8a medium [133], enriched air with 
3% CO2 (v/v) and continuous average irradiation of 80 µmol m-2 s-1. Male urine 
was collected from waterless urinals at the sub-department of Environmental 
Technology, Wageningen University, the Netherlands. Urine was diluted six times 
with demi water to support equal biomass growth in all batches. Urine was stored 
at 4°C prior to the start of the experiments. AnBW was collected from a UASB 
reactor operated at 25°C and HRT of 37 days treating black water from 60 
households in Sneek, The Netherlands. AnBW was diluted three times to support 
equal biomass growth in all batches and was stored at 4°C prior to the 
experiments. Urea-based synthetic urine was prepared to mimic non-hydrolysed 
urine and consisted of (in 1L) 600 mg urea (CO(NH2)2), 56 mg K2SO4, 110 mg 
K2HPO4, 30 mg Na2HPO4.2H2O, 320 mg NaCl, 21.2 mg CaCl2.2H2O and 73.8 mg 
MgSO4.7H2O. M8a medium was used as a reference medium for biomass growth 
in urine and AnBW [133]. M8a medium was diluted two times to support equal 
biomass growth in all batches. Dilutions to support equal biomass growth for all 
media were based on preliminary experiments. Composition of all media is shown 
in Table 5.1. 
All media were filtered over Whatman® Ashless, Grade 589/1 paper filters 
with pore size Ø 12-25 µm. Iron and micronutrients were added to the diluted 
urine, synthetic urine and diluted AnBW to obtain final concentrations of 160 μM 
EDTA ferric sodium salt, 100 μM Na2EDTA.2H2O, 0.5 μM H3BO3, 33 μM MnCl2.4H2O, 
5.5 μM ZnSO4.7H2O and 3.7 μM CuSO4.5H2O. At the beginning of the experiment 
all media were buffered with 75 mM Hepes at pH 7.0. During the experiment the 
pH was manually controlled with 2M HCl or 2M NaOH at pH 7.0. 
 
Table 5.1 Composition of urine, AnBW, synthetic urine and M8a medium. 
Medium Dilution factor 
PO4-P 
(mg/L) 
Ptotal 
(mg/L) 
NH4-N 
(mg/L) 
Ntotal 
(mg/L) 
Urine 6 24.7 25.2 540 854 
AnBW 3 24.5 24.7 235 236 
Synthetic Urine -  21.2  305 
M8a medium 2  107.7  257 
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5.2.3 Experimental set-up 
Batch experiments were performed in 500 mL sterilized Erlenmeyer flasks, 
closed with sterile cotton-wool stoppers. The flasks were filled with 300 mL 
medium, inoculated with 1.66 x 105 cell/mL C. sorokiniana, and spiked with a 
solution of micropollutants in a final concentration of 100-350 μg/L (Table S5.1). 
Spiking of micropollutants was necessary to obtain sufficient LC-MS response 
(>100 times higher than the limit of quantification). After spiking, the 
concentrations of the pharmaceuticals were in the same order of magnitude as the 
maximal concentrations reported in AnBW and source-separated urine (Table 
S5.1). Batch experiments were performed at ten different conditions, with each 
condition performed in triplicate (Table 5.2). Batches without algal inoculum were 
started one month later to prevent cross-contamination from other batches in the 
incubator. All batches were run until the algal growth curves reached the stationary 
phase. 
Batches were incubated at 35°C (Infors HT® Multitron incubator) with a 
continuous average illumination of 68 µmol m-2 s-1. The incubator headspace was 
enriched with 3% CO2 (v/v) and humidity controlled at 75%. Batches were 
continuously shaken and randomized daily for equal light distribution. Abiotic 
batches were set up to test the non-biological micropollutant removal. Biological 
activity was supressed in the abiotic batches by addition of 0.2 g/L NaN3. Liquid 
samples of 3 mL were taken from each replicate at intervals during the 31 day 
incubation period to monitor biomass growth. Duplicate samples of 5 mL were 
taken from each replicate for micropollutant analysis on day 0, 1, 3, 10, 17, 23 
and 31.  
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Table 5.2 Overview of the batch experiments (each variation reproduced in triplicate). 
Medium Algae MP NaN3 Comments 
M8a medium + - - Unlimited algal growth 
Urine + - - Algal growth in urine 
AnBW + - - Algal growth in AnBW 
Synthetic urine + + - MP removal in synthetic urine with algae 
Urine + + - MP removal in urine with algae 
AnBW + + - MP removal in AnBW with algae 
Urine - + - MP removal in urine without algae 
AnBW - + - MP removal in AnBW without algae 
Urine - + + MP removal in urine at abiotic conditions 
AnBW - + + MP removal in AnBW at abiotic conditions 
MP - Micropollutants 
 
5.2.4 Biomass growth determination  
Chlorophyll-a concentrations were measured with a Phyto-PAM (Heinz Walz 
GmbH, Germany). Chlorophyll-a concentrations provide an estimate of the amount 
of algal biomass. As a measure of actual versus optimal algae growth, chlorophyll-
a results are presented as relative concentrations compared to M8a (Cx/Cmax_M8a) 
regarding M8a as the most optimal growth medium for algae in this experiment.  
The optical density at 750 nm (OD750) was used as a non-specific indicator 
of microbial biomass growth. OD750 was determined by spectrometry analyses 
(Heλios UV, Unicam, UK). The measured OD750 values of the batches were 
corrected for initial OD750 values of the media.  
Dry weight was measured before and after the experiment. Samples were 
filtered over pre-washed 0.2 μm glass microfiber filters (GF/F filter, Whatman Plc., 
UK) and dried overnight at 60°C. The filters were cooled to room temperature in 
a desiccator prior to the weighing. Dry weight produced during the experiment was 
calculated as the difference between dry weight measured at the last and first day 
of the experiment. 
 
5.2.5 Nutrient analysis 
The concentrations of nitrogen and phosphorus were measured with Hach 
Lange test kits in the batches at the beginning and end of the experiment (Ntotal – 
LCK338, NH4-N – LCK303, NO2-N – LCK342, NO3-N – LCK340, Ptotal – LCK350 and 
PO4-P – LCK350). Mg2+ was measured with Inductively Coupled Plasma Optical 
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Emission Spectrometer (ICP-OES, Perkin-Elmer Optima 5000 DV) at the end of the 
experiment. 
The samples for nutrients analysis were centrifuged at 3400 rpm for 10 
minutes and filtered through <2 µm pore size paper filter. Nitrogen removal is 
presented as the difference between Ntotal at the beginning and NH4+-N at the end 
of the experiment, as NO2-N and NO3-N were not found in the batches at the end 
of the experiment. Absolute phosphorus removal is presented as the difference 
between initial and final PO4-P concentrations. Relative nitrogen and phosphorus 
removal is presented as Cx/C0. 
 
5.2.6 Micropollutant analysis 
Samples for micropollutant analysis were centrifuged at 3400 rpm for 10 
minutes directly after sampling for separation of liquid phase from suspended 
matter, which represents algal biomass. Liquid samples and solid pellets were 
stored separately at -20ºC until analysis. Liquid samples were directly injected 
onto the LC-MS/MS. Solid pellets were mixed in 5 mL of acetonitrile and sonicated 
during 20 minutes for micropollutant extraction. The extract was separated from 
the solids by centrifugation. For pharmaceuticals analysis 2 mL of extract was 
evaporated till dryness in the vacuum chamber under a gentle nitrogen stream. 
The precipitate was dissolved in methanol, then diluted with milliQ in a ratio 9:1 
and injected into the column. For estrogen analysis 1 mL of extract was evaporated 
till dryness. The precipitate was dissolved in 50 µL of 0.1 M Na2CO3 solution and 
50 µL of dansyl chloride solution in dried acetone and incubated at 60ºC during 10 
minutes according to the modified method of Anari et al. [9]. 0.2 mL of acetonitrile 
and 0.2 mL of milliQ were added to the extract after incubation before injection to 
the column. 
Analysis of micropollutants was performed by LC-MS/MS consisting of 
Agilent 1200 HPLC with Agilent 6410 triple quadruple MS/MS operated with Agilent 
Masshunter software. A Phenomenex Kinetex Phenyl-Hexyl column (100x2.1 mm, 
100 Å pore size) was used for separation of pharmaceuticals, and a Phenomenex 
Gemini Phenyl-Hexyl column (150x3.0 mm, 110 Å pore size) was used for 
separation of estrogens. The injection volumes, composition of elution solvents, 
elution gradients and mobile phase flows are presented in Table S5.2. The MS/MS 
was working in multiple reaction monitoring (MRM) mode. The temperature of 
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electrospray ionization source was 320°C with nitrogen used as a collision gas. The 
nebulizer pressure was 50 psi and a capillary voltage 4000 V. The retention times, 
monitored ions and MS parameters of the studied compounds are presented in 
Table S5.3. 
The internal standards were spiked to liquid samples prior to injection and 
to solid samples prior to extraction (Table S5.1). The samples for calibration curves 
(7-point calibration for liquid samples and 8-point calibration for solid samples) 
were prepared in triplicates separately for liquid and solid samples by dissolution 
of analytes in milliQ. Calibration samples were treated in the same way as liquid 
and solid samples. The precision of the method was determined as a relative 
standard deviation between triplicate measurements and was below 15% for each 
analysed concentration. For recovery determination analytes were spiked to the 
liquid samples taken on day 0 and to the solid samples (Table S5.4). Recoveries 
were determined as the ratio of the measured amount of an analyte in a spiked 
sample minus the measured background amount of an analyte in a sample divided 
by the spiked amount of an analyte. A signal-to-noise ratio (S/N) of three was 
used to estimate limits of detection and signal-to-noise ratio of ten was used for 
estimate limits of quantification (Table S5.5).  
 
 
 
  
Chapter 5 
109 
 
A 
 
B 
 
Figure 5.2 Chlorophyll-a levels (A), expressed concentration divided over maximal 
concentration in M8a medium and optical densities at 750 nm (B). Error bars represent 
standard deviations between triplicates 
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electrospray ionization source was 320°C with nitrogen used as a collision gas. The 
nebulizer pressure was 50 psi and a capillary voltage 4000 V. The retention times, 
monitored ions and MS parameters of the studied compounds are presented in 
Table S5.3. 
The internal standards were spiked to liquid samples prior to injection and 
to solid samples prior to extraction (Table S5.1). The samples for calibration curves 
(7-point calibration for liquid samples and 8-point calibration for solid samples) 
were prepared in triplicates separately for liquid and solid samples by dissolution 
of analytes in milliQ. Calibration samples were treated in the same way as liquid 
and solid samples. The precision of the method was determined as a relative 
standard deviation between triplicate measurements and was below 15% for each 
analysed concentration. For recovery determination analytes were spiked to the 
liquid samples taken on day 0 and to the solid samples (Table S5.4). Recoveries 
were determined as the ratio of the measured amount of an analyte in a spiked 
sample minus the measured background amount of an analyte in a sample divided 
by the spiked amount of an analyte. A signal-to-noise ratio (S/N) of three was 
used to estimate limits of detection and signal-to-noise ratio of ten was used for 
estimate limits of quantification (Table S5.5).  
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5.3 Results and Discussion 
5.3.1 Algae growth and nutrient removal 
Algal biomass growth, presented as chlorophyll-a (Figure 5.2a), and non-
specific biomass growth, presented as OD750 (Figure 5.2b), and dry weight (Figure 
5.3) were determined in all batches to assess possible toxic effects of spiked 
micropollutants on algae. During the first week of the experiment all inoculated 
batches displayed a similar increase in chlorophyll-a and OD750, except for the 
more pronounced increase in OD750 in spiked AnBW. The similarities in biomass 
growth up to day 14, regardless of the medium, confirmed the absence of acute 
toxic effects of the spiked micropollutants to C. sorokiniana. Experiments were 
stopped when no further algae growth was expected. Urine batches were incubated 
for 23 days, all other batches for 31 days. Final chlorophyll-a levels, OD750 and dry 
weights were similar between spiked and non-spiked inoculated AnBW, spiked and 
non-spiked inoculated urine and synthetic urine and M8a medium, except for OD750 
in AnBW. The final OD750 in the non-spiked AnBW was 33% higher than in the 
spiked AnBW. However, chlorophyll-a levels and dry weights in these batches were 
similar. Apparently the spiked micropollutants were not toxic for C. sorokiniana at 
the applied concentrations (~100-350 µg/L) within the timeframe of the 
experiment. 
 
 
Figure 5.3 Dry weight of the algal biomass grown on the different media. Error bars 
represent standard deviations between triplicates; MP – Micropollutants. 
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only, most likely due to the presence of bacteria, fine particles and precipitate 
formation in the form of struvite, calcium phosphate, or other precipitates during 
the experiment [279]. Average OD750 in non-inoculated and abiotic batches was 
more than an order of magnitude lower than in inoculated urine. As optical density 
is proportional to bacterial density throughout the bacterial growth phase no 
noticeable bacterial growth occurred in the non-inoculated and abiotic batches 
[189].  
Despite no difference observed between growth of algae in spiked and non-
spiked batches, differences in biomass growth parameters were found between 
the media used in the experiments (Figure 5.2, Figure 5.3). Depletion of essential 
nutrients in the media was investigated as the possible reason of the observed 
differences. Nitrogen and phosphorus were completely removed in AnBW and 
synthetic urine at the end of the experiment (Figure 5.4). Complete nitrogen 
removal is in accordance with other studies on nutrient removal by algae [276, 
285]. 
 
 
Figure 5.4 Nitrogen (red bars) and phosphorus (blue bars) removal in the inoculated 
batches at the end of the experiment (23 days for urine batches and 31 days for other 
batches); MP – Micropollutants. 
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Molar N:P ratios in AnBW and synthetic urine in this study were 21:1 and 
32:1 respectively, which is above the average N:P ratio in algal biomass (16:1), 
also known as Redfield ratio [214]. However, both nutrients were depleted in 
AnBW and synthetic urine, whereas only phosphorus depletion was expected based 
on the Redfield ratio. Tuantet, et al. [276] and Vasconcelos Fernandes, et al. [285] 
found N:P ratios of 15:1 to 33:1 in C. sorokiniana biomass grown on human urine 
and AnBW, showing similar deviations of actual N:P ratios from the Redfield ratio. 
The N:P ratios reported by Tuantet, et al. [276] and Vasconcelos Fernandes, et al. 
[285] evince the possibility of simultaneous nitrogen and phosphorus depletion 
observed in this experiment . 
Growth on M8a medium was nitrogen limited. Batches with M8a medium 
showed the highest absolute phosphorus removal but lowest removal efficiency 
(25%). This was expected as the molar N:P ratio in the medium was only 5:1 
which is much lower than the Redfield ratio (16:1). 
Algal biomass growth on urine was not limited by nitrogen or phosphorus. 
Both nutrients were still present in urine at the end of the experiment, while the 
absolute nitrogen removal was two times higher than in the other batches. 
However, growth of algal biomass on urine was already lower than that on AnBW 
and synthetic urine on day 14. Tuantet et al. [275] demonstrated that magnesium 
(Mg2+) deficiency in urine can limit algae growth. Dry weight magnesium content 
in Chlorella sp. ranges between 0.36% and 0.8% [86] indicating the required initial 
Mg2+ concentrations in the medium equal to 6.5 – 20 mg/L based on their biomass 
densities of 2.5 and 1.8 g/L, respectively. Literature reports Mg2+ concentrations 
of 77 mg/L [279], 119 mg/L [86] and 145 mg/L [163] in fresh urine and 0 to 11.1 
mg/L [175], 0.14 to 0.77 mg/L [276] and 1 mg/L [279] in hydrolysed urine. About 
60% of the urine was hydrolysed by the beginning of the experiment. Moreover, 
prior to pH controlling and buffering the pH in the collected urine was 9.1. 
Hypothesized is that due to the hydrolysis and high pH most of Mg2+ precipitated 
and thus became unavailable for uptake by algal cells. This assumption is 
confirmed by measurements of magnesium concentrations, giving 16.8±0.6 mg/L 
Mg2+ in AnBW and 0.9±0.4 mg/L Mg2+ in urine by the end of the experiment. 
Therefore Mg2+ deficiency limited further algae growth and nutrients removal in 
the inoculated urine batches. 
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5.3.2 Micropollutant removal 
The removal of spiked pharmaceuticals from the liquid phase in batches with 
and without algal inoculum and in abiotic batches is presented as the relative 
concentration (Cx/C0) (Figure 5.5). 
Diclofenac removal (40% to 60%) was observed in all batches. As the 
removal was similar in all batches, including the abiotic ones, it is most likely 
attributed to phototransformation. Indeed, direct photolysis plays an important 
role for removal of diclofenac [140], while biodegradation of diclofenac in 
wastewater treatment systems is insignificant [321].  
Ibuprofen removal was observed in all batches, with a higher removal in 
AnBW as growth medium. Indirect photodegradation in the presence of 
photosensitizers, such as dissolved organic matter (DOM) is a possible pathway of 
ibuprofen removal [160]. Canonica et al. [39] showed that the rate of indirect 
photolysis can vary depending on the DOM species used as sensitizer, thus, the 
faster removal of ibuprofen in AnBW could be explained by better photosensitizing 
properties of DOM species present in AnBW compared to other used media. 
Paracetamol was rapidly removed in all batches, except for the urine under abiotic 
conditions. Paracetamol is a readily biodegradable compound, as indicated by a 
reported biodegradation constant kbio >102 L gss-1 day-1 [124]. Additionally, De 
Laurentiis et al. [64] reported that direct photolysis is an important mechanism of 
paracetamol removal in surface waters. Both mechanisms could have been 
involved in the paracetamol removal in this study, because the compound was 
removed in the inoculated batches and abiotic AnBW. However, no sound 
explanation for the absence of paracetamol removal in abiotic urine batches was 
found.  
Complete removal of metoprolol was achieved in batches with algae grown 
on synthetic urine and AnBW. Approximately 70% of this compound was removed 
in the non-inoculated batches with AnBW. Lower removal was observed in the 
urine batches. However, high standard deviations in the urine batches did not allow 
to conclude on the extent of metoprolol removal in urine. Biotransformation was 
the dominant mechanism responsible for the removal of metoprolol, as no removal 
was observed in the abiotic batches. The removal of carbamazepine did not exceed 
10% except for the batch with algae grown on AnBW, where it reached 30%. Low 
removal of carbamazepine is consistent with the data of other researchers, who 
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showed that carbamazepine is stable towards biodegradation under aerobic 
conditions and phototransformation [11, 321]. 
Trimethoprim removal did not exceed 40%, except for the batch with algae 
grown on AnBW, where removal reached 60%. It is consistent with findings of 
Suarez et al. [255], who reported high resistance of trimethoprim to biological 
removal in aerobic conditions. Removal of trimethoprim in the abiotic batches 
reached 20% indicating that photolysis, apart from biotransformation, is a possible 
mechanism of trimethoprim removal in urine and AnBW, as was also demonstrated 
in previous studies [227]. 
The observed removal of paracetamol, ibuprofen, metoprolol, 
carbamazepine and trimethoprim correlates with published aerobic 
biodegradability of these compounds [124, 256]. Algae did contribute to the 
removal of metoprolol, as a higher removal was observed in batches inoculated 
with algae compared to the non-inoculated batches. This is explained by 
mixotrophic nature of microalgae, including Chlorella species, and their ability to 
degrade micropollutants [257]. However, removal of the other micropollutants was 
neither enhanced nor decreased in the presence of algae. Therefore 
biotransformation of these micropollutants was possibly attributed to activity of 
natural present microorganisms in AnBW and urine. 
In addition to biotransformation, photolysis appears to be a major removal 
mechanism in algal treatment systems. Unlike most other biological treatment 
processes, the algal treatment systems use illumination for biomass growth, which 
increases the removal of the light-sensitive micropollutants. For example, removal 
of diclofenac and metoprolol in a conventional sewage treatment plant (STP) 
operated at SRTs of 10 days is less than 25%, as reported by Radjenović, et al. 
[210]. Removal of these compounds in the algal treatment system studied in the 
present paper is higher, e.g. 40-60% removal of diclofenac and complete removal 
of metoprolol [210]. Removal of paracetamol (99%), ibuprofen (99%), 
trimethoprim (40-60%) and carbamazepine (30%) is similar to that reported for 
STP (99%, 99%, 40% and <30%, respectively) [210, 321]. Hence algal 
wastewater treatment systems are at least as good as conventional STPs with 
respect to pharmaceutical removal. Removal of micropollutants and recovery of 
nutrients could be also expected in microalgal biofilms treating the effluent of STP, 
as described by Boelee, et al. [28].   
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Figure 5.5 Pharmaceuticals removal from liquid phase, expressed as triplicate averaged 
concentration divided over concentration at the beginning of the experiment (Cx/C0) Error 
bars represent standard deviations between triplicates; MP – Micropollutants. 
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The potential of more intensively illuminate algal treatment systems with respect 
to higher micropollutant removal is therefore an interesting topic for further 
research. 
The concentrations of spiked micropollutants in suspended matter at the 
end of the experiment of the batches with AnBW and urine were compared (Table 
5.3). Diclofenac, trimethoprim, carbamazepine and ethinylestradiol were adsorbed 
to the suspended matter in both growth media. Natural estrogens and metoprolol 
were only adsorbed to the suspended matter in the batches with urine. Ibuprofen 
and paracetamol were not detected in suspended matter. 
According to the data (Table 5.3), only limited sorption of the studied 
pharmaceuticals to the suspended matter was observed. The results are 
comparable with the previous studies of Lai et al. [142], who showed that only 6% 
of estrogens were adsorbed to algal biomass and of Hirooka et al. [108], who 
observed no accumulation of bisphenol A in algal cells. Concentration limits for 
pharmaceuticals and hormones in organic fertilizers do not exist yet, which makes 
it impossible to assess the feasibility of application of algae as fertilizer from a 
legislative point of view. However, the environmental impact of algae applied as 
fertilizer can be assessed by the model, developed by Rieß [220] and extended by 
Hammer and Clemens [102].  
 
Table 5.3 Sorption of micropollutants to suspended matter. 
Compound 
Concentration, ug/g 
% adsorbed (of initial 
concentration) 
% adsorbed (of 
removed amount) 
urine AnBW urine AnBW urine AnBW 
Diclofenac 2.9 ± 1.5 1.4 ± 0.6 7.5 5.5 15.6 9.1 
Ibuprofen <LOD <LOD <0.5 <0.6 <0.5 <0.6 
Paracetamol <LOD <LOD <0.1 <0.1 <0.1 <0.1 
Metoprolol 0.2 ± 0.1 <LOD 0.4 <0.1 0.8 <0.1 
Trimethoprim 0.7 ± 0.4 1.2 ± 0.4 1.1 3.7 3.8 7.6 
Carbamazepine 0.9 ± 0.4 1.2 ± 0.5 2.6 5.0 12.3 16.7 
Estrone 10.2 ± 2.5 <LOD n.d. n.d. n.d. n.d. 
β-estradiol 0.1 ± 0.1 <LOD n.d. n.d. n.d. n.d. 
Ethinylestradiol 2.5 ± 1.4 0.2 ± 0.1 n.d. n.d. n.d. n.d. 
n.d. – not detected 
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The model assumes that a certain input of nutrients to the agricultural soil 
(N – 170 kg ha-1 year-1, P – 26.4 kg ha-1 year-1, K – 132.8 kg ha-1 year-1) is required 
for crop production. To prevent over fertilization, the application of organic 
fertilizers is limited by the nutrient concentration. The nutrient with the lowest 
fertilizing demand will determine the application rate. According to the elemental 
composition of biomass (C H1.75±0.02 O0.42±0.04 N0.15±0.02 P0.008±0.003 
Mg0.002±0.0003) [276], C. sorokiniana contains in weight percentages 9.2% of 
nitrogen and 1% of phosphorus. Nitrogen is the limiting nutrient with 1.9 ton ha-1 
year-1 of algal biomass required to meet the nitrogen demand. If algal biomass 
from this study would be applied as fertilizer, the annual input of micropollutants 
is 0.0055 kg ha-1 diclofenac, 0.0017 kg ha-1 carbamazepine, 0.01938 kg ha-1 
estrone and 0.0048 kg ha-1 ethinylestradiol. These values are considerably lower 
than the annual input of diclofenac (2.9 kg ha-1), carbamazepine (26.6 kg ha-1), 
estrone (0.275 kg ha-1) and comparable to the annual input of ethinylestradiol 
(0.0025 kg ha-1) predicted from direct application of raw urine as a fertilizer [102]. 
Thus, agricultural application of algal biomass, grown on urine or AnBW is 
preferred over direct application of urine to achieve lower inputs of micropollutants 
to soil.  
Biomass grown on AnBW contains lower concentrations of micropollutants 
than biomass grown in urine, as shown in this study. This is probably due to the 
low biomass yield in the urine batches as a result of the low Mg2+ content in the 
hydrolysed urine. Unless the urine is freshly collected and used for microalgae 
growth, addition of Mg2+ directly to the microalgae culture would be a relatively 
simple option. The nutrient ratio in AnBW is favourable for algal growth. 
Additionally, micropollutants can be removed during the anaerobic treatment 
process, reducing their loads for the algal treatment system and, potentially, 
sorption to the algal biomass. For example, trimethoprim is stable under aerobic 
conditions, while being removed during anaerobic treatment [62].  
 
  
VTreatment in an algal photobioreactor 
116 
 
The potential of more intensively illuminate algal treatment systems with respect 
to higher micropollutant removal is therefore an interesting topic for further 
research. 
The concentrations of spiked micropollutants in suspended matter at the 
end of the experiment of the batches with AnBW and urine were compared (Table 
5.3). Diclofenac, trimethoprim, carbamazepine and ethinylestradiol were adsorbed 
to the suspended matter in both growth media. Natural estrogens and metoprolol 
were only adsorbed to the suspended matter in the batches with urine. Ibuprofen 
and paracetamol were not detected in suspended matter. 
According to the data (Table 5.3), only limited sorption of the studied 
pharmaceuticals to the suspended matter was observed. The results are 
comparable with the previous studies of Lai et al. [142], who showed that only 6% 
of estrogens were adsorbed to algal biomass and of Hirooka et al. [108], who 
observed no accumulation of bisphenol A in algal cells. Concentration limits for 
pharmaceuticals and hormones in organic fertilizers do not exist yet, which makes 
it impossible to assess the feasibility of application of algae as fertilizer from a 
legislative point of view. However, the environmental impact of algae applied as 
fertilizer can be assessed by the model, developed by Rieß [220] and extended by 
Hammer and Clemens [102].  
 
Table 5.3 Sorption of micropollutants to suspended matter. 
Compound 
Concentration, ug/g 
% adsorbed (of initial 
concentration) 
% adsorbed (of 
removed amount) 
urine AnBW urine AnBW urine AnBW 
Diclofenac 2.9 ± 1.5 1.4 ± 0.6 7.5 5.5 15.6 9.1 
Ibuprofen <LOD <LOD <0.5 <0.6 <0.5 <0.6 
Paracetamol <LOD <LOD <0.1 <0.1 <0.1 <0.1 
Metoprolol 0.2 ± 0.1 <LOD 0.4 <0.1 0.8 <0.1 
Trimethoprim 0.7 ± 0.4 1.2 ± 0.4 1.1 3.7 3.8 7.6 
Carbamazepine 0.9 ± 0.4 1.2 ± 0.5 2.6 5.0 12.3 16.7 
Estrone 10.2 ± 2.5 <LOD n.d. n.d. n.d. n.d. 
β-estradiol 0.1 ± 0.1 <LOD n.d. n.d. n.d. n.d. 
Ethinylestradiol 2.5 ± 1.4 0.2 ± 0.1 n.d. n.d. n.d. n.d. 
n.d. – not detected 
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(N – 170 kg ha-1 year-1, P – 26.4 kg ha-1 year-1, K – 132.8 kg ha-1 year-1) is required 
for crop production. To prevent over fertilization, the application of organic 
fertilizers is limited by the nutrient concentration. The nutrient with the lowest 
fertilizing demand will determine the application rate. According to the elemental 
composition of biomass (C H1.75±0.02 O0.42±0.04 N0.15±0.02 P0.008±0.003 
Mg0.002±0.0003) [276], C. sorokiniana contains in weight percentages 9.2% of 
nitrogen and 1% of phosphorus. Nitrogen is the limiting nutrient with 1.9 ton ha-1 
year-1 of algal biomass required to meet the nitrogen demand. If algal biomass 
from this study would be applied as fertilizer, the annual input of micropollutants 
is 0.0055 kg ha-1 diclofenac, 0.0017 kg ha-1 carbamazepine, 0.01938 kg ha-1 
estrone and 0.0048 kg ha-1 ethinylestradiol. These values are considerably lower 
than the annual input of diclofenac (2.9 kg ha-1), carbamazepine (26.6 kg ha-1), 
estrone (0.275 kg ha-1) and comparable to the annual input of ethinylestradiol 
(0.0025 kg ha-1) predicted from direct application of raw urine as a fertilizer [102]. 
Thus, agricultural application of algal biomass, grown on urine or AnBW is 
preferred over direct application of urine to achieve lower inputs of micropollutants 
to soil.  
Biomass grown on AnBW contains lower concentrations of micropollutants 
than biomass grown in urine, as shown in this study. This is probably due to the 
low biomass yield in the urine batches as a result of the low Mg2+ content in the 
hydrolysed urine. Unless the urine is freshly collected and used for microalgae 
growth, addition of Mg2+ directly to the microalgae culture would be a relatively 
simple option. The nutrient ratio in AnBW is favourable for algal growth. 
Additionally, micropollutants can be removed during the anaerobic treatment 
process, reducing their loads for the algal treatment system and, potentially, 
sorption to the algal biomass. For example, trimethoprim is stable under aerobic 
conditions, while being removed during anaerobic treatment [62].  
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5.4 Conclusions 
Our results show that the tested micropollutants did not inhibit C. 
sorokiniana growth at spiked concentrations (100-350 µg/L). In our batches, 
ibuprofen and diclofenac were photolytically removed, whereas the combination of 
photolysis and biodegradation was responsible for the removal of metoprolol and 
paracetamol. Carbamazepine and trimethoprim were recalcitrant towards both 
biodegradation and photolysis. Algae enhanced metoprolol removal, but did not 
enhance nor constrain removal of the other micropollutants. Removal of 
metoprolol and diclofenac in the studied algal treatment system is higher than in 
the conventional STP with a SRT of 10 days showing the removal potential of algae 
based systems. Sorption to the algal biomass accounted for <20% of the removed 
micropollutants, showing that the use of algal biomass grown on urine or AnBW as 
fertilizer introduces less micropollutants to soil compared to the direct application 
of urine. Therefore algal treatment systems have a potential to remove 
micropollutants while simultaneously closing the cycle of nutrients in a safer way. 
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Supplementary Information 
 
Table S5.1 Measured initial concentrations (µg/L) of the studied pharmaceuticals in the 
batches after spiking. 
Compound 
Measured initial 
concentrations (C0) 
Maximal reported 
concentrations in AnBW 
Maximal reported 
concentrations in urine 
Ibuprofen 317 ± 33 456 [62] 794 [271] 
Diclofenac 147 ± 9 59.1 [62] 72 [27] 
Carbamazepine 117 ± 17 6.2 [62] 29 [271] 
Metoprolol 181 ± 62 91.4 [36] n.f.* 
Paracetamol 337 ± 23 602 [62] n.f.* 
Trimethoprim 202 ± 30 2.1 [62] 1300 [27] 
n.f. – data not found 
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Table S5.2 Composition of mobile phases and elution gradient programs for LC separation 
of the studied micropollutants. 
Mobile phases 
Mobile 
phase A 
Pharmaceuticals (positive electrospray ionization): 2.5 l H2O + 1.5 mL 
CH2O2 + 0.5 mL C4HF7O2 + 30 mg C2H2O4 
Pharmaceuticals (negative electrospray ionization): 2.5 l H2O + 0.75 mL 
CH2O2 + 1.5 mL NH3 
Estrogens (positive electrospray ionization): 2.5 l H2O + 1 mL CH2O2  
+ 1 mL NH3 
Mobile 
phase B 
Pharmaceuticals (positive electrospray ionization): C2H3N + 0.1% CH2O2 
Pharmaceuticals (negative electrospray ionization): C2H3N 
Estrogens (positive electrospray ionization): C2H3N 
Gradient elution programs 
Pharmaceuticals  
(positive electrospray 
ionization)a 
Pharmaceuticals  
(negative electrospray 
ionization)b 
Estrogens  
(positive electrospray 
ionization)c 
Time, 
min 
Mobile 
phase B, 
% 
Pump, 
ml/min 
Time 
(min) 
Mobile 
phase B, 
% 
Pump, 
ml/min 
Time 
(min) 
Mobile 
phase B, 
% 
Pump, 
ml/min 
0.0 2 0.35 0.0 5 0.35 0.0 10 0.5 
1.0 2 0.35 1.0 5 0.35 2.0 10 0.5 
8.0 100 0.35 7.0 100 0.35 3.0 75 0.5 
9.0 100 0.35 9.0 100 0.35 8.0 75 0.5 
9.5 2 0.35 9.5 5 0.35 8.5 100 0.5 
15.0 2 0.35 15.0 5 0.35 11.0 100 0.5 
      11.1 10 0.5 
      15.0 10 0.5 
a - injection volume 3 µL; b - injection volume 10 µL; c- injection volume 2 µL 
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Table S5.2 Composition of mobile phases and elution gradient programs for LC separation 
of the studied micropollutants. 
Mobile phases 
Mobile 
phase A 
Pharmaceuticals (positive electrospray ionization): 2.5 l H2O + 1.5 mL 
CH2O2 + 0.5 mL C4HF7O2 + 30 mg C2H2O4 
Pharmaceuticals (negative electrospray ionization): 2.5 l H2O + 0.75 mL 
CH2O2 + 1.5 mL NH3 
Estrogens (positive electrospray ionization): 2.5 l H2O + 1 mL CH2O2  
+ 1 mL NH3 
Mobile 
phase B 
Pharmaceuticals (positive electrospray ionization): C2H3N + 0.1% CH2O2 
Pharmaceuticals (negative electrospray ionization): C2H3N 
Estrogens (positive electrospray ionization): C2H3N 
Gradient elution programs 
Pharmaceuticals  
(positive electrospray 
ionization)a 
Pharmaceuticals  
(negative electrospray 
ionization)b 
Estrogens  
(positive electrospray 
ionization)c 
Time, 
min 
Mobile 
phase B, 
% 
Pump, 
ml/min 
Time 
(min) 
Mobile 
phase B, 
% 
Pump, 
ml/min 
Time 
(min) 
Mobile 
phase B, 
% 
Pump, 
ml/min 
0.0 2 0.35 0.0 5 0.35 0.0 10 0.5 
1.0 2 0.35 1.0 5 0.35 2.0 10 0.5 
8.0 100 0.35 7.0 100 0.35 3.0 75 0.5 
9.0 100 0.35 9.0 100 0.35 8.0 75 0.5 
9.5 2 0.35 9.5 5 0.35 8.5 100 0.5 
15.0 2 0.35 15.0 5 0.35 11.0 100 0.5 
      11.1 10 0.5 
      15.0 10 0.5 
a - injection volume 3 µL; b - injection volume 10 µL; c- injection volume 2 µL 
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Table S5.4a Recoveries of the studied micropollutants in liquid samples (in %). 
Compound 
Medium content 
Synthetic 
urine + 
algae 
Urine 
+ 
algae 
AnBW 
+ 
algae 
Urine AnBW 
Urine 
(abiotic) 
AnBW 
(abiotic) 
Ibuprofen 89.8 96.8 96.8 95.0 92.0 94.9 92.6 
Diclofenac 113.3 119.8 102.4 111.9 111.9 103.6 116.4 
Carbamazepine 94.1 100.2 71.1 108.1 109.6 114.9 115.7 
Metoprolol 105.8 81.9 109.1 92.0 80.0 148.4 103.2 
Paracetamol 85.7 79.8 75.1 85.8 100.9 86.8 98.0 
Trimethoprim 73.9 66.3 67.7 74.4 71.7 92.1 83.7 
 
 
Table S5.4b Recoveries of the studied micropollutants in solid samples (in %). 
Compound 
Medium content 
Synthetic 
urine + 
algae 
Urine 
+ 
algae 
AnBW 
+ 
algae 
Ibuprofen 110.0 101.2 98.4 
Diclofenac 73.6 80.0 80.1 
Carbamazepine 126.0 120.0 131.9 
Metoprolol 120.2 125.3 112.4 
Paracetamol 136.4 127.4 161.6 
Trimethoprim 174.4 123.2 137.2 
Estrone 113.3 116.0 110.1 
Β-Estradiol 105.8 129.3 99.7 
Ethinylestradiol 103.9 167.3 114.2 
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Table S5.4b Recoveries of the studied micropollutants in solid samples (in %). 
Comp u d 
Medium content 
Synthetic 
urine + 
algae 
Urine 
+ 
algae 
AnBW 
+ 
algae 
Ibuprofen 1 0 01 2 98.4 
Diclof nac 73.6 80.0 80.1 
Carbamazepine 26 0 0 0 1 9
Met prolol 20 2 25 3 2 4
Paracetamol 36 4 7 4 161.6 
Trimethoprim 74 4 23 2 37
Estrone 113.3 116.0 110.1 
Β-Estradiol 105.8 129.3 99.7 
Ethinylestradiol 103.9 167.3 114.2 
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Table S5.5 Limits of detection and quantification of the studied micropollutants in liquid 
samples (in µg/L) and in solid samples (µg/g). 
Compound 
Limits of detection Limits of quantification 
Liquid phase, 
µg/L 
Solid phase, 
µg/g 
Liquid phase, 
µg/L 
Solid phase, 
µg/g 
Ibuprofen 0.25 0.29 0.84 0.96 
Diclofenac 0.05 0.01 0.15 0.03 
Carbamazepine 0.41 0.13 1.36 0.42 
Metoprolol 0.26 0.03 0.87 0.09 
Paracetamol 0.48 0.03 1.59 0.10 
Trimethoprim 0.35 0.07 1.17 0.24 
Estrone n.d. 0.01 n.d. 0.02 
Estradiol n.d. 0.00 n.d. 0.01 
Ethinylestradiol n.d. 0.00 n.d. 0.01 
n.d. – not detected 
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6.1 The need for safe water 
Worldwide drinking water supply systems are under increasing pressure as 
water scarcity, climate change, population growth, demographic changes and 
urbanization challenges the provision of safe drinking water [305]. Limited 
accessibility to safe drinking water is on the political agendas globally already for 
several decades. As a result, the seventh goal of the United Nations Millennium 
Development Goals (MDG) established in 2000 aims at reducing the proportion of the 
world’s population without sustainable access to safe water by 2015 [281]. Although 
big steps were made during these 15 years, by 2015 still 2.1 billion people did not 
have access to “safely managed drinking water services” which is defined as drinking 
water from an improved water source that is located on premises, available when 
needed, and free from faecal and priority chemical contamination [305]. Of these 
people, 1.3 billion had access to basic drinking water services (i.e. improved drinking 
water availability within a round trip of 30 minutes), the other 844 million people even 
lacked basic drinking water services. Because of the inaccessibility to clean drinking 
water the United Nations Sustainable Development Goals established in 2015 included 
the following targets on water quality; 6.1 “By 2030, achieve universal and equitable 
access to safe and affordable drinking water for all” and 6.3 “By 2030, improve water 
quality by reducing pollution, eliminating dumping and minimizing release of 
hazardous chemicals and materials, halving the proportion of untreated wastewater 
and substantially increasing recycling and safe reuse globally” [282]. The increasing 
pressure on safe drinking water supply is a worldwide problem, not only affecting 
developing countries. For instance, droughts over the past 16 years in the southern 
states of the U.S. caused historically low water levels in the Colorado river leading to 
water scarcity and thereby a high pressure on the drinking water supply [13].  
An important strategy to overcome issues regarding drinking water supply is 
the reuse of wastewater for water recovery [305]. The reuse of WWTP effluents for 
drinking water production is already practiced over 50 years in many countries [69]. 
In most cases this concerns an indirect reuse, applying a natural system such as a 
groundwater aquifer for additional treatment, retention and dilution with other water 
streams between the WWTP effluent and drinking water intake. However, over the 
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past decade the direct reuse of WWTP effluent for drinking water production has also 
been applied. Especially in the U.S., Southern Africa and Singapore multiple projects 
have started applying the direct reuse for drinking water production as additional 
treatment processes are able to eliminate contaminants to drinking water inlet 
standards [69, 148]. Nevertheless, there is an ongoing debate regarding the public 
health, treatment of emerging contaminants, monitoring, costs and maintenance 
aspects of direct reuse [69]. In addition to the reuse for drinking water purposes, 
reuse of WWTP effluents for other purposes such as irrigation, industrial application, 
urban uses and environmental purposes like flow restoration have also been 
extensively studied [202]. Even in countries like the Netherlands where droughts and 
water scarcity are no major issues the debate of using non-traditional drinking water 
sources is conducted as costs for drinking water production increase due to 
environmental issues such as pollution and salinization of aquifers [253].  
The presence of numerous micropollutants is one of the main issues when reuse 
of WWTP effluent for other purposes is considered [305]. Among the broad suite of 
micropollutants covering pharmaceuticals, pesticides, herbicides, personal care 
products, hormones and many others contaminants, the focus of this dissertation is 
only on pharmaceuticals. Chapter 1 describes the effects which pharmaceuticals can 
have on the environment and human health when discharged to surface waters as 
currently practiced. Both the (direct) reuse and the discharge to surface waters of 
WWTP effluents motivate the elimination of pharmaceuticals and other 
micropollutants at the WWTP and call for immediate action. Different treatment 
processes for the removal of pharmaceuticals are therefore presented in this 
dissertation. In this chapter these processes are further discussed with respect to 
their functioning and how they can contribute to a strategy towards a safer water 
reuse or discharge. The parameters and processes identified for the research 
presented in this dissertation are presented in Table 6.1 were. 
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reuse of WWTP effluents for other purposes such as irrigation, industrial application, 
urban uses and environmental purposes like flow restoration have also been 
extensively studied [202]. Even in countries like the Netherlands where droughts and 
water scarcity are no major issues the debate of using non-traditional drinking water 
sources is conducted as costs for drinking water production increase due to 
environmental issues such as pollution and salinization of aquifers [253].  
The presence of numerous micropollutants is one of the main issues when reuse 
of WWTP effluent for other purposes is considered [305]. Among the broad suite of 
micropollutants covering pharmaceuticals, pesticides, herbicides, personal care 
products, hormones and many others contaminants, the focus of this dissertation is 
only on pharmaceuticals. Chapter 1 describes the effects which pharmaceuticals can 
have on the environment and human health when discharged to surface waters as 
currently practiced. Both the (direct) reuse and the discharge to surface waters of 
WWTP effluents motivate the elimination of pharmaceuticals and other 
micropollutants at the WWTP and call for immediate action. Different treatment 
processes for the removal of pharmaceuticals are therefore presented in this 
dissertation. In this chapter these processes are further discussed with respect to 
their functioning and how they can contribute to a strategy towards a safer water 
reuse or discharge. The parameters and processes identified for the research 
presented in this dissertation are presented in Table 6.1 were. 
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Table 6.1 Overview of the parameters and processes studied for pharmaceutical removal in 
the chapters of this dissertation. 
Parameter/Process Chapter 2 Chapter 3 Chapter 4 Chapter 5 
Biological treatment     
Redox conditions X    
Mixed inoculum  X X  
TOC removal   X  
Real wastewater   X X 
Algae    X 
Chemical treatment     
UV-LED TiO2 
photocatalysis 
 
X 
  
Ozonation   X  
Photolysis    X 
 
6.2 Pharmaceutical removal by biological treatment  
Conventional WWTPs are not designed for pharmaceutical elimination and 
optimization of the current treatment processes or extension with other treatment 
processes is needed to obtain an improved pharmaceutical removal. WWTPs typically 
employ biological processes for bulk organic matter, nitrogen and phosphorous 
removal as they are regarded robust and more cost-effective compared to other 
treatment processes. Based on these arguments biological treatment for 
pharmaceutical removal is therefore desired. Multiple factors and parameters 
influence the biological removal processes in wastewater treatment of which many 
cannot be adjusted as they relate to the incoming wastewater, e.g. amounts of 
organic matter, nutrients, trace elements, toxins, etc. Others can be used to steer 
the process performance, e.g. hydraulic and solid retention times, redox conditions, 
type of biomass, biomass attachment, substrate dosage and substrate availability in 
individual treatment steps. The influence of redox conditions, the effect of 
biodegradable substrates and the application of alternative microorganisms is 
elucidated in this dissertation and further elaborated and discussed in this section. 
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6.2.1 Influence of redox conditions 
The influence of redox conditions is of great importance for any biological 
conversion. In Chapter 2 we demonstrated that aerobic conditions exert the most 
optimal biological removal of pharmaceuticals. However, under deeply anaerobic 
conditions, i.e. sulfate reducing or methanogenic conditions, we also found high 
pharmaceutical removal. Intermediate redox conditions like micro-aerophilic and 
nitrate reducing conditions were less effective. In general aerobic conditions are 
reported in the literature to be most favourable for the biodegradation of a wide 
variety of pharmaceuticals [7, 26, 83, 215, 247]. However, some individual 
pharmaceuticals are better degraded under a specific redox condition. For instance, 
sulfamethoxazole was better removed under micro-aerophilic conditions compared to 
fully aerobic and anoxic/aerobic cycling [247]. Moreover, sulfamethoxazole and 
trimethoprim were better removed under methanogenic conditions compared to 
aerobic conditions [7] and venlafaxine, diatrizoate and tramadol were better removed 
under iron reducing, sulfate reducing and methanogenic conditions compared to 
aerobic conditions [83]. This suggests that a biological process covering a redox 
gradient from aerobic to methanogenic conditions has advantages over a single redox 
condition which is therefore recommended for all biological processes aiming at 
pharmaceutical removal.  
 
6.2.2 Effects of biodegradable substrates 
The presence of easily biodegradable substrates in high concentrations is 
hypothesized to negatively influence the pharmaceutical removal (Chapter 1). In 
Chapter 4 a relatively high pharmaceutical removal was observed in the investigated 
biological reactor of the BO3B process compared to the literature on pharmaceutical 
removal in WWTPs. In comparison with WWTPs the applied HRT in our system was 
short and biomass levels were low, which would suggest a low pharmaceutical 
removal. However, the observed removal was high which is most likely related to the 
difference in organic matter (OM) concentration and composition of the feed solutions 
as the BO3B process was running on secondary clarified effluent. Whereas raw 
wastewater entering WWTPs contains high amounts of OM (80-260 mg TOC/L) with 
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a high BOD/TOC ratio (1.2-2.0), the secondary effluent is typically low in OM (<20 
mg TOC/L) and less biodegradable (BOD/TOC 0.2-0.5) as OM removal (i.e. BOD 
removal) is one of the main objectives of wastewater treatment [261]. The negative 
influence of OM on the pharmaceutical removal is also described in other studies. In 
column experiments mimicking managed aquifer recharge (MAR) systems the 
removal of pharmaceuticals enhanced at lower biodegradable organic matter (BOM) 
concentrations, i.e. biodegradable dissolved organic carbon concentrations of 0.69 
mg/L versus 1.55 mg/L [155]. A higher microbial density at increasing ratios of BOM 
over OM was reported, whereas both the microbial diversity and the metabolic 
capability of the microorganisms to degrade pharmaceuticals declined. Moreover, at 
low compared to high OM levels higher microbial diversities and lower microbial 
densities were found in field and laboratory scale MAR systems, demonstrating that 
high substrate levels limit the capacity of a microbiome to degrade a broad array of 
compounds [154]. Additionally, in MAR systems the biological removal of 
pharmaceuticals could be linked to co-metabolism rather than to direct substrate 
utilization by comparing the pharmaceutical removal in a pre-exposed microbial 
community to a unexposed community [4]. The authors found a similar 
pharmaceutical removal in pre-exposed and unexposed microbial communities, 
suggesting that microbial adaptation to pharmaceuticals did not occur. Hence, the 
utilization of pharmaceuticals as primary substrate is unlikely which is further 
supported by the high concentration difference between pharmaceuticals and other 
substrates in MAR systems. Instead of adaptation, the capacity for pharmaceutical 
degradation is dictated by other factors which influence the microbial community such 
as the composition and concentration of primary substrates [4]. In most 
environments primary substrates are present in higher concentrations than 
pharmaceuticals, e.g. raw wastewater, primary clarified effluent, secondary clarified 
effluent, surface water and groundwater, most likely favouring co-metabolic 
degradation. Similarly, the work presented in Chapter 3 showed that photocatalytic 
products enhanced the subsequent biodegradation of atorvastatin, caffeine, 
diclofenac, gemfibrozil and ibuprofen. Based on the literature it was postulated that 
biodegradation of photocatalytic products generated intracellular electron carriers 
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that initiated the initial mono-oxygenation reaction for biodegradation of the 
pharmaceuticals, suggesting that co-metabolisms was highly important. In contrast, 
adaptation to pharmaceuticals was found in Chapter 2 as pharmaceutical removal in 
batch experiments enhanced after re-spiking pharmaceuticals. Pharmaceuticals 
dissolved in methanol were added multiple times without the addition of other OM 
sources. As every re-spike contained the same ratio of pharmaceuticals to methanol 
the observed increase in removal efficiency could be related to adaptation or to an 
increase of pharmaceutical degrading biomass. Hence, the role of microbial 
adaptation and co-metabolic degradation in the biological removal of pharmaceuticals 
remains ambiguous. Likely, the microbial adaptation differs per individual 
pharmaceutical as was also found for non-pharmaceutical contaminants by Spain and 
Van Veld [246]. In their study on pre-exposed and unexposed microbial communities 
adaptation was found towards 2,4-dichlorophenoxyacetic acid and p-nitrophenol, 
whereas no adaptation was found to trifluralin and p-cresol was well degraded in both 
communities. Moreover, the contaminant concentration during pre-exposure was 
found to affect the adaptation, e.g. lower concentrations p-nitrophenol were needed 
to achieve adaptation than for methyl parathion [245]. These findings on 
pharmaceuticals and non-pharmaceutical contaminants stress the need for additional 
research as adaptation can potentially enhance the biodegradation in real 
applications. Therefore further investigations should focus on the functioning of 
microbial adaptation and unravel the parameters that steer the adaptation which can 
be used in application. 
 
6.2.3 Algae and fungi 
Biological processes for treatment of various contaminants reported in the 
literature mainly concern the utilization of bacteria, e.g. wastewater treatment with 
activated sludge, anaerobic sludge digestion, in-situ soil remediation and sand 
filtration in drinking water production. However, also other microorganisms such as 
algae or fungi are known for their capacities to degrade or take up various 
contaminants [66, 74, 87, 192]. The use of algal wastewater treatment processes is 
of increasing interest as they provide a clean effluent, and enable resource recovery 
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applications. Therefore further investigations should focus on the functioning of 
microbial adaptation and unravel the parameters that steer the adaptation which can 
be used in application. 
 
6.2.3 Algae and fungi 
Biological processes for treatment of various contaminants reported in the 
literature mainly concern the utilization of bacteria, e.g. wastewater treatment with 
activated sludge, anaerobic sludge digestion, in-situ soil remediation and sand 
filtration in drinking water production. However, also other microorganisms such as 
algae or fungi are known for their capacities to degrade or take up various 
contaminants [66, 74, 87, 192]. The use of algal wastewater treatment processes is 
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in the form of fertilizer, protein-rich feed or biofuel via the harvested algal biomass 
[55]. Most studies focus on the resource recovery by algae, whereas the removal of 
pharmaceuticals which are also present in those systems is only limitedly studied. 
Chapter 5 describes an algal treatment process for the simultaneous removal of 
nitrogen and phosphorus and pharmaceuticals in an alternative sanitation system. It 
was found that algae contributed to the removal of pharmaceuticals while also 
recovering nitrogen and phosphate from the wastewater. For instance, metoprolol 
removal enhanced in the presence of algae. Sorption and uptake of pharmaceuticals 
by algae was limited and was hypothesized be safe for the application of algal biomass 
as fertilizer. The photobioreactor in which the algae were cultivated had a positive 
effect on the pharmaceutical removal as compounds susceptible to photolysis such as 
diclofenac were effectively removed by photodegradation. Moreover, the naturally 
present microbes in the wastewater also contributed to the pharmaceutical removal. 
Hence, a synergy was found in the combination of algal-, microbial- and 
photodegradation for the removal of pharmaceuticals. Similarly, Matamoros et al. 
[174] also concluded that algae contributed to the removal of pharmaceuticals from 
wastewater as the presence of algae enhanced ibuprofen and caffeine removal. 
Moreover, they did not found uptake of pharmaceuticals by the algae. In an outdoor 
pilot scale algal treatment plant an effective pharmaceutical removal and a 
subsequent reduction in hazard quotient were found when operated in a warm 
(25±1°C) and cold season (13±1°C) [173]. Nevertheless, this was achieved at HRTs 
of 4 and 8 days and a reactor of depth of 0.3 cm to allow sunlight penetration into 
the reactor. Hence, these HRTs and reactor depths exhibit a large surface footprint 
and are thereby unrealistic design parameters for densely populated countries like 
the Netherlands where available land is scarce and costly. Moreover, algal treatment 
systems require light input and moderate to high temperatures for algae growth. 
Climate conditions in the Netherlands were found unsuitable for WWTP effluent post-
treatment by algal biofilm reactors as solar irradiance levels and temperatures were 
not high enough to support sufficient algal biomass growth [29]. Therefore outdoor 
solar based algal reactors for resource recovery and pharmaceutical removal are 
hypothesized not to be a feasible treatment option in the Netherlands. However, for 
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locations at lower latitudes (e.g. in Spain), for events like festivals or campsites during 
summer in the Netherlands when irradiation and temperatures are higher or for 
systems running on artificial light sources like LED-UV systems in temperature 
controlled greenhouses an algae based process might be a versatile treatment 
system. The continuous improvements of LED irradiation suggest that LED based algal 
treatment systems, preferably combined with solar irradiance, can become a cost-
effective wastewater treatment process. Further research is recommended to focus 
on the technical and financial feasibility of LED based algal treatment systems in 
greenhouses for the cost-effective recovery of nutrients and simultaneous 
pharmaceutical removal from wastewater. Moreover, research has to include a much 
wider pallet of pharmaceuticals and toxicity assessment of the effluent as both are 
currently limitedly understood.  
Among the various fungi species used in biological treatment processes, white-
rot fungi and their enzymes have been well studied for the removal of pharmaceuticals 
[56]. These organisms have a ligninolytic enzymatic system allowing them to produce 
extracellular enzymes which can target various contaminants in a non-specific and 
radical based manner [45]. Their ability to produce strong oxidants like peroxide 
effectively targets compounds that persist in other biological treatment processes 
such as the recalcitrant pharmaceutical carbamazepine [223]. Although white-rot 
fungi are promising for pharmaceutical removal, issues related to the contamination 
of the reactors, and thereby the competition with other microorganism suppressing 
the fungi, have been identified when culturing them under non-sterile conditions using 
real wastewater [19, 156]. This might be one of the reasons why implementation of 
fungal based technologies in domestic wastewater treatment is limited. 
 
6.2.4 Opportunities in biological treatment 
Multiple biological processes and the parameters influencing these processes 
have been studied for the removal of pharmaceuticals. Findings of these studies have 
resulted in a better understanding of biological treatment processes and relevant 
aspects for the design and operation of them. Nevertheless none of them, nor a 
combination of them, has been found adequate to achieve a complete removal of the 
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pharmaceuticals typically found in wastewater [1, 83, 164, 222]. Similarly, in this 
dissertation (Chapters 2-5) it was demonstrated that biological processes do not form 
an effective barrier against all pharmaceuticals. Large molecules typically persist 
during biological treatment, whereas intermediate or small size molecules are easily 
biodegraded or even mineralized [165]. In combination with additional treatment 
steps targeting large molecules, biological removal might therefore be a versatile 
treatment process. Reflecting on the outcomes of this dissertation several 
recommendations are given regarding the design and operation of biological 
processes when biological treatment is considered for pharmaceutical removal. 
Concerning bacterial based processes, it is recommended to incorporate multiple 
redox stages, including fully aerobic and methanogenic conditions, to create niches 
for a diverse microbial community targeting a wide spectrum of pharmaceuticals. In 
addition, pharmaceutical removal can be best accomplished under oligotrophic 
conditions, i.e. in a post-treatment step where primary substrate levels are low. In 
case of sub-optimal performance of the secondary treatment and clarification, a two-
step process might be desired to remove primary substrates in the first and 
pharmaceuticals in the second step. When irradiance levels and temperatures allow a 
cost-effective algae growth, algal treatment systems are recommended as they form 
a barrier against multiple pharmaceuticals and provide opportunities for resource 
recovery. However, algal treatment systems have their limitations regarding 
pharmaceutical removal. For a safe direct reused or discharge effluents of algal 
treatment systems the non-removed pharmaceuticals should therefore be additionally 
treated by other treatment processes. Therefore it is recommended for future 
research focusing on sustainable water treatment to employ algal treatment systems 
in combination with other processes for the efficient resource-recovery and a safe 
effluent production.  
Research on biological removal processes is ongoing and will continue, 
nevertheless it is questionable with the obtained knowledge of the past decades 
whether it can be expected that a biological process will remove the highly complex 
mixture of structurally diverse pharmaceuticals. Considering that pharmaceuticals are 
only part of the micropollutants which are currently detected in wastewater the entire 
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load of harmful compounds at low concentrations is much higher which further 
complicates an adequate elimination of all of these insidious compounds. Nonetheless, 
biological processes can be part of a broader treatment system for the cost-effective 
removal of micropollutants which justifies the further investigation and understanding 
into biological processes. Research opportunities lie, amongst others, in the further 
unravelling of metabolic pathways of pharmaceutical degradation. A better 
understanding of degradation pathways can result in the further optimization of 
biological processes by steering for specific conditions favouring enzymatic systems 
involved in pharmaceutical degradation. Moreover, insight in the diversity of involved 
metabolic pathways can indicate to what extend different enzymatic systems are 
needed for the degradation of a broad spectrum of pharmaceuticals. This can be 
useful for the design of a comparted biological treatment, creating optimal conditions 
for specific metabolic pathways in each compartment to target specific 
pharmaceuticals. First steps have been made in the field of understanding the 
metabolic pathways involved in pharmaceutical degradation [97, 182, 299, 300]. Yet, 
to date, there is still a limited understanding of all enzymatic processes involved in 
pharmaceutical degradation. Although research suggests that biological 
pharmaceutical removal follows co-metabolic degradation pathways conclusive 
enzymatic evidence to confirm this is still lacking [4].  
 
6.3 Pharmaceutical removal by chemical treatment  
Chemical treatment processes involving ozonation, photolysis, photocatalysis, 
hydrogen peroxide, chlorination, Fenton’s reagent, electrolysis, ultrasound, ionising 
radiation, microwaves and pulsed plasma have been applied for drinking water 
treatment, industrial wastewater treatment as well as in domestic wastewater 
treatment [52, 264].  
In drinking water sources numerous contaminants and matrix constituents are 
present at very low (ng/L) and low (mg/L) concentrations, respectively [264]. Hence, 
the production of drinking water free of contaminants and low in matrix constituents 
favours one or more generic treatment steps. Industrial wastewaters typically contain 
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metabolic pathways can indicate to what extend different enzymatic systems are 
needed for the degradation of a broad spectrum of pharmaceuticals. This can be 
useful for the design of a comparted biological treatment, creating optimal conditions 
for specific metabolic pathways in each compartment to target specific 
pharmaceuticals. First steps have been made in the field of understanding the 
metabolic pathways involved in pharmaceutical degradation [97, 182, 299, 300]. Yet, 
to date, there is still a limited understanding of all enzymatic processes involved in 
pharmaceutical degradation. Although research suggests that biological 
pharmaceutical removal follows co-metabolic degradation pathways conclusive 
enzymatic evidence to confirm this is still lacking [4].  
 
6.3 Pharmaceutical removal by chemical treatment  
Chemical treatment processes involving ozonation, photolysis, photocatalysis, 
hydrogen peroxide, chlorination, Fenton’s reagent, electrolysis, ultrasound, ionising 
radiation, microwaves and pulsed plasma have been applied for drinking water 
treatment, industrial wastewater treatment as well as in domestic wastewater 
treatment [52, 264].  
In drinking water sources numerous contaminants and matrix constituents are 
present at very low (ng/L) and low (mg/L) concentrations, respectively [264]. Hence, 
the production of drinking water free of contaminants and low in matrix constituents 
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a limited number of contaminants present at high concentrations (g/L) in simple 
matrices which eases a tailor made design of effective treatment processes [165].  
In contrast, domestic WWTP effluents comprise a highly diverse mixture of 
matrix constituents typically present at orders of magnitude higher concentrations 
compared to contaminants like pharmaceuticals. Moreover, WWTP effluent 
contaminants cover an array of structurally different compounds. Chemical treatment 
processes effectively oxidize large molecules into smaller intermediates, however full 
mineralization in the chemical treatment is often cost-intensive and thereby 
undesired. Therefore, combining chemical and biological processes for a complete 
mineralisation can be a favourable approach [165]. Even though chemical treatment 
processes can be highly effective for the removal of waterborne contaminants, the 
ratio between matrix and contaminant concentrations and the diversity in 
contaminant chemical structures complicates the design of cost-effective and 
sustainable treatment processes. Processes targeting specific contaminants do not 
provide the removal of a broad spectrum of contaminants, whereas more generic 
processes inevitably result in the reaction with matrix constituents reducing the 
removal efficiency for target contaminants. As a result, each individual situation 
therefore requires the assessment of the most adequate and cost-effective treatment 
system.  
Recently, chemical treatment processes of a more generic character like 
ozonation and AC filtration have been well studied and locally implemented at WWTPs 
in post-treatment steps for pharmaceutical removal [73]. First results of their full 
scale implementation indicate that these processes can result in the effective removal 
of pharmaceuticals. Nevertheless, ozonation still raises concerns on the formation of 
potentially toxic transformation products, whereas AC filtration requires the 
regeneration or replacement of the AC questioning the sustainability and cost-
effectiveness of the process. In addition, a one to one translation of these results to 
other places is hampered by differences in local raw wastewater qualities and the site-
specific performance of primary and secondary treatment processes. For example, 
OM concentrations in secondary clarified effluents from individual Swiss, Japanese 
and U.S. WWTPs are two to ten times lower compared to those from individual 
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Australian, German, U.S. and Dutch WWTPs (Chapter 4) [109, 111, 117, 150, 193, 
265, 298, 329]. At high OM concentrations or in the presence of specific molecular 
size OM fractions, pharmaceutical removal efficiencies in ozonation or AC filtration 
drastically decrease [151, 327]. An investigated solution to overcome this problem is 
the combination of pre-ozonation followed by AC filtration in which the incoming OM 
is partially converted by ozonation into smaller molecule sizes which only limitedly 
compete with pharmaceuticals for AC sorption sites [218, 328]. This is however a 
resource intensive and costly treatment and might not be the most sustainable 
combination of processes.  
In other chemical processes employing oxidants such as hydrogen peroxide or 
Fenton’s reagent for pharmaceutical removal OM matter is also known to reduce 
process efficiencies since it acts as an oxidant scavenger [22]. This suggests that pre-
treatment processes targeting OM removal could be of great interest as they increase 
chemical treatment of pharmaceuticals. Some pre-treatment processes have been 
investigated like the use of anion exchange. This process effectively removed the OM 
humic acid fraction of a WWTP effluent and resulted in an 84% lower energy demand 
for the subsequent UV/H2O2 treatment process aiming at pharmaceutical removal 
[109]. Nevertheless, the costs associated to the combination of anion exchange and 
subsequent UV/H2O2 treatment are relatively high as they increase the wastewater 
treatment costs by approximately 75% [280]. Overall, there is a need for more cost-
effective and sustainable treatment processes including combinations of chemical and 
biological processes, as currently there are only a few available for wastewater 
treatment [198]. 
 
6.4 Synergy between biological and chemical treatment processes 
for pharmaceutical removal 
Multiple combinations of biological and chemical treatment processes have 
been demonstrated to be advantageous over single processes [120, 235]. In 
industries this concept is well introduced as combined process are used to treat 
textile, paper mill, winery, distillery and olive mill wastewaters [198]. The capacity of 
chemical treatment processes targeting non-biodegradable compounds to increase 
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their biodegradability by for instance a strong oxidant attack is the most known 
combination. Chemical treatment is effective for oxidation of large molecules into 
smaller intermediates, but not for full mineralization, whereas biological treatment 
can effectively degrade and mineralize intermediate and small size molecules [165]. 
The tipping point after which further chemical treatment is no more attractive and 
biological treatment performs better is depicted in Figure 6.1. Moreover, as biological 
treatment is generally cheaper and more sustainable than chemical treatment, the 
latter is typically used as a short pre-treatment increasing the biodegradability and 
reducing the overall treatment costs [52]. Although in industries the combination of 
biological and chemical treatment processes is well introduced [198], it is only 
limitedly applied in wastewater treatment. Chapters 3, 4 and 5 of this dissertation 
describe combinations of biological and chemical processes for pharmaceutical 
removal from wastewater with a focus on an unique combination in each chapter. The 
studied combinations are further discussed in this section. 
 
 
Figure 6.1 The concept of combined chemical and biological treatment (adapted from [165])  
 
General discussion; towards lower pharmaceutical emissions 
138 
 
their biodegradability by for instance a strong oxidant attack is the most known 
combination. Chemical treatment is effective for oxidation of large molecules into 
smaller intermediates, but not for full mineralization, whereas biological treatment 
can effectively degrade and mineralize intermediate and small size molecules [165]. 
The tipping point after which further chemical treatment is no more attractive and 
biological treatment performs better is depicted in Figure 6.1. Moreover, as biological 
treatment is generally cheaper and more sustainable than chemical treatment, the 
latter is typically used as a short pre-treatment increasing the biodegradability and 
reducing the overall treatment costs [52]. Although in industries the combination of 
biological and chemical treatment processes is well introduced [198], it is only 
limitedly applied in wastewater treatment. Chapters 3, 4 and 5 of this dissertation 
describe combinations of biological and chemical processes for pharmaceutical 
removal from wastewater with a focus on an unique combination in each chapter. The 
studied combinations are further discussed in this section. 
 
 
Figure 6.1 The concept of combined chemical and biological treatment (adapted from [165])  
 
Chapter 6 
139 
 
6.4.1 Chemical pre-treatment for enhanced biological pharmaceutical 
removal 
Photocatalysis utilizing TiO2 to catalyse the reaction of UV-light with organic 
contaminants is a well-known treatment process and widely employed in diverse 
water treatment systems [52, 103, 126]. Sunlight based TiO2 photocatalytic 
processes have been successfully demonstrated, but are limitedly applied compared 
to systems using UV-lamps as the UV content of solar irradiation reaching the earth 
surface is only 3-5% [10, 22]. The use of UV-LED as alternative to traditional energy 
intensive UV-lamps has greatly increased the process resource efficiency [194]. 
Furthermore, the ongoing research on immobilized forms of TiO2 is hypothesized to 
further improve the sustainability and cost-effectiveness of TiO2 photocatalysis [16]. 
Successful removal of pharmaceuticals from wastewater by TiO2 photocatalysis is 
reported, however the type and concentration of TiO2 and the process reaction time 
highly influence the degree of removal, i.e. good removal is achieved at high TiO2 
levels and long irradiation times [272]. Moreover, TiO2 photocatalytic pharmaceutical 
removal is associated to the formation of toxic transformation products. These 
undesirable aspects can hamper the implementation of this promising technology, but 
can possibly be overcome when combining photocatalysis with biodegradation.  
Chapter 3 therefore describes a mild photocatalytic TiO2 process followed by 
biological treatment for pharmaceutical removal as a resource efficient alternative to 
single TiO2 photocatalysis. Similar to the literature, a selection of pharmaceuticals 
was removed by the employed photocatalysis whereas other persisted [15]. 
Unexpectedly, in the subsequent biological treatment the degradation of atorvastatin, 
caffeine, gemfibrozil and ibuprofen enhanced after photocatalytic pre-treatment, even 
though most of them were not targeted by photocatalysis. In addition, the 
biodegradation of diclofenac was observed after photocatalytic pre-treatment 
whereas it persisted in biological control experiments without pre-treatment. Based 
on the literature on photocatalytic products and biodegradation pathways it was 
postulated that intermediates formed during photocatalysis stimulated the 
biodegradation of pharmaceuticals. Hence, besides the benefits of combining chemical 
pre-treatment with biological treatment for cost-effective mineralization of large 
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molecules it can be stated that the biological treatment of pharmaceuticals also 
benefits from the presence of photocatalytic products for the enhanced 
biodegradation of parent compounds, i.e. pharmaceuticals. Next to the ongoing 
advancements on TiO2 immobilization and UV-LED application, employing a mild 
photocatalysis with subsequent biological treatment further increases the 
sustainability. Overall, the enhanced biodegradation and improved sustainability are 
expected to stimulate the implementation of this combined treatment process. It 
should be noted that our findings were obtained using a clean matrix and powdered 
TiO2, therefore further research on real WWTP effluents and using immobilized TiO2 
is strongly recommended. Moreover, the toxicity of the final effluent should be 
carefully assessed albeit potentially toxic photocatalytic products will most likely be 
removed during the biological treatment. 
 
6.4.2 Biological pre-treatment for enhanced chemical pharmaceutical 
removal 
The strong oxidative power of ozone towards a broad spectrum of 
micropollutants including pharmaceuticals is well studied and locally implemented as 
post-treatment in wastewater treatment [73]. Equal to the approach of combining 
chemical treatment followed by biological treatment used in industries, ozonation is 
followed by sand-filtration for the initial chemical oxidative of large molecules and the 
subsequent biodegradation for their further degradation or even mineralization [111, 
165]. This is an effective strategy when concentrations of matrix constituents like OM, 
nitrite or other compounds competing for ozone with the target contaminants are 
present at minute levels. In case matrix composition and concentration are in 
competition with contaminants for ozone other strategies should be employed. A 
three-step design was therefore presented in Chapter 4 incorporating biological 
treatment, ozonation and biological treatment as the investigated secondary clarified 
effluent comprised relatively high OM levels, i.e. 17 mg TOC/L. These OM levels 
required an opposing paradigm to the industrial design scheme where chemical 
treatment supports the biological treatment. In the proposed BO3B design biological 
pre-treatment facilitates the ozone treatment by removing matrix constituents that 
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scavenge the ozone reaction with biorecalcitrant pharmaceuticals prior to entering 
the ozone reactor. As 38% TOC removal was accomplished during biological pre-
treatment, this design allowed a minimal ozone input. The BO3B process effectively 
removed biodegradable and biorecalcitrant pharmaceuticals, as the removal 
mechanisms of biological treatment and ozonation targeted different 
pharmaceuticals. Finally, the ozonation transformation products are biodegraded in 
the last biological treatment step before being discharged into the environment. 
Although the BO3B design incorporates three reactors, the estimated costs are low 
and would increase the costs for current treatment by less than 15%. The BO3B 
process is therefore a versatile alternative combination of treatment processes 
compared to combinations such as ozonation and AC filtration which have been 
demonstrated to effectively remove pharmaceuticals [218]. However, the 
combination of biological treatment with ozonation instead of AC filtration with 
ozonation makes the process more sustainable as no regeneration or replacement of 
AC is needed and cost associated to biological treatment are generally lower than 
those for AC filtration. 
 
6.4.3 Simultaneous biological and chemical treatment for 
pharmaceutical removal 
Chemical treatment processes applied for the removal of organic compounds 
also exhibit disinfection properties. In drinking water production disinfection is one of 
the main reasons why chemical processes are employed [242, 294]. As disinfection 
has negative effects on microorganisms applied in biological treatment, there are only 
a few examples of versatile combinations of simultaneous biological and chemical 
treatment processes. A well-known combination are algal treatment systems, such as 
the photobioreactors investigated in Chapter 5. Treatment systems employing algae 
are a combination of chemical and biological processes as the metabolism of algae 
requires photons, i.e. light. Thus, photodegradation and biodegradation can occur 
simultaneously. We observed effective removal by photodegradation alone or in 
combination with biodegradation of pharmaceuticals such as diclofenac and 
metoprolol, respectively. Although the findings of the investigated combination are 
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promising, major drawbacks have been identified. For instance, only a selection of 
pharmaceuticals can be effectively removed by photolysis as not all compounds are 
susceptible to photolysis, or at an insignificant rate for application in wastewater 
treatment [12, 140, 143, 160]. General applicability of photolytic processes is also 
hampered by the differences in wastewaters as matrix constituents like OM, nitrate 
and bicarbonate influence the photolysis of pharmaceuticals in different ways 
requiring a site-specific evaluation of the photolytic efficiency [143]. This might 
explain why Matamoros, et al. [174] did not observe photodegradation of ibuprofen 
in their algal photobioreactor running on primary clarified wastewater whereas in 
Chapter 5 we found that in anaerobically treated black water ibuprofen was 
photodegraded. Irradiance intensities are also highly important as they influence the 
photodegradation efficiency of pharmaceuticals [12]. Hence, solar based systems will 
perform poorly at higher latitudes indicating the need of artificial irradiance.  
Although photolytic and biological pharmaceutical removal are complementary 
processes for pharmaceutical removal, they do not target all pharmaceuticals. 
Biorecalcitrant and photorecalcitrant pharmaceuticals, such as carbamazepine, 
persist in algal treatment processes. Hence, algal treatment processes exhibit great 
benefits with respect to resource recovery, and for that purpose should be considered 
in wastewater treatment. While they can recover nutrients and remove 
pharmaceuticals simultaneously, additional treatment is required for a full 
pharmaceutical removal.  
Another well-studied combination of simultaneous biological and chemical 
processes is the intimately coupled photocatalysis and biodegradation [307]. Carriers 
with an photocatalytic outer surface and attached microorganisms inside the carrier 
have demonstrated an effective removal of contaminants like the antibiotic 
tetracycline. The main advantage of this combination is the close distance between 
the reactive photocatalytic surface and the microorganisms which facilitates the 
instant biodegradation of formed photocatalytic products. To date, this combination 
is mainly tested on lab-scale, therefore it is unknown how effective this process will 
be on full-scale running on real wastewater. 
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6.5 Outlook, opportunities for lower pharmaceutical emissions 
The ongoing contamination of worldwide freshwater bodies by countless 
micropollutants, including pharmaceuticals, jeopardizing the environment and human 
health is one of the main challenges humanity is facing [233]. Discharge of treated 
and untreated domestic wastewater is one of the major micropollutant sources as 
micropollutants are ineffectively removed during conventional wastewater treatment 
[234]. This dissertation and research by others has demonstrated the capacity of 
various treatment processes to remove pharmaceuticals from wastewater minimizing 
the further contamination of worldwide freshwater bodies. The use of complementary 
biological and chemical treatment processes has been found highly effective as major 
disadvantages of single processes like resource intensiveness or transformation 
product discharge can be tackled by combined treatment processes. A clear outcome 
of this dissertation is the inability of single processes for the cost-effectively removal 
of a broad array of structurally highly different molecules in a complex matrix like 
wastewater effluent. Both biological processes and chemical processes have their 
limitations in targeting specific pharmaceuticals and are therefore recommended to 
be combined to form an adequate barrier against micropollutants like 
pharmaceuticals.  
 
Table 6.2 Synergy between biological and chemical processes for pharmaceutical removal 
Process combination Synergy Chapter 
Mild UV-LED TiO2 
photocatalysis 
Biological 
treatment 
Enhanced biodegradation of biodegradable 
and otherwise recalcitrant pharmaceuticals 
3 
Biological 
treatment 
Ozonation 
Reduced ozone input by biological TOC 
removal 
4 
Ozonation 
Biological 
treatment 
Biological removal of ozonation products 4 
Algal photobioreactor: 
Simultaneous photolysis and 
biological treatment 
Single reactor system with multiple 
pharmaceutical removal mechanisms 
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Different combinations of biological and chemical treatment processes have 
been investigated in this dissertation. Synergy was found for all the studied 
combinations, though the way this synergy was expressed differed per combination 
(Table 6.2). Mild photocatalytic pre-treatment was found to enhance the subsequent 
biological treatment, even for pharmaceuticals that were not targeted by 
photocatalysis. Biological pre-treatment removing ozone scavenging OM increased 
the cost-effectiveness of ozonation for pharmaceutical removal where after potentially 
toxic ozonation products were biodegraded during subsequent biological treatment. 
Simultaneously photodegradation and biodegradation in algal photobioreactors 
demonstrated that in this specific case biological and chemical treatment can also be 
integrated into a single reactor. Complementariness was found in all the studied 
combinations increasing the spectrum of targeted pharmaceuticals and the cost-
effectiveness of the combination compared to single processes. Based on these results 
and the literature on combined treatment processes for various contaminants it is 
postulated that other combinations than the three studied in this dissertation can be 
cost-effective for the removal of pharmaceuticals. Moreover, the differences among 
the synergies found in the studies presented in this dissertation suggest that there 
may be even a wider range of synergy when other combinations of biological and 
chemical processes are included. Therefore it is recommended to further study 
combined treatment processes to identify optimal solutions for the wide suite of 
wastewater effluents to be treated.  
The worldwide variety among raw wastewater compositions and treatment 
plant configurations which both affect the effluent quality, complicates the design and 
development of a robust universal treatment process for pharmaceutical removal. 
Rather, there should be a focus on site-specific solutions as there is a wide arsenal of 
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improving biological and chemical treatment processes and the synergy when 
combining processes, as mentioned earlier in this chapter.  
For locations where the wastewater effluent composition is well known, e.g. 
the WWTP of Bennekom studied in this dissertation, investigated combinations can 
be scaled up towards pilot installations. Upscaling of the BO3B treatment process and 
the algal treatment process is viable as lab-scale systems were successfully tested on 
real wastewater. Moreover, the BO3B process was successfully run in a continuous 
set-up for almost one year. In addition, the BO3B process performs better than other 
combinations for estimated costs and sustainability aspects [109, 125]. Hence, the 
promising results motivate the upscaling of this combined treatment process, 
especially with respect to the energy savings for ozonation by TOC removal in a 
biological pre-treatment. Main points of attention concern the design and operation 
of the biological reactors for the removal of TOC, pharmaceuticals and transformation 
products. Full-scale sand-filters are regularly back-flushed to prevent clogging, 
however, the lab-scale reactors used in this dissertation were not regularly back 
flushed to prevent the wash-out of specific TOC and pharmaceutical degrading 
microorganisms. Thus, on pilot-scale the need for regular back flushing should be well 
evaluated or performed in a manner that valuable biomass will not be flushed out. 
Moreover, the lab-scale reactors were operated with a counter current air flow to 
achieve fully aerobic conditions favouring the pharmaceutical degradation and to 
prevent clogging of the reactors. For larger scale reactors it might be more challenging 
to obtain fully aerobic conditions in a cost-efficient way and this aspect requires 
attention during the reactor design. Ozonation on full-scale is already applied for 
pharmaceutical removal, and experiences from these projects can be used for a BO3B 
pilot. Furthermore, a broader array of contaminants should be studied in a pilot plant, 
including non-pharmaceutical micropollutants, to assess the effectiveness of the BO3B 
process for numerous compounds at real WWTP effluent concentrations. Lastly, 
bioassays with D. magna, P. subcapitata and V. fischeri showed no acute toxic effects 
when exposed to the BO3B process effluent, however these assays cannot be regarded 
as a full toxicological assessment. Chronic toxicity assays and specific toxicity assays, 
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e.g. genotoxicity or carcinogenicity assessment, should therefore be conducted to 
obtain a better understanding of the toxicity potential of the BO3B process effluent. 
The algal treatment process is currently being up scaled at the NIOO building 
(Wageningen, the Netherlands). By means of vacuum toilets a concentrated black 
water stream is collected separately from the other wastewater streams and 
anaerobically digested after which it is fed into the algal treatment system. In tubular 
algal reactors located in a greenhouse the resource recovery, i.e. algae growth and 
harvesting, is further studied on pilot-scale. When the resource recovery on pilot scale 
will be successful, further investigations into the removal of pharmaceuticals is highly 
recommended as these will be present in high concentrations due to the separate 
collection of the black water.  
Pharmaceutical removal by the combination of photocatalysis and 
biodegradation was only investigated in a clean matrix and therefore requires further 
lab-scale testing with real wastewater before upscaling. Next to the effects of matrix 
constituents on the pharmaceutical removal the immobilization or recovery of TiO2 
should be investigated as the current process with powdered TiO2 is not sustainable. 
Various methods to immobilize TiO2 have been developed, each with its own 
characteristics like isoelectric point which do influence the photocatalysis of for 
instance pharmaceuticals [15]. Understanding the correlation between different TiO2 
immobilization methods and the removal of pharmaceuticals in a subsequent 
biological treatment process is therefore highly relevant. 
The BO3B process seems the most versatile treatment process for 
implementation on a short horizon taking into account the observed synergies 
between the investigated biological and chemical processes and the upscaling 
potential. Especially for wastewater effluents with relatively high OM concentrations 
the complementariness between biological treatment and ozonation seems most 
useful for application, like for instance at WWTP Bennekom. 
The detection and identification of numerous pharmaceuticals in wastewater 
only revealed the tip of the iceberg as it is already know that in the human body, in 
the sewer and during wastewater treatment countless metabolites and transformation 
products can be formed. Indications that some of these compounds might be more 
General discussion; towards lower pharmaceutical emissions 
146 
 
e.g. genotoxicity or carcinogenicity assessment, should therefore be conducted to 
obtain a better understanding of the toxicity potential of the BO3B process effluent. 
The algal treatment process is currently being up scaled at the NIOO building 
(Wageningen, the Netherlands). By means of vacuum toilets a concentrated black 
water stream is collected separately from the other wastewater streams and 
anaerobically digested after which it is fed into the algal treatment system. In tubular 
algal reactors located in a greenhouse the resource recovery, i.e. algae growth and 
harvesting, is further studied on pilot-scale. When the resource recovery on pilot scale 
will be successful, further investigations into the removal of pharmaceuticals is highly 
recommended as these will be present in high concentrations due to the separate 
collection of the black water.  
Pharmaceutical removal by the combination of photocatalysis and 
biodegradation was only investigated in a clean matrix and therefore requires further 
lab-scale testing with real wastewater before upscaling. Next to the effects of matrix 
constituents on the pharmaceutical removal the immobilization or recovery of TiO2 
should be investigated as the current process with powdered TiO2 is not sustainable. 
Various methods to immobilize TiO2 have been developed, each with its own 
characteristics like isoelectric point which do influence the photocatalysis of for 
instance pharmaceuticals [15]. Understanding the correlation between different TiO2 
immobilization methods and the removal of pharmaceuticals in a subsequent 
biological treatment process is therefore highly relevant. 
The BO3B process seems the most versatile treatment process for 
implementation on a short horizon taking into account the observed synergies 
between the investigated biological and chemical processes and the upscaling 
potential. Especially for wastewater effluents with relatively high OM concentrations 
the complementariness between biological treatment and ozonation seems most 
useful for application, like for instance at WWTP Bennekom. 
The detection and identification of numerous pharmaceuticals in wastewater 
only revealed the tip of the iceberg as it is already know that in the human body, in 
the sewer and during wastewater treatment countless metabolites and transformation 
products can be formed. Indications that some of these compounds might be more 
Chapter 6 
147 
 
harmful than the parent compounds, i.e. the consumed pharmaceuticals, implies that 
further research on this topic is needed. Understanding the behaviour, fate, effects 
and treatability of pharmaceuticals took an enormous effort of the scientific 
community over the last decades and is still ongoing. Hence, fully understanding the 
role and impact of metabolites and transformation products is even more challenging 
and is expected to provide numerous research needs to be addressed over the coming 
decades. In addition to pharmaceuticals high numbers of other micropollutants are 
also present in wastewater and should be taken into account in future research on 
the design of removal processes [234]. Moreover, non-chemical contamination like 
antibiotic resistant genes and bacteria can pose a serious threat to public health and 
should therefore also be studied [41, 48]. Ideally, the disinfection properties of 
chemical treatment processes can be applied to target micropollutant and antibiotic 
resistant genes and bacteria, for example, as ozonation employed for micropollutant 
removal also demonstrated disinfection of secondary clarified effluent [20]. 
Pharmaceuticals are only one group of all the different waterborne 
contaminants discharged with the effluent. Future research should therefore mainly 
focus on effect based removal strategies as the final goal of wastewater treatment 
processes is to provide a safe effluent posing none or minimal effects to the 
subsequent compartments of the water cycle. Advanced analytical methods at leading 
institutes on micropollutant research can detect and quantify over 300 different 
micropollutants present in aqueous matrices in a single run [177]. Even though this 
is a great achievement and the amount of detectable compounds will most likely even 
further increase, these methods do not provide an accurate assessment of the risk of 
the tested sample, i.e. the posed toxicity of the sample constituents mixture towards 
the ecosystem or humans [208]. Development of comprehensive and practically 
applicable assays to screen for toxicological effects, especially for chronic effects, is 
therefore highly needed. Going beyond the performance assessment of treatment 
processes based on chemical parameters, effect based removal strategies 
incorporating in vivo and in vitro bioassays can provide a better insight in the obtained 
removal efficiency.  
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It is difficult to value the environmental and public health benefits for 
diminished pharmaceutical emissions via wastewater effluents, especially as the 
chronic effects of exposure to mixtures of pharmaceuticals at low concentrations are 
so far limitedly understood. Conducting a thorough cost-benefit analysis is therefore 
very difficult, or even impossible. Nevertheless, indications that pharmaceuticals can 
severely affect the aquatic ecosystem and the worldwide need for wastewater reuse 
motivates investments to mitigate the problem of effluent pharmaceutical emissions. 
Estimated costs for the BO3B process implementation would result in increased 
wastewater treatment costs of 15% for the Netherlands. Expressed per population 
equivalent this is around €5 per year, which is small compared to the yearly tariff for 
wastewater treatment of €55 per population equivalent. Moreover, this increase is 
only 0.014% of the Dutch average yearly spendable income [43]. Similarly, estimated 
tariff increases of additional pharmaceutical removal processes in the literature are 
€5-20 per person per year and only 0.1% per person for primary energy consumption 
[125]. Deciding to wait for a detailed cost-benefit analysis further jeopardizes the 
environment and the public health. The unknown risks and the limited costs 
associated to additional wastewater treatment processes for pharmaceutical removal 
costs therefore justify their implementation. 
Interventions at other stages in the chain from pharmaceutical manufacturing 
to drinking water treatment can be undertaken rather than the end-of-pipe solutions 
which are the focus of this dissertation and most literature. On the one hand, WWTPs 
are a main hub in the water cycle which motivates effective end-of-pipe solutions as 
they can safeguard the next compartments in the water cycle such as surface, ground 
and drinking water. On the other hand, measures taken at earlier stages in the 
pharmaceutical chain can positively influence subsequent stages reducing the overall 
impact. Initiated by the Dutch national government and the wastewater and drinking 
water authorities in the Netherlands, a chain-approach is formulated aiming at 
increased awareness of all chain-actors and when possible facilitating interventions 
to reduce the negative impacts on subsequent [221, 290]. For example, in the 
province of Flevoland, the Netherlands, pharmacists and family doctors were informed 
by the local water authorities on the treatability and environmental impact of 
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pharmaceuticals [181]. They agreed that in case there are biodegradable alternatives 
available to prescribe these over non-biodegradable pharmaceuticals, thereby 
reducing the pharmaceutical loads into the environment. A successful experiment was 
performed In the hospital of Deventer by distributing urine collection bags to patients 
who ingested contrast media for X-ray scanning [67]. Contrast media are known to 
persist during wastewater treatment which favours their separate collection and 
treatment. Patients were asked to collect their urine during 24 hours after ingestion 
and dispose the bags with the municipal solid waste. After collection this waste is 
incinerated whereby the contrast media are effectively eliminated. Another aspect of 
the Dutch chain approach is the support of Green Pharmacy, i.e. the development of 
degradable pharmaceuticals. Moreover, the chain approach aims at implementing the 
environmental effect based assessment during the regulatory approval of 
pharmaceuticals. Raising awareness among the general public on the proper disposal 
of pharmaceuticals and the environmental and human health related effects of 
pharmaceuticals is also included in the chain approach. Even though the removal of 
pharmaceuticals at WWTPs will most likely remain the main stage in the entire 
pharmaceutical chain, improvements at earlier stages like the examples mentioned 
above can significantly impact the quantity and quality of the loads entering WWTPs 
and contribute to reduced emissions to the environment and are therefore strongly 
recommended. 
Switzerland is to date the only example where the discharge of micropollutants 
including pharmaceuticals is restricted by legislation which forces the monitoring and 
80% removal of 5 out of 12 micropollutants [232]. Also for other countries, like the 
Netherlands, stricter legislation on WWTP effluent quality is required to manage the 
discharge of pharmaceuticals and other contaminants into the environment. The 
current knowledge on the negative effects and possible risks of mixtures of discharged 
contaminants on the environment and the public health motivates the implementation 
of the precautionary principle. By this policy makers can enforce more restrictive 
discharge regulations as without further legislation implementation of additional 
treatment processes is expected to be minimal. 
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General discussion; towards lower pharmaceutical emissions 
150 
 
In a wider perspective, alternative sanitation systems should be seriously 
considered as the current wastewater collection and treatment systems are not 
optimal for resource recovery, water usage minimization and pharmaceutical 
removal. Alternative sanitation systems such as the decentralised sanitation and 
reuse concept are based on separation at source principles which promote the 
separation of individual wastewater streams, their specific treatment and the use of 
cost-effective wastewater collection systems [136, 200]. On neighbourhood and office 
building scale this concept has been locally implemented and demonstrated to be a 
sustainable alternative allowing resource recovery and the demand minimization of 
precious drinking water for toilet flushing [251, 285, 318]. This concept offers 
opportunities for a more cost-effective removal of pharmaceuticals as by the use of 
vacuum toilets a highly concentrated black water stream is obtained with much higher 
pharmaceutical concentrations compared to conventional centralised systems [62]. 
Although the design of most alternative sanitation systems aims at resource recovery 
and water demand minimization, a better pharmaceutical removal has been observed 
in such an alternative sanitation full scale system than in conventional WWTPs [36]. 
Additional treatment steps aiming specifically at pharmaceuticals is postulated to be 
more cost-effective than similar steps at conventional WWTPs as the high 
pharmaceutical concentration and the low flow rate of the black water stream ease 
the specific targeting of pharmaceuticals. The large-scale implementation of 
alternative sanitation systems requires a willingness to innovate of the main actors 
regarding legislative and construction aspects of sanitation systems, i.e. 
municipalities, water boards and construction companies. The rigorously different way 
of wastewater collection in alternative sanitation systems, i.e. two streams of which 
one collected by vacuum, requires the costly replacement of the current sewer 
infrastructure. The limited willingness to innovate and the high replacement costs of 
conventional sewers hamper the rapid implementation of alternative sanitation 
systems. However, for new to build neighbourhoods and offices this concept offers 
serious advantages over the conventional gravitational sewer and wastewater 
treatment system, including benefits for pharmaceutical removal, and is therefore 
strongly recommended. 
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Knowing that pharmaceuticals are only one of the contaminants jeopardising 
freshwater bodies, a more general approach towards all chemical and non-chemical 
contaminants including other micropollutants like hormones, pesticides and personal 
care products and antibiotic resistant bacteria and genes should be applied. Hence, 
well-designed treatment systems targeting multiple contaminants can prevent the 
costly implementation of additional treatment processes for each individual type of 
contaminant. Only with a broader scope going beyond pharmaceuticals the further 
contamination of the environment by effluent emissions can be prevented. The 
current indications that numerous contaminants pose adverse effects to the 
environment and human health demands an immediate action. The lack of legislation 
should not be used as an excuse to wait, but calls upon the responsibility of water 
authorities and other stakeholders to act now. As long as chronic effects on the 
environment and public health are insufficiently understood the precautionary 
principle should be applied to strive for the safe reuse of wastewater effluent and the 
harmless discharge into the environment. For the implementation of the 
precautionary principle, combined biological and chemical treatment processes are 
foreseen to play a crucial role in the cost-effective removal of contaminants from 
wastewater effluents. 
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MS  Mass Spectrometer 
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TiO2  Titanium dioxide 
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UV  Ultraviolet 
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Samenvatting 
 
Wereldwijd worden in toenemende mate geneesmiddelen geconsumeerd, en 
de verwachting is dat dit op de korte termijn niet afneemt. Enkele uren tot dagen na 
inname van geneesmiddelen scheidt het menselijk lichaam deze uit via urine of 
ontlasting. Door geavanceerde afvoermechanismen in het menselijk lichaam worden 
geneesmiddelen (gedeeltelijk) uitgescheden als zogenoemde metabolieten, d.w.z. in 
een andere moleculaire vorm dan het originele geneesmiddel. Geneesmiddelen en 
metabolieten komen via het toilet en het riool uiteindelijk in de 
rioolwaterzuiveringsinstallatie terecht. 
Huidige rioolwaterzuiveringsinstallaties, gebruikmakend van actief slib, zijn 
ontworpen om bulkverontreinigingen,  zoals organisch materiaal, stikstof en fosfaat, 
te verwijderen. Deze installaties zijn echter niet ontworpen op het verwijderen van 
het brede spectrum aan geneesmiddelen dat in het afvalwater aanwezig is. Deze 
groep stoffen met zeer uiteenlopende en complexe moleculaire structuren, aanwezig 
in nano- tot microgrammen per liter, wordt daardoor doorgaans slechts minimaal 
verwijderd. De geneesmiddelen waarvan wel biologische afbraak wordt waargenomen 
worden in de regel niet gemineraliseerd tot CO2 en H2O, maar enkel omgezet tot 
transformatieproduct met een licht veranderde structuur ten opzichte van het 
originele geneesmiddel. Dit resulteert in de emissie van ontelbare geneesmiddelen, 
metabolieten en transformatieproducten naar het milieu. 
De aanwezigheid van deze potentieel gevaarlijke stoffen in het milieu is een 
van de grote uitdagingen van deze tijd omdat ze een serieuze bedreiging vormen voor 
de kwaliteit van het aquatisch milieu en de volksgezondheid. Negatieve gevolgen 
zoals de vervrouwelijking van vissen zijn goed beschreven in literatuur en vormen 
een bedreiging voor het gehele ecosysteem. Aanzienlijke concentraties aan 
geneesmiddelen in drinkwaterbronnen afkomstig van rioolwaterzuiveringsinstallaties 
vormen een gevaar voor de volksgezondheid indien drinkwater niet voldoende 
gezuiverd wordt. Daarnaast belemmert de aanwezigheid van geneesmiddelen het 
hergebruik van afvalwater, terwijl wereldwijde waterschaarste juist gedeeltelijk 
opgelost zou kunnen worden door hergebruik van afvalwater. De opsomming van de 
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hierboven beschreven negatieve aspecten motiveert de verwijdering van 
geneesmiddelen uit afvalwater voordat deze het aquatisch milieu bereiken. 
Als een van de hoofdschakels in de waterketen zijn 
rioolwaterzuiveringsinstallaties een optimale locatie voor een barrière tegen 
geneesmiddelenemissies naar het milieu. Meerdere biologische en chemische 
processen zijn bestudeerd voor de verwijdering van geneesmiddelen, waarvan 
sommige reeds lokaal geïmplementeerd zijn. Desalniettemin tonen veel van deze 
processen een onvolledige verwijdering van geneesmiddelen of worden ze 
gekenmerkt door hoge kosten en lage duurzaamheid. Oftewel, er is een tekort aan 
kost-effectieve processen voor geneesmiddelenverwijdering. Deze dissertatie gaat 
daarom in op verschillende processen voor de kost-effectieve verwijdering van 
geneesmiddelen uit afvalwater met een focus op de synergie tussen biologische en 
chemische zuiveringsprocessen voor een verbeterde geneesmiddelen verwijdering 
(Hoofdstuk 1).
De doorgaans lage kosten voor biologische zuiveringsprocessen begunstigen 
de  toekomstige implementatie ervan en stimuleren het onderzoek ernaar. Van alle 
parameters die invloed hebben op de werking van biologische processen worden 
redox-condities gezien als een van de belangrijkste. Uit batch- en kolomexperimenten 
met sediment van helofytenfilters is gebleken dat geneesmiddelen het best worden 
verwijderd onder aërobe, d.w.z. zuurstofrijke, sulfaat reducerende en methanogene 
condities (Hoofdstuk 2). Microaërofiele en nitraat reducerende condities zijn minder 
effectief. Biologische afbraak en sorptie aan sediment zijn geïdentificeerd als 
onderliggende verwijderingsmechanismen van geneesmiddelen en worden beide 
beïnvloed door de heersende redox-condities. Van de onderzochte geneesmiddelen 
vertoonde propranolol de hoogste sorptiecoëfficiënt. Voor propranolol vond onder de 
meest optimale redox-conditie verzadiging van de sediment sorptieplekken plaats na 
300 porie volumewisselingen. Dit toont aan dat in biologische filtratieprocessen 
geneesmiddelenverwijdering middels sorptie aan sediment slechts een minimale rol 
speelt ten opzichte van biodegradatie. De persistentie van biorecalitrante 
geneesmiddelen zoals carbamazepine in biologische zuiveringsprocessen benadrukt 
de onvolkomenheid van deze processen en onderschrijft de noodzaak voor additionele 
niet-biologische zuiveringsstappen.  
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Milde UV-LED TiO2 fotokatalyse gecombineerd met een nageschakeld biologisch 
zuiveringsproces toonde een verbeterde geneesmiddelenverwijdering ten opzichte 
van beide afzonderlijke processen (Hoofdstuk 3). Drie van de negen onderzochte 
geneesmiddelen werden verwijderd door milde fotokatalyse. Vier geneesmiddelen 
vertoonden een verbeterde geneesmiddelenverwijdering tijdens biologische zuivering 
na milde fotokatalytische voorbehandeling. Verrassend genoeg, was slechts één van 
deze vier geneesmiddelen verwijderd gedurende milde fotokatalyse. Bovendien werd 
diclofenac biologisch afgebroken na voorbehandeling terwijl er zonder 
voorbehandeling geen afbraak plaats vond. Afgaande op literatuur is gepostuleerd 
dat afbraakproducten van de drie door milde fotokatalyse verwijderde 
geneesmiddelen hebben geleid tot de activering van enzymatische systemen die 
betrokken zijn bij de initiële reacties voor de biodegradatie van organische moleculen. 
Naast geneesmiddelen zijn er talrijke andere (onschadelijke) organische 
stoffen aanwezigheid in rioolwaterzuivering effluent. In het geval ozonisatie wordt 
toegepast als additioneel zuiveringsproces voor geneesmiddelenverwijdering, vangen 
deze stoffen een grote fractie van het ozon af waarmee de ozonisatie van 
geneesmiddelen sterk in effectiviteit reduceert. Hoge totale organisch 
koolstofconcentraties (TOC), zoals 17,3 mg TOC/L in het voor deze studie 
onderzochte afvalwater, resulteren derhalve in een hoog ozonverbruik waardoor de 
kost-effectiviteit van ozonisatie afneemt. Om die reden is een bio-ozon-bio-proces 
(BO3B) bestaande uit twee identieke druppelfilters met zand als dragermateriaal en 
een ozonreactor ontworpen (Hoofdstuk 4). Met als doel het ontwikkelen van een kost-
effectieve zuivering zijn verschillende hydraulische verblijftijden en ozondoseringen 
onderzocht. Over de eerste biologische zuiveringsstap is bij een relatief korte 
verblijftijd van 1,5 uur een TOC-verwijdering van 38% behaald, waardoor het ozon 
verbruik in de daaropvolgende ozonisatiestap evenredig verlaagd kon worden. 
Vergeleken met het actief-slibproces, zoals toegepast in huidige 
rioolwaterzuiveringsinstallaties, presteerde de eerste biologische zuiveringsstap van 
het BO3B proces beter op geneesmiddelenverwijdering, ondanks de lage verblijftijd 
en lage biomassaconcentratie. Zelfs enkele moeilijk afbreekbare geneesmiddelen 
zoals sulfamethoxazol werden biologisch verwijderd. Met een lage ozondosis van 0.02 
g O3/g TOC werden in de ozonisatiestap biorecalcitrante geneesmiddelen zoals 
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Milde UV-LED TiO2 fotokatalyse gecombineerd met een nageschakeld biologisch 
zuiveringsproces toonde een verbeterde geneesmiddelenverwijdering ten opzichte 
van beide afzonderlijke processen (Hoofdstuk 3). Drie van de negen onderzochte 
geneesmiddelen werden verwijderd door milde fotokatalyse. Vier geneesmiddelen 
vertoonden een verbeterde geneesmiddelenverwijdering tijdens biologische zuivering 
na milde fotokatalytische voorbehandeling. Verrassend genoeg, was slechts één van 
deze vier geneesmiddelen verwijderd gedurende milde fotokatalyse. Bovendien werd 
diclofenac biologisch afgebroken na voorbehandeling terwijl er zonder 
voorbehandeling geen afbraak plaats vond. Afgaande op literatuur is gepostuleerd 
dat afbraakproducten van de drie door milde fotokatalyse verwijderde 
geneesmiddelen hebben geleid tot de activering van enzymatische systemen die 
betrokken zijn bij de initiële reacties voor de biodegradatie van organische moleculen. 
Naast geneesmiddelen zijn er talrijke andere (onschadelijke) organische 
stoffen aanwezigheid in rioolwaterzuivering effluent. In het geval ozonisatie wordt 
toegepast als additioneel zuiveringsproces voor geneesmiddelenverwijdering, vangen 
deze stoffen een grote fractie van het ozon af waarmee de ozonisatie van 
geneesmiddelen sterk in effectiviteit reduceert. Hoge totale organisch 
koolstofconcentraties (TOC), zoals 17,3 mg TOC/L in het voor deze studie 
onderzochte afvalwater, resulteren derhalve in een hoog ozonverbruik waardoor de 
kost-effectiviteit van ozonisatie afneemt. Om die reden is een bio-ozon-bio-proces 
(BO3B) bestaande uit twee identieke druppelfilters met zand als dragermateriaal en 
een ozonreactor ontworpen (Hoofdstuk 4). Met als doel het ontwikkelen van een kost-
effectieve zuivering zijn verschillende hydraulische verblijftijden en ozondoseringen 
onderzocht. Over de eerste biologische zuiveringsstap is bij een relatief korte 
verblijftijd van 1,5 uur een TOC-verwijdering van 38% behaald, waardoor het ozon 
verbruik in de daaropvolgende ozonisatiestap evenredig verlaagd kon worden. 
Vergeleken met het actief-slibproces, zoals toegepast in huidige 
rioolwaterzuiveringsinstallaties, presteerde de eerste biologische zuiveringsstap van 
het BO3B proces beter op geneesmiddelenverwijdering, ondanks de lage verblijftijd 
en lage biomassaconcentratie. Zelfs enkele moeilijk afbreekbare geneesmiddelen 
zoals sulfamethoxazol werden biologisch verwijderd. Met een lage ozondosis van 0.02 
g O3/g TOC werden in de ozonisatiestap biorecalcitrante geneesmiddelen zoals 
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carbamazepine effectief verwijderd. De 17% TOC-verwijdering over de laatste 
biologische zuiveringsstap is vermoedelijk toe te schrijven aan de biologische 
verwijdering van ozonisatie producten. 
In algen-fotobioreactoren is het gelukt om uit anaëroob behandeld zwart water 
en uit pure urine geneesmiddelenverwijdering en nutriënten terugwinning gelijktijdig 
te bewerkstelligen (Hoofdstuk 5). Uit literatuur is bekend dat algen in staat zijn 
stikstof en fosfor op te nemen uit brongescheiden afvalwaterstromen. Uit onze 
experimenten blijkt dat ze daarnaast ook bijdragen aan geneesmiddelenverwijdering 
uit afvalwater. Controle-experimenten toonden aan dat zowel algen, bacteriën als ook 
de belichting van de reactor bijdragen aan de geneesmiddelenverwijdering in de 
algen-fotobioreactoren. Geneesmiddelen die vatbaar zijn voor licht zoals diclofenac 
werden verwijderd middels fotolyse, terwijl andere, zoals paracetamol en metoprolol, 
door een combinatie van fotolyse en biodegradatie verwijderd werden. Sorptie van 
geneesmiddelen aan algen bleek minimaal waardoor het gebruik van deze 
nutriëntrijke biomassastroom als meststof voordelen heeft over bemesting met urine. 
De bevindingen van deze dissertatie geven inzicht in de tekortkomingen van 
individuele biologische en chemische processen voor geneesmiddelenverwijdering uit 
afvalwater, en benadrukken de waarde van combinaties van complementaire 
processen waarbij de nadelen van individuele processen wordt overstegen (Hoofdstuk 
6). Omdat er geen universele kost-effectieve combinatie van processen bestaat, 
bepalen locatiespecifieke omstandigheden zoals de afvalwatercompositie welke 
combinatie lokaal het meest effectief is. De implementatie van aanvullende 
zuiveringsstappen dient daarom uit te gaan van op maat gemaakte combinaties. 
Hierbij kan worden geput uit het reeds bestaande arsenaal aan biologische en 
chemische processen voor afvalwaterzuivering en eventuele nog te ontwikkelen 
processen. Om de kost-effectiviteit van combinatieprocessen verder te verbeteren zal 
toekomstig onderzoek moeten focussen op de onderliggende 
verwijderingsmechanismen, waaronder de enzymatische routes waarlangs 
geneesmiddelen verwijderd worden en de formatie en afbraak van 
transformatieproducten. 
Voor de in deze dissertatie bestudeerde verwijderingsprocessen is een 
vooruitzicht geschetst betreffende vervolgonderzoek en opschaling. Het BO3B-proces 
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en het zuiveringsproces met algen zijn rijp om op pilot-schaal getest te worden. 
Voornamelijk de potentie van het BO3B-proces is hoog omdat dit reeds een jaar lang 
succesvol op werkelijk afvalwater is getest. Gedurende deze periode is op kost-
effectieve wijze een hoog verwijderingsrendement bereikt. Opschaling zou zich 
voornamelijk moeten richten op het bedrijven van de biologische zuiveringsstappen, 
omdat deze de hoge kosten van het ozonisatieproces reduceren. 
Het zuiveringsproces met algen wordt momenteel bestudeerd op pilot-schaal. 
Hiervoor wordt aanbevolen, net als voor andere vervolgonderzoeken, naast 
geneesmiddelen ook andere microverontreinigingen te bestuderen. De combinatie 
van fotokatalyse en biologische zuivering vereist verder laboratoriumonderzoek, 
omdat deze combinatie enkel op een schone watermatrix getest is. Daarnaast dient 
er voor de verduurzaming van het proces naar TiO2-immobilisatie gekeken te worden. 
Vergaarde kennis van de afgelopen decennia onderstreept het belang van 
effect-gebaseerde verwijderingsstrategieën en dient te worden meegenomen in 
toekomstig onderzoek en implementatie. De meeste studies echter, inclusief deze 
dissertatie, zijn voornamelijk gestoeld op chemische parameters zoals 
geneesmiddelen concentraties en gaan daardoor voorbij aan de effecten van de 
onderzochte stoffen op het aquatische milieu. 
Interventies in de geneesmiddelenketen van farmaceutische industrie tot 
drinkwaterproductie waarmee end-of-pipe-oplossingen minder nodig zijn, evenals de 
implementatie van striktere wet- en regelgeving omtrent het voorkomen van 
geneesmiddelenemissies, worden beide sterk aanbevolen om de 
geneesmiddelenemissies naar het milieu te verminderen. Daarnaast wordt ook het 
realiseren van brongescheiden sanitatiesystemen aanbevolen, waarmee in 
vergelijking tot gemengde afvalwaterstromen een kost-effectievere 
geneesmiddelenverwijdering kan worden bewerkstelligd. 
Afsluitend kan gesteld worden dat de bevindingen beschreven in deze 
dissertatie aanvullend inzicht geven in het combineren van biologische en chemische 
processen ten behoeve van verregaande geneesmiddelenverwijdering uit afvalwater 
en daarbij onderdeel uitmaken van een groter geheel aan handelingen die 
noodzakelijk zijn ter voorkoming van verdere bedreiging die geneesmiddelenemissies 
vormen voor mens en milieu. 
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carbamazepine effectief verwijderd. De 17% TOC-verwijdering over de laatste 
biologische zuiveringsstap is vermoedelijk toe te schrijven aan de biologische 
verwijdering van ozonisatie producten. 
In algen-fotobioreactoren is het gelukt om uit anaëroob behandeld zwart water 
en uit pure urine geneesmiddelenverwijdering en nutriënten terugwinning gelijktijdig 
te bewerkstelligen (Hoofdstuk 5). Uit literatuur is bekend dat algen in staat zijn 
stikstof en fosfor op te nemen uit brongescheiden afvalwaterstromen. Uit onze 
experimenten blijkt dat ze daarnaast ook bijdragen aan geneesmiddelenverwijdering 
uit afvalwater. Controle-experimenten toonden aan dat zowel algen, bacteriën als ook 
de belichting van de reactor bijdragen aan de geneesmiddelenverwijdering in de 
algen-fotobioreactoren. Geneesmiddelen die vatbaar zijn voor licht zoals diclofenac 
werden verwijderd middels fotolyse, terwijl andere, zoals paracetamol en metoprolol, 
door een combinatie van fotolyse en biodegradatie verwijderd werden. Sorptie van 
geneesmiddelen aan algen bleek minimaal waardoor het gebruik van deze 
nutriëntrijke biomassastroom als meststof voordelen heeft over bemesting met urine. 
De bevindingen van deze dissertatie geven inzicht in de tekortkomingen van 
individuele biologische en chemische processen voor geneesmiddelenverwijdering uit 
afvalwater, en benadrukken de waarde van combinaties van complementaire 
processen waarbij de nadelen van individuele processen wordt overstegen (Hoofdstuk 
6). Omdat er geen universele kost-effectieve combinatie van processen bestaat, 
bepalen locatiespecifieke omstandigheden zoals de afvalwatercompositie welke 
combinatie lokaal het meest effectief is. De implementatie van aanvullende 
zuiveringsstappen dient daarom uit te gaan van op maat gemaakte combinaties. 
Hierbij kan worden geput uit het reeds bestaande arsenaal aan biologische en 
chemische processen voor afvalwaterzuivering en eventuele nog te ontwikkelen 
processen. Om de kost-effectiviteit van combinatieprocessen verder te verbeteren zal 
toekomstig onderzoek moeten focussen op de onderliggende 
verwijderingsmechanismen, waaronder de enzymatische routes waarlangs 
geneesmiddelen verwijderd worden en de formatie en afbraak van 
transformatieproducten. 
Voor de in deze dissertatie bestudeerde verwijderingsprocessen is een 
vooruitzicht geschetst betreffende vervolgonderzoek en opschaling. Het BO3B-proces 
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geneesmiddelenemissies, worden beide sterk aanbevolen om de 
geneesmiddelenemissies naar het milieu te verminderen. Daarnaast wordt ook het 
realiseren van brongescheiden sanitatiesystemen aanbevolen, waarmee in 
vergelijking tot gemengde afvalwaterstromen een kost-effectievere 
geneesmiddelenverwijdering kan worden bewerkstelligd. 
Afsluitend kan gesteld worden dat de bevindingen beschreven in deze 
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Резюме 
 
Употребление лекарственных препаратов растет повсеместно и тенденции 
к снижению их использования в ближайшем будущем не предвидится. Спустя 
несколько часов, а то и дней, после приема медикаментов человеческий организм 
выводит их с мочой или фекалиями. Но благодаря совершенным «механизмам 
дренажа» человека, фармацевтические препараты частично выделяются, в виде 
метаболитов (то есть в другой молекулярной форме, чем исходный препарат). 
Через туалет и канализацию медикаменты и метаболиты попадают на пункты 
очистки сточных вод.  
Нынешние очистные сооружения, работающие на базе активного ила, 
предназначены для удаления стандартных, объемных загрязнений, таких как 
органика, азот и фосфат. Концентрация этих веществ в сточных водах 
исчисляется миллиграммами на литр. Однако современные установки не 
рассчитаны на удаление широкого спектра фармацевтических продуктов, 
присутствующих в сточных водах. Таким образом, эта группа соединений, 
выраженная разнообразными и сложными молекулярными структурами и 
присутствующая в нано-микрограммах в литре жидкости, удаляется минимально. 
Кроме того, те лекарственные средства, у которых наблюдается биодеградация 
(биологический распад), как правило, не минерализуются в СО2 и Н2О, а лишь 
преобразуются в продукт трансформации со слегка отличающейся от исходного 
лекарственного препарата химической структурой. Таким образом, в 
окружающую среду попадает бесчисленное количество медицинских препаратов, 
метаболитов и продуктов трансформации. 
Присутствие этих потенциально опасных веществ в окружающей среде 
является одной из главных проблем нашего времени, поскольку они реально 
угрожают качеству состояния водной среды и, как следствие, здоровью 
человечества. Отрицательные последствия этих процессов, такие как, например, 
феминизация рыб (развитие у особи мужского пола вторичных половых 
признаков, характерных для женской особи), также представляют угрозу для 
всей экосистемы. Оказалось, что источники питьевой воды, уже содержат 
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высокие концентрации фармацевтических веществ, которые выделяются в 
экосистему очистными сооружениями. Вода, производимая подобными 
источниками и очищенная ненадлежащим образом, создает реальную опасность 
для здоровья населения. В связи с этим, присутствие фармацевтических 
препаратов в сточных водах препятствует их повторному использованию, в то 
время как глобальная нехватка воды на планете могла бы быть частично решена 
именно путем повторного использования сточных вод. Перечисленные выше 
негативные аспекты мотивируют на удаление медикаментов из сточных вод, 
прежде чем они достигнут водной среды. 
Будучи одним из главных звеньев водной цепи, очистные сооружения 
являются оптимальным местом для перехвата фармацевтических препаратов до 
их попадания в окружающую среду. Уже изучен ряд биологических и химических 
процессов удаления медицинских средств, часть из них уже применяется. Тем не 
менее, многие из этих методов либо не способны удалять медицинские препараты 
полностью, либо являются дорогостоящими и недолговечными. Иными словами, 
сегодня существует реальная нехватка доступных, с экономической точки 
зрения, и эффективных процессов удаления фармацевтических препаратов. 
Поэтому данная диссертация посвящена исследованию различных процессов 
рентабельного удаления медицинских средств из сточных вод. В работе был 
сделан акцент на синергизм биологических и химических процессов очистки для 
улучшенного удаления лекарственных препаратов (глава 1).
В целом же низкая стоимость биологических процессов очистки сточных 
вод способствует их внедрению в будущем и стимулирует их исследования. Среди 
различных параметров, влияющих на биологические процессы, окислительно-
восстановительные условия считаются одними из наиболее важных. Из batch и 
колоночных экспериментов, с использованием искусственных болот, стало 
понятно, что удаление фармацевтических препаратов проходило наиболее 
эффективно в аэробных, сульфатно-восстановительных и метаногенных 
условиях (глава 2). В то время как, микроаэрофильные и нитрат-
восстановительные условия оказались менее эффективными. Биодеградация и 
сорбция были идентифицированы как основные механизмы удаления 
лекарственных препаратов. Также было установлено, что эффективность этих 
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двух процессов (биодеградации и сорбции) зависит от окислительно-
восстановительных условий (redox). Из всех исследуемых лекарственных 
средств, пропранолол показал самый высокий коэффициент сорбции. Было также 
обнаружено, что насыщение сорбционных участков пропранолом происходит 
после 300-кратного изменения объема пор при наиболее благоприятных 
окислительно-восстановительных условиях. Это говорит о том, что в процессах 
биологической фильтрации сорбция фармацевтических препаратов имеет 
второстепенное значение по сравнению с биодеградацией. Устойчивость био-
рекальцитрантов, таких как карбамазепин, к процессам биологической очистки 
подчеркивает их несовершенство и указывает на необходимость в 
дополнительных небиологических этапах очистки. 
Так мягкий фотокатализ в присутствии УФ-светодиода и TiO2 в сочетании с 
последующей биологической обработкой продемонстрировал улучшенное 
удаление лекарственных средств по сравнению с этими же процессами, 
проведенными по отдельности (глава 3). Три из девяти исследуемых 
фармацевтических препаратов были частично удалены путем мягкой 
фотокаталитической обработки. Биодеградация четырех других медицинских 
препаратов также улучшилась после мягкой предварительной обработки 
фотокатализом. И лишь один из этих четырех препаратов был частично удален 
во время легкого фотокатализа. Кроме того, мягкая предварительная 
фотокаталитическая обработка способствовала биодеградированию 
диклофенака, который продемонстрировал устойчивость к однократной 
биологической обработке. Также выдвинуто предположение, что продукты 
распада трех медицинских препаратов, удаляемые мягким фотокатализом, 
приводят к активации биологических систем, участвующих в первоначальных 
реакциях биодеградации органических молекул. 
Наряду с фармацевтическими препаратами в сточных водах также 
присутствует множество безвредных органических веществ. В этом случае, в 
качестве дополнительного процесса очистки сточных вод, используется их 
озонирование. Однако эти органические вещества захватывают большую часть 
самого озона, что значительно снижает эффективность этого процесса. Высокие 
концентрации общего органического углерода (ООУ) (17,3 мг ООУ/литр) в 
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высокие концентрации фармацевтических веществ, которые выделяются в 
экосистему очистными сооружениями. Вода, производимая подобными 
источниками и очищенная ненадлежащим образом, создает реальную опасность 
для здоровья населения. В связи с этим, присутствие фармацевтических 
препаратов в сточных водах препятствует их повторному использованию, в то 
время как глобальная нехватка воды на планете могла бы быть частично решена 
именно путем повторного использования сточных вод. Перечисленные выше 
негативные аспекты мотивируют на удаление медикаментов из сточных вод, 
прежде чем они достигнут водной среды. 
Будучи одним из главных звеньев водной цепи, очистные сооружения 
являются оптимальным местом для перехвата фармацевтических препаратов до 
их попадания в окружающую среду. Уже изучен ряд биологических и химических 
процессов удаления медицинских средств, часть из них уже применяется. Тем не 
менее, многие из этих методов либо не способны удалять медицинские препараты 
полностью, либо являются дорогостоящими и недолговечными. Иными словами, 
сегодня существует реальная нехватка доступных, с экономической точки 
зрения, и эффективных процессов удаления фармацевтических препаратов. 
Поэтому данная диссертация посвящена исследованию различных процессов 
рентабельного удаления медицинских средств из сточных вод. В работе был 
сделан акцент на синергизм биологических и химических процессов очистки для 
улучшенного удаления лекарственных препаратов (глава 1).
В целом же низкая стоимость биологических процессов очистки сточных 
вод способствует их внедрению в будущем и стимулирует их исследования. Среди 
различных параметров, влияющих на биологические процессы, окислительно-
восстановительные условия считаются одними из наиболее важных. Из batch и 
колоночных экспериментов, с использованием искусственных болот, стало 
понятно, что удаление фармацевтических препаратов проходило наиболее 
эффективно в аэробных, сульфатно-восстановительных и метаногенных 
условиях (глава 2). В то время как, микроаэрофильные и нитрат-
восстановительные условия оказались менее эффективными. Биодеградация и 
сорбция были идентифицированы как основные механизмы удаления 
лекарственных препаратов. Также было установлено, что эффективность этих 
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сточных водах, используемых для данного исследования, требуют ввода больших 
доз озона, что снижает экономическую эффективность озонирования. Поэтому в 
рамках исследования был разработан трехступенчатый био-озоно-биопроцесс 
(BO3B), включающий озоновый реактор и два одинаковых фильтра с насадкой, 
использующих песок в качестве носителей биомассы (глава 4). В целях 
разработки рентабельной системы очистки были исследованы различные 
времена гидравлического удержания (ВГУ) и дозы озона. Первый биологический 
реактор удалял 38% ООУ при ВГУ в 1,5 часа, что пропорционально уменьшало 
потребность в озоне в последующем озоновом реакторе. Улучшенное удаление 
фармацевтических препаратов по сравнению с обычной очисткой сточных вод 
наблюдалось в первом биологическом реакторе, несмотря на короткое ВГУ и 
низкое количество биомассы в системе BO3B. Эффективная биодеградация была 
продемонстрирована даже для таких трудноразлагаемых лекарственных средств, 
как сульфаметоксазол. Био-рекальцитранты, такие как карбамазепин, 
эффективно удалялись при низких дозах озона (до 0,2 г O3/г ООУ). Удаление 17% 
ООУ в последнем биологическом реакторе свидетельствовало об удалении 
продуктов трансформации, образовавшихся во время озонирования. 
Одновременное извлечение биогенов и удаление фармацевтических 
препаратов было обнаружено в фотобиореакторах с культивацией водорослей, 
работающих на анаэробно обработанной черной воде или моче (глава 5). Было 
обнаружено, что водоросли, которые, как известно, способны поглощать азот и 
фосфор из этих высококонцентрированных источников сточных вод, также 
способствовали удалению из них фармацевтических препаратов. Контрольные 
эксперименты еще раз подтвердили факт содействия водорослей, бактерий и 
света в удалении фармацевтических препаратов. Нужно также отметить 
поведение медицинских препаратов, оказавшихся чувствительными к фотолизу. 
Так, например, диклофенак, после применения этой химической реакции, 
фотодеградировал, тогда как парацетамол и метопролол удалились лишь при 
комбинирование био- и фото- деградаций. Сорбция фармацевтических 
препаратов для водорослей оказалась минимальной, что позволяет 
рекомендовать использование этой богатой питательными веществами биомассы 
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низкое количество биомассы в системе BO3B. Эффективная биодеградация была 
продемонстрирована даже для таких трудноразлагаемых лекарственных средств, 
как сульфаметоксазол. Био-рекальцитранты, такие как карбамазепин, 
эффективно удалялись при низких дозах озона (до 0,2 г O3/г ООУ). Удаление 17% 
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препаратов было обнаружено в фотобиореакторах с культивацией водорослей, 
работающих на анаэробно обработанной черной воде или моче (глава 5). Было 
обнаружено, что водоросли, которые, как известно, способны поглощать азот и 
фосфор из этих высококонцентрированных источников сточных вод, также 
способствовали удалению из них фармацевтических препаратов. Контрольные 
эксперименты еще раз подтвердили факт содействия водорослей, бактерий и 
света в удалении фармацевтических препаратов. Нужно также отметить 
поведение медицинских препаратов, оказавшихся чувствительными к фотолизу. 
Так, например, диклофенак, после применения этой химической реакции, 
фотодеградировал, тогда как парацетамол и метопролол удалились лишь при 
комбинирование био- и фото- деградаций. Сорбция фармацевтических 
препаратов для водорослей оказалась минимальной, что позволяет 
рекомендовать использование этой богатой питательными веществами биомассы 
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в качестве удобрения, поскольку она имеет большие преимущества перед 
применением для таких же целей мочи.  
Таким образом, результаты данной работы дают представление о 
недостатках отдельно проведенных биологических и химических процессов 
удаления фармацевтических препаратов из сточных вод и подчеркивают 
ценность их комбинирования (глава 6). Специфические для каждой конкретной 
ситуации условия, такие как, например состав сточных вод, определяют, какая 
комбинация процессов будет наиболее выгодна в данном случае, поскольку 
универсальной экономически-эффективной комбинации процессов не 
существует. Поэтому внедрение дополнительных этапов очистки должно быть 
сосредоточено на поиске индивидуальных комбинаций для каждого конкретного 
случая. Для дальнейшего повышения рентабельности комбинированных 
процессов будущие исследователи должны сосредоточить свое внимание на 
основных механизмах удаления, включая ферментативные пути деградации 
фармацевтических препаратов, а также образование и удаление продуктов 
трансформации. 
Изученные и описанные в этой диссертации процессы очистки 
представляют собой прекрасную перспективу для дальнейших исследований и 
укрепления opschaling (увеличения масштабов процессов). Так, например, 
процесс BO3B и система очистки при помощи водорослей проведены в рамках 
пилотного проекта и готовы к последующим изучениям и экспериментам. Нужно 
отметить, что система BO3B была успешно протестирована в лабораторных 
условиях на реальных сточных водах в течение года и продемонстрировала 
высокую эффективность удаления фармацевтических препаратов и оказалась 
экономически доступным способом. 
Будущим исследователям также необходимо сфокусироваться на работе 
биологических реакторов, поскольку именно они способствуют рентабельности 
процесса BO3B, и на удалении широкого спектра микрозагрязнений. Комбинация 
фотокатализа и биодеградации также требует дальнейших лабораторных 
исследований, поскольку для улучшения устойчивости системы должен быть 
решен вопрос иммобилизации TiO2; к тому же, данная система была проверена 
только на чистой матрице. 
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сточных водах, используемых для данного исследования, требуют ввода больших 
доз озона, что снижает экономическую эффективность озонирования. Поэтому в 
рамках исследования был разработан трехступенчатый био-озоно-биопроцесс 
(BO3B), включающий озоновый реактор и два одинаковых фильтра с насадкой, 
использующих песок в качестве носителей биомассы (глава 4). В целях 
разработки рентабельной системы очистки были исследованы различные 
времена гидравлического удержания (ВГУ) и дозы озона. Первый биологический 
реактор удалял 38% ООУ при ВГУ в 1,5 часа, что пропорционально уменьшало 
потребность в озоне в последующем озоновом реакторе. Улучшенное удаление 
фармацевтических препаратов по сравнению с обычной очисткой сточных вод 
наблюдалось в первом биологическом реакторе, несмотря на короткое ВГУ и 
низкое количество биомассы в системе BO3B. Эффективная биодеградация была 
продемонстрирована даже для таких трудноразлагаемых лекарственных средств, 
как сульфаметоксазол. Био-рекальцитранты, такие как карбамазепин, 
эффективно удалялись при низких дозах озона (до 0,2 г O3/г ООУ). Удаление 17% 
ООУ в последнем биологическом реакторе свидетельствовало об удалении 
продуктов трансформации, образовавшихся во время озонирования. 
Одновременное извлечение биогенов и удаление фармацевтических 
препаратов было обнаружено в фотобиореакторах с культивацией водорослей, 
работающих на анаэробно обработанной черной воде или моче (глава 5). Было 
обнаружено, что водоросли, которые, как известно, способны поглощать азот и 
фосфор из этих высококонцентрированных источников сточных вод, также 
способствовали удалению из них фармацевтических препаратов. Контрольные 
эксперименты еще раз подтвердили факт содействия водорослей, бактерий и 
света в удалении фармацевтических препаратов. Нужно также отметить 
поведение медицинских препаратов, оказавшихся чувствительными к фотолизу. 
Так, например, диклофенак, после применения этой химической реакции, 
фотодеградировал, тогда как парацетамол и метопролол удалились лишь при 
комбинирование био- и фото- деградаций. Сорбция фармацевтических 
препаратов для водорослей оказалась минимальной, что позволяет 
рекомендовать использование этой богатой питательными веществами биомассы 
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ценность их комбинирования (глава 6). Специфические для каждой конкретной 
ситуации условия, такие как, например состав сточных вод, определяют, какая 
комбинация процессов будет наиболее выгодна в данном случае, поскольку 
универсальной экономически-эффективной комбинации процессов не 
существует. Поэтому внедрение дополнительных этапов очистки должно быть 
сосредоточено на поиске индивидуальных комбинаций для каждого конкретного 
случая. Для дальнейшего повышения рентабельности комбинированных 
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укрепления opschaling (увеличения масштабов процессов). Так, например, 
процесс BO3B и система очистки при помощи водорослей проведены в рамках 
пилотного проекта и готовы к последующим изучениям и экспериментам. Нужно 
отметить, что система BO3B была успешно протестирована в лабораторных 
условиях на реальных сточных водах в течение года и продемонстрировала 
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Знания, полученные в течение последних десятилетий, подчеркивают 
важность усовершенствования стратегий очистки и нацелены на конечный 
эффект. Исследования же, проведенные в рамках этой диссертации, обращены 
на оптимизацию химических показателей, таких как концентрации отдельных 
фармацевтических препаратов, и не учитывают конечный эффект этих 
препаратов, например, на водную среду. Системы санитарии (source separation), 
работающие на разделении сточных вод на выходе «из дома», позволяют 
перехватить и экономически-эффективно удалить фармацевтические препараты 
еще на ранних этапах очистки сточных вод. Кроме того, source separation 
уменьшают потребность в очистке в конце технологического цикла, а также 
являются настоятельно рекомендуемыми для повсеместного внедрения. Более 
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